US20020164760A1 - Catalytically active recombinant memapsin and methods of use thereof - Google Patents

Catalytically active recombinant memapsin and methods of use thereof Download PDF

Info

Publication number
US20020164760A1
US20020164760A1 US09/795,903 US79590301A US2002164760A1 US 20020164760 A1 US20020164760 A1 US 20020164760A1 US 79590301 A US79590301 A US 79590301A US 2002164760 A1 US2002164760 A1 US 2002164760A1
Authority
US
United States
Prior art keywords
memapsin
substrate
leu
ala
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/795,903
Inventor
Xinli Lin
Gerald Koelsch
Jordan Tang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation filed Critical Oklahoma Medical Research Foundation
Priority to US09/795,903 priority Critical patent/US20020164760A1/en
Publication of US20020164760A1 publication Critical patent/US20020164760A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478—Aspartic endopeptidases (3.4.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Definitions

  • AD Alzheimer's disease
  • AD is associated with neuritic plaques measuring up to 200 ⁇ m in diameter in the cortex, hippocampus, subiculum, hippocampal gyrus, and amygdala.
  • amyloid which is stained by Congo Red (Fisher (1983); Kelly Microbiol. Sci. 1(9):214-219 (1984)).
  • Amyloid plaques stained by Congo Red are extracellular, pink or rust-colored in bright field, and birefringent in polarized light.
  • the plaques are composed of polypeptide fibrils and are often present around blood vessels, reducing blood supply to various neurons in the brain.
  • Amyloid plaques are abundantly present in AD patients and in Down's Syndrome individuals surviving to the age of 40.
  • the overexpression of APP in Down's Syndrome is recognized as a possible cause of the development of AD in Down's patients over thirty years of age (Rumble et al., New England J. Med. 20 320:1446-1452 (1989); Mann et al., Neurobiol. Aging 10:397-399 (1989)).
  • the plaques are also present in the normal aging brain, although at a lower number. These plaques are made up primarily of the amyloid ⁇ peptide (A ⁇ ; sometimes also referred to in the literature as ⁇ -amyloid peptide or ⁇ peptide) (Glenner and Wong, Biochem.
  • amyloid is a filamentous material that is arranged in beta-pleated sheets.
  • a ⁇ is a hydrophobic peptide comprising up to 43 amino acids.
  • APP forms of APP cDNA have been identified, including the three most abundant forms, APP695, APP751, and APP770. These forms arise from a single precursor RNA by alternate splicing. The gene spans more than 175 kb with 18 exons (Yoshikai et al. (1990)).
  • APP contains an extracellular domain, a transmembrane region and a cytoplasmic domain.
  • a ⁇ consists of up to 28 amino acids just outside the hydrophobic transmembrane domain and up to 15 residues of this transmembrane domain. A ⁇ is normally found in brain and other tissues such as heart, kidney and spleen. However, A ⁇ deposits are usually found in abundance only in the brain.
  • APP is processed in vivo at three sites.
  • the evidence suggests that cleavage at the ⁇ -secretase site by a membrane associated metalloprotease is a physiological event.
  • This site is located in APP 12 residues away from the lumenal surface of the plasma membrane.
  • Cleavage of the ⁇ -secretase site (28 residues from the plasma membrane's lumenal surface) and the ⁇ -secretase site (in the transmembrane region) results in the 40/42-residue ⁇ -amyloid peptide (A ⁇ ), whose elevated production and accumulation in the brain are the central events in the pathogenesis of Alzheimer's disease (for review, see Selkoe, D. J.
  • Presenilin 1 another membrane protein found in human brain, controls the hydrolysis at the APP ( ⁇ -secretase site and has been postulated to be itself the responsible protease (Wolfe, M. S. et al., Nature 398:513-517 (1999)). Presenilin 1 is expressed as a single chain molecule and its processing by a protease, presenilinase, is required to prevent it from rapid degradation (Thinakaran, G. et al., Neuron 17:181-190 (1996) and Podlisny, M. B., et al., Neurobiol. Dis. 3:325-37 (1997)).
  • inhibitors effective in decreasing amyeloid plaque formation is dependent on the identification of the critical enzyme(s) in the cleavage of APP to yield the 42 amino acid peptide, the A ⁇ 1-42 form of A ⁇ . Although several enzymes have been identified, it has not been possible to produce active enzyme. Without active enzyme, one cannot confirm the substrate specificity, determine the subsite specificity, nor determine the kinetics or critical active site residues, all of which are essential for the design of inhibitors.
  • Memapsin 2 belongs to the aspartic protease family. It is homologous in amino acid sequence to other eukaryotic aspartic proteases and contains motifs specific to that family. These structural similarities predict that memapsin 2 and other eukaryotic aspartic proteases share common catalytic mechanism Davies, D. R., Annu. Rev. Biophys. Chem. 19, 189 (1990). The most successful inhibitors for aspartic proteases are mimics of the transition state of these enzymes.
  • inhibitors have substrate-like structure with the cleaved planar peptide bond between the carbonyl carbon and the amide nitrogen replaced by two tetrahedral atoms, such as hydroxyethylene [—CH(OH)—CH 2 —], which was originally discovered in the structure of pepstatin (Marciniszyn et al., 1976).
  • BBB blood brain barrier
  • the substrate and subsite specificity information was used to design substrate analogs of the natural memapsin 2 substrate that can inhibit the function of memapsin 2.
  • the substrate analogs are based on peptide sequences, shown to be related to the natural peptide substrates for memapsin 2.
  • the substrate analogs contain at least one analog of an amide (peptide) bond which is not capable of being cleaved by memapsin 2.
  • Processes for the synthesis of two substrate analogues including isosteres at the sites of the critical amino acid residues were developed and the substrate analogues, OMR99-1 and OM99-2, were synthesized.
  • OM99-2 is based on an octapeptide Glu-Val-Asn-Leu-Ala-Ala-Glu-Phe (SEQ ID NO:28) with the Leu-Ala peptide bond substituted by a transition-state isostere hydroxyethylene group.
  • the inhibition constant of OM99-2 is 1.6 ⁇ 10 ⁇ 9 M against recombinant pro-memapsin 2. Crystallography of memapsin 2 bound to this inhibitor was used to determine the three dimensional structure of the protein, as well as the importance of the various residues in binding.
  • This information can be used by those skilled in the art to design new inhibitors, using commercially available software programs and techniques familiar to those in organic chemistry and enzymology, to design new inhibitors.
  • the side chains of the inhibitors may be modified to produce stronger interactions (through hydrogen bonding, hydrophobic interaction, charge interaction and/or van der Waal interaction) in order to increase inhibition potency.
  • the residues with minor interactions may be eliminated from the new inhibitor design to decrease the molecular weight of the inhibitor.
  • the side chains with no structural hindrance from the enzyme may be cross-linked to lock in the effective inhibitor conformation. This type of structure also enables the design of peptide surrogates which may effectively fill the binding sites of memapsin 2 yet produce better pharmaceutical properties.
  • the examples demonstrate the production of catalytically active enzyme, design and synthesis of inhibitors, and how the crystal structure was obtained.
  • the examples thereby demonstrate how the methods and materials described herein can be used to screen libraries of compounds for other inhibitors, as well as for design of inhibitors. These inhibitors are useful in the prevention and/or treatment of Alzheimer's disease as mediated by the action of the beta secretase memapsin 2, in cleaving APP.
  • FIG. 1 depicts the plasmid construct of vector pET-11a-memapsin 2-T1 and pET-11a-memapsin 2-T2.
  • the T7 promotor, amino acid sequence from the vector (T7 protein) (SEQ ID NO:3), and the beginning and ending of the memapsin 2 T1 and T2 construct are shown.
  • Construct promemapsin 2-T1 was used in the preparation of protein for crystallization and includes residues 1v-15v which are derived from vector pET-11a.
  • Residues 1p-48p are putative pro-peptide.
  • Residues 1-393 correspond to the mature protease domain and C-terminal extension.
  • the residue numbering of memapsin 2 starts at the aligned N-terminal position of pepsin (FIG. 3).
  • FIGS. 3A and 3B are the chemical structures of memapsin 2 inhibitors, OM99-2 and OM99-1.
  • FIG. 6 is a stereo view of crystal structure of memapsin 2 protease domain with bound OM99-2.
  • the polypeptide backbone of memapsin 2 is shown as a ribbon diagram.
  • the N-lobe and C-lobe are blue and yellow, respectively, except the insertion loops (designated A to G, see FIG. 2) in the C-lobe are magenta and the C-terminal extension is green.
  • the inhibitor bound between the lobes is shown in red.
  • FIG. 8 is a schematic presentation of interaction between OM99-2 and memapsin 2 protease domain.
  • the S 3 ′ and S 4 ′ subsites are not defined.
  • FIG. 9 is a stereo presentation of interactions between inhibitor OM99-2 (orange) and memapsin 2 (light blue). Nitrogen and oxygen atoms are marked blue and red, respectively. Hydrogen bonds are indicated in yellow dotted lines. Memapsin 2 residues which comprise the binding subsites are included. Residues P 4 , P 3 , P 2 , P 1 and P 1 ′ (defined in FIG. 8) of OM99-2 are in an extended conformation. Inhibitor chain turns at residue P2′ which makes a distinct kink at this position. The backbone of P 3 ′ and P4′ directs the inhibitor to exit the active site.
  • FIG. 10 are schematics of the cross linking between P 3 Val and P 1 Leu side chains in the design of new inhibitors for memapsin 2 based on the current crystal structure.
  • R and R′ at positions P 2 and P 1 ′ indicate amino acid side chains.
  • Other structural elements of inhibitor are omitted for clarity.
  • FIG. 11 are schematics of the cross linking between P 4 Glu and P 2 Asn side chains in the design of new inhibitors for memapsin 2 based on the current crystal structure.
  • R at position P 3 indicates amino acid side chain.
  • Other structural elements of inhibitor are omitted for clarity.
  • FIG. 13 is a schematic of the design of two six-membered rings in the inhibitor structure by the addition of atoms A and B.
  • the ring formation involves the P 1 -Leu side chain the the peptide backbone near P 1 , P 2 , and P 3 .
  • the new bonds are in dotted lines.
  • a methyl group can be added to the beta-carbon of P 1 -Leu.
  • Other structural elements of inhibitor are omitted for clarity.
  • Memapsin 2 was cloned and the nucleotide (SEQ ID NO. 1) and predicted amino acid (SEQ ID NO. 2) sequences were determined, as described in Example 1.
  • the cDNA was assembled from the fragments.
  • the nucleotide and the deduced protein sequence are shown in SEQ ID NOs. 1 and 2, respectively.
  • the protein is the same as the aspartic proteinase 2 (ASP2) described in EP 0 855 444 A by SmithKline Beecham Pharmaceuticals, (published Jul. 29, 1998), and later reported by Sinha, et al., Nature 402, 537-540 (Dec. 1999) and Vassar, et al., Science 286, 735-741 (Oct. 22, 1999).
  • Pro-memapsin 2 is homologous to other human aspartic proteases. Based on the alignments, Pro-memapsin 2 contains a pro region, an aspartic protease region, and a trans-membrane region near the C-terminus. The C-terminal domain is over 80 residues long.
  • the active enzyme is memapsin 2 and its pro-enzyme is pro-memapsin 2.
  • the protein is dissolved into 8 M urea/100 mM beta-mercaptoethanol then rapidly diluted into 20 volumes of 20 mM-Tris, pH 9.0, which is then slowly adjusted to pH 8 with 1 M HCl.
  • the refolding solution was then kept at 4° C. for 24 to 48 hours before proceeding with purification.
  • an equal volume of 20 mM Tris, 0.5 mM oxidized/1.25 mM reduced glutathione, pH 9.0 is added to rapidly stirred pro-memapsin 2 in 8 M urea/10 mM beta-mercaptoethanol. The process is repeated three more times with 1 hour intervals.
  • the resulting solution is then dialyzed against sufficient volume of 20 mM Tris base so that the final urea concentration is 0.4 M.
  • the pH of the solution is then slowly adjusted to 8.0 with 1 M HCl.
  • the refolded protein is then further purified by column chromatography, based on molecular weight exclusion, and/or elution using a salt gradient, and analyzed by SDS-PAGE analysis under reduced and non-reduced conditions.
  • memapsin 2 The tissue distribution of the memapsin 2 was determined, as described in Example 2.
  • M2 memapsin 2
  • APP ⁇ -amyloid precursor protein
  • the M2 three-dimensional structure modeled as a type I integral membrane protein.
  • the model suggested that its globular protease unit can hydrolyze a membrane anchored polypeptide at a distance range of 20-30 residues from the membrane surface.
  • APP is a potential substrate and its beta-secretase site, located about 28 residues from the plasma membrane surface, is within in the range for M2 proteolysis.
  • a synthetic peptide derived from this site (SEVKM/DAEFR) (SEQ ID NO:4) was hydrolyzed by M2 pd (modified M2 containing amino acids from Ala ⁇ 8P to Ala 326 ) at the beta-secretase site (marked by /)
  • a second peptide (SEVNL/DAEFR) (SEQ ID NO:5) derived from the APP beta-secretase site and containing the ‘Swedish mutation’ (Mullan, M. el al., Nature Genet. 2:340-342 (1992)), known to elevate the level of alpha-beta production in cells (Citron, M.
  • the kinetic parameters indicate that both presenilin 1 (k cat , 0.67 s ⁇ 1 ; K m , 15.2 mM; k cat /K m , 43.8 s ⁇ 1 M ⁇ 1 ) and native APP peptides (k cat /K m , 39.9 s ⁇ 1 M ⁇ 1 ) are not as good substrates as the Swedish APP peptide (k cat , 2.45 s ⁇ 1 ,K m , 1 mM; k cat /K m , 2450 s ⁇ 1 M ⁇ 1 ).
  • memapsin 2 was transiently expressed in HeLa cells (Lin, X., et al., FASEB J. 7:1070-1080 (1993)), metabolically pulse-labeled with 35 S-Met, then immunoprecipitated with anti-APP antibodies for visualization of APP-generated fragments after SDS-polyacrylamide electrophoresis and imaging.
  • SDS-PAGE patterns of immuno-precipitated APP N ⁇ -fragment (97 kD band) from the conditioned media (2 h) of pulse-chase experiments showed that APP was cleaved by M2.
  • Controls transfected with APP alone and co-transfected with APP and M2 with Bafilomycin A1 added were performed.
  • SDS-PAGE patterns of APP ⁇ C-fragment (12 kD) were immunoprecipitated from the conditioned media of the same experiment as discussed above.
  • Controls transfected with APP alone; co-transfected with APP and M2; co-transfected with APP and M2 with Bafilomycin A1; transfections of Swedish APP; and co-transfections of Swedish APP and M2 were performed.
  • SDS-PAGE gels were also run of immuno-precipitated M2 (70 kD), M2 transfected cells; untransfected HeLa cells after long time film exposure; and endogenous M2 from HEK 293 cells.
  • SDS-PAGE patterns of APP fragments 100 kD betaN-fragment and 95 kD betaN-fragment recovered from conditioned media after immuno-precipitation using antibodies specific for different APP regions indicated that memapsin 2 cleaved APP.
  • M2 processes the beta-secretase site of APP in acidic compartments such as the endosomes.
  • the pulse-labeled cells were lysed and immuno-precipitated by anti-M2 antibodies.
  • a 70 kD M2 band was seen in cells transfected with M2 gene, which has the same mobility as the major band from HEK 293 cells known to express beta-secretase (Citron, M. et al., Nature 260:672-674 (1992)).
  • a very faint band of M2 is also seen, after a long film exposure, in untransfected HeLa cells, indicating a very low level of endogenous M2, which is insufficient to produce betaN- or betaC-fragments without M2 transfection.
  • Antibody alpha-beta 1-17 which specifically recognizes residues 1-17 in alpha-beta peptide, was used to confirm the correct beta-secretase site cleavage. In cells transfected with APP and M2, both beta N- and beta N-fragments are visible using an antibody recognizing the N-terminal region of APP present in both fragments.
  • Antibody Abeta 1-17 recognize the beta N-fragment produced by endogenous beta-secretase in the untransfected cells.
  • betaN-fragment is the product of beta-secretase site cut by M2, which abolished the recognition epitope of alpha-beta 1-17 .
  • M2 pd cleaved its pro peptide (2 sites) and the protease portion (2 sites) during a 16 h incubation after activation (Table 1). Besides the three peptides discussed above, M2 pd also cleaved oxidized bovine insulin B chain and a synthetic peptide Nch. Native proteins were not cleaved by M2 pd .
  • the five human aspartic proteases have homologous amino acid sequences and have similar three-dimensional structures. There are two aspartic residues in the active site and each residue is found within the signature aspartic protease sequence motif, Asp-Thr/Ser-Gly- (SEQ ID NO:8). There are generally two homologous domains within an aspartic protease and the substrate binding site is positioned between these two domains, based on the three-dimensional structures. The substrate binding sites of aspartic proteases generally recognize eight amino acid residues. There are generally four residues on each side of the amide bond which is cleaved by the aspartic protease.
  • each amino acid is involved in the specificity of the substrate/aspartic protease interaction.
  • the side chain of each substrate residue is recognized by regions of the enzyme which are collectively called sub-sites.
  • the generally accepted nomenclature for the protease sub-sites and their corresponding substrate residues are shown below, where the double slash represents the position of bond cleavage.
  • each protease has a very different substrate specificity and breadth of specificity.
  • inhibitors can be designed based on that specificity, which interact with the aspartic protease in a way that prevents natural substrate from being efficiently cleaved.
  • Some aspartic proteases have specificities which can accommodate many different residues in each of the sub-sites for successful hydrolysis.
  • Pepsin and cathepsin D have this type of specificity and are said to have “broad” substrate specificity. When only a very few residues can be recognized at a sub-site, such as in renin, the aspartic protease is said to have a stringent or narrow specificity.
  • aspartic proteases cleave amide bonds by a hydrolytic mechanism. This reaction mechanism involves the attack by a hydroxide ion on the ⁇ -carbon of the amino acid. Protonation must occur at the other atom attached to the ⁇ -carbon through the bond that is to be cleaved.
  • Transition state theory indicates that it is the transition state intermediate of the reaction which the enzyme catalyzes for which the enzyme has its highest affinity. It is the transition state structure, not the ground state structure, of the substrate which will have the highest affinity for its given enzyme.
  • the transition state for the hydrolysis of an amide bond is tetrahedral while the ground state structure is planar.
  • a typical transition-state isostere of aspartic protease is —CH(OH)—CH 2 —, as was first discovered in pepstatin by Marciniszyn et al. (1976).
  • the transition-state analogue principles have been successfully applied to inhibitor drugs for human immunodeficiency virus protease, an aspartic protease. Many of these are currently in clinical use.
  • Substrate analog compositions are generally of the general formula X-L 4 -P 4 -L 3 -P 3 -L 2 -P 2 -L 1 -P 1 -L 0 -P 1 ′-L 1 ′-P 2 ′-L 2 ′-P 3 ′-L 3 ′-P 4 ′-L 4 ′-Y.
  • the substrate analog compositions are analogs of small peptide molecules. Their basic structure is derived from peptide sequences that were determined through structure/function studies. It is understood that positions represented by P x represent the substrate specificity position relative to the cleavage site which is represented by an -L 0 -. The positions of the compositions represented by L x represent the linking regions between each substrate specificity position, P X .
  • a P X -L x pair would represent a single amino acid of the peptide which is to be cleaved.
  • each P x part of the formula refers to the ⁇ -carbon and side chain functional group of each would be amino acid.
  • the P x portion of an P x L x pair for alanine represents HC—CH 3 .
  • the general formula representing the P x portion of the general composition is —R 1 CR 3 —.
  • R 1 can be either CH 3 (side chain of alanine), CH(CH 3 ) 2 (side chain of valine), CH 2 CH(CH 3 ) 2 (side chain of leucine), (CH 3 )CH(CH 2 CH 3 ) (side chain of isoleucine), CH 2 (Indole) (side chain of tryptophan), CH 2 (Benzene) (side chain of phenylalanine), CH 2 CH 2 SCH 3 (side chain of methionine), H (side chain of glycine), CH 2 OH (side chain of serine), CHOHCH 3 (side chain of threonine), CH 2 (Phenol) (side chain of tyrosine), CH 2 SH (side chain of cysteine), CH 2 CH 2 CONH 2 (side chain of glutamine), CH 2 CONH 2 (side chain of asparagine), CH 2 CH 2 CH 2 CH 2 NH 2 (side chain of lysine), CH 2 CH 2 CH 2 NHC(NH)(NH 2 )
  • R 3 is a single H.
  • R 3 can be alkenyl, alkynal, alkenyloxy, and alkynyloxy groups that allow binding to memapsin 2.
  • alkenyl, alkynyl, alkenyloxy and alkynyloxy groups have from 2 to 40 carbons, and more preferably from 2 to 20 carbons, from 2 to 10 carbons, or from 2 to 3 carbons., and functional natural and non-natural derivatives or synthetic substitutions of these.
  • L x portion of the P X -L x pair represents the atoms linking the P x regions together.
  • L x represents the ⁇ -carbon attached to the amino portion of what would be the next amino acid in the chain.
  • L x would be represented by —CO—NH—.
  • the general formula for L x is represented by R 2 .
  • R 2 can be CO—HN (amide), CH(OH)(CH 2 ) (hydroxyethylene), CH(OH)CH(OH) (dihydroxyethylene), CH(OH)CH 2 NH (hydroxyethylamine), PO(OH)CH 2 (phosphinate), CH 2 NH, (reduced amide). It is understood that more than one L- maybe an isostere as long as the substrate analog functions to inhibit aspartic protease function.
  • Ls which are not isosteres may either be an amide bond or mimetic of an amide bond that is non-hydrolyzable.
  • X and Y represent molecules which are not typically involved in the recognition by the aspartic protease recognition site, but which do not interfere with recognition. It is preferred that these molecules confer resistance to the degradation of the substrate analog.
  • Preferred examples would be amino acids coupled to the substrate analog through a non-hydrolyzable bond.
  • Other preferred compounds would be capping agents.
  • Still other preferred compounds would be compounds which could be used in the purification of the substrate analogs such as biotin.
  • alkyl refers to substituted or unsubstituted straight, branched or cyclic alkyl groups
  • alkoxyl refers to substituted or unsubstituted straight, branched or cyclic alkoxy.
  • alkyl and alkoxy groups have from 1 to 40 carbons, and more preferably from 1 to 20 carbons, from 1 to 10 carbons, or from 1 to 3 carbons.
  • alkenyl refers to substituted or unsubstituted straight chain or branched alkenyl groups
  • alkynyl refers to substituted or unsubstituted straight chain or branched alkynyl groups
  • alkenyloxy refers to substituted or unsubstituted straight chain or branched alkenyloxy
  • alkynyloxy refers to substituted or unsubstituted straight chain or branched alkynyloxy.
  • alkenyl, alkynyl, alkenyloxy and alkynyloxy groups have from 2 to 40 carbons, and more preferably from 2 to 20 carbons, from 2 to 10 carbons, or from 2 to 3 carbons.
  • alkaryl refers to an alkyl group that has an aryl substituent
  • aralkyl refers to an aryl group that has an alkyl substituent
  • heterocyclic-alkyl refers to a heterocyclic group with an alkyl substituent
  • alkyl-heterocyclic refers to an alkyl group that has a heterocyclic substituent.
  • the substituents for alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, and alkynyloxy groups can be halogen, cyano, amino, thio, carboxy, ester, ether, thioether, carboxamide, hydroxy, or mercapto Further, the groups can optionally have one or more methylene groups replaced with a heteroatom, such as O, NH or S.
  • the primary specificity site for a memapsin 2 substrate is subsite position, P 1 ′.
  • P 1 ′ The primary specificity site for a memapsin 2 substrate is subsite position, P 1 ′.
  • P 1 ′ This means that the most important determinant for substrate specificity in memapsin 2 is the amino acid, S1′.
  • P 1 ′ must contain a small side chain for memapsin 2 to recognize the substrate.
  • Preferred embodiments are substrate analogs where R 1 of the P 1 ′ position is either H (side chain of glycine), CH 3 (side chain of alanine), CH 2 OH (side chain of serine), or CH 2 OOH (side chain of aspartic acid).
  • Embodiments that have an R1 structurally smaller than CH 3 (side chain of alanine) or CH 2 OH (side chain of serine) are also preferred.
  • At least two of the remaining seven positions, P 4 , P 3 , P 2 , P 1 , P 2 ′, P 3 ′, and P 4 ′, must have an R 1 which is made up of a hydrophobic residue. It is preferred that there are at least three hydrophobic residues in the remaining seven positions, P 4 , P 3 , P 2 , P 1 , P 2 ′, P 3 ′, and P 4 ′.
  • R 1 groups for the positions that contain a hydrophobic group are CH 3 (side chain of alanine), CH(CH 3 ) 2 (side chain of valine), CH 2 CH(CH 3 ) 2 (side chain of leucine), (CH 3 )CH(CH 2 CH 3 ) (side chain of isoleucine), CH 2 (INDOLE) (side chain of tryptophan), CH 2 (Benzene) (side chain of phenylalanine), CH 2 CH 2 SCH 3 (side chain of methionine) CH 2 (Phenol) (side chain of tyrosine). It is more preferred that the hydrophobic group be a large hydrophobic group.
  • R 1 s which contain large hydrophobic groups are CH(CH 3 ) 2 (side chain of valine), CH 2 CH(CH 3 ) 2 (side chain of leucine), (CH 3 )CH(CH 2 CH 3 ) (side chain of isoleucine), CH 2 (Indole) (side chain of tryptophan), CH 2 (Benzene) (side chain of phenylalanine), CH 2 CH 2 SCH 3 (side chain of methionine) CH 2 (Phenol) (side chain of tyrosine).
  • positions with a hydrophobic R 1 are CH(CH 3 ) 2 (side chain of valine), CH 2 CH(CH 3 ) 2 (side chain of leucine), CH 2 (Benzene) (side chain of phenylalanine), CH 2 CH 2 SCH 3 (side chain of methionine), or CH 2 (Phenol) (side chain of tyrosine).
  • a substrate analog could have X-P 2 -L 1 -P 1 -L 0 -P 1 ′-L 1 ′-P 2 ′-L 2 ′-P 3 ′-L 3 ′-Y or it could have X-L 1 -P 1 -L 0 -P 1 ′-L 1 ′-P 2 ′-L 2 ′ -P 3 ′-L 3 ′-P 4 ′-L 4 ′-Y.
  • Preferred substrate analogs are analogs having the sequences disclosed in Table 1, with the non-hydrolyzable analog between P1 and P1′.
  • Combinatorial chemistry includes but is not limited to all methods for isolating molecules that are capable of binding either a small molecule or another macromolecule.
  • Proteins, oligonucleotides, and polysaccharides are examples of macromolecules.
  • oligonucleotide molecules with a given function, catalytic or ligand-binding can be isolated from a complex mixture of random oligonucleotides in what has been referred to as “in vitro genetics” (Szostak, TIBS 19:89, 1992).
  • isolating proteins either have de novo activity or a modifed activity.
  • phage display libraries have been used for a number of years.
  • a preferred method for isolating proteins that have a given function is described by Roberts and Szostak (Roberts R. W. and Szostak J. W. Proc. Natl. Acad. Sci. USA, 94(23)12997-302 (1997).
  • Another preferred method for combinatorial methods designed to isolate peptides is described in Cohen et al. (Cohen B. A., et al., Proc. Natl. Acad. Sci. USA 95(24): 14272-7 (1998)).
  • This method utilizes a modified two-hybrid technology.
  • Yeast two-hybrid systems are useful for the detection and analysis of protein:protein interactions.
  • the two-hybrid system initially described in the yeast Saccharomyces cerevisiae, is a powerful molecular genetic technique for identifying new regulatory molecules, specific to the protein of interest (Fields and Song, Nature 340:245-6 (1989)).
  • Cohen et al. modifed this technology so that novel interactions between synthetic or engineered peptide sequences could be identified which bind a molecule of choice.
  • the benefit of this type of technology is that the selection is done in an intracellular environment.
  • the method utilizes a library of peptide molecules that attach to an acidic activation domain.
  • a peptide of choice for example an extracellular portion of memapsin 2 is attached to a DNA binding domain of a transcriptional activation protein, such as Gal 4.
  • a transcriptional activation protein such as Gal 4.
  • Another way to isolate inhibitors is through rational design. This is achieved through structural information and computer modeling.
  • Computer modeling technology allows visualization of the three-dimensional atomic structure of a selected molecule and the rational design of new compounds that will interact with the molecule.
  • the three-dimensional construct typically depends on data from x-ray crystallographic analyses or NMR imaging of the selected molecule.
  • the molecular dynamics require force field data.
  • the computer graphics systems enable prediction of how a new compound will link to the target molecule and allow experimental manipulation of the structures of the compound and target molecule to perfect binding specificity.
  • Another good example is based on the three-dimensional structure of a calcineurin/FKBP12/FK506 complex determined using high resolution X-ray crystallography to obtain the shape and structure of both the calcineurin active site binding pocket and the auxiliary FKBP12/FK506 binding pocket (U.S. Pat. No. 5,978,740 to Armistead).
  • researchers can have a good understanding of the association of natural ligands or substrates with the binding pockets of their corresponding receptors or enzymes and are thus able to design and make effective inhibitors.
  • Chem. Soc. 111, 1082-1090 Other computer programs that screen and graphically depict chemicals are available from companies such as BioDesign, Inc., Pasadena, Calif., Allelix, Inc, Mississauga, Ontario, Canada, and Hypercube, Inc., Cambridge, Ontario.
  • potential inhibitors are typically identified using high throughput assays, in which enzyme, substrate (preferably a chromogenic substrate) and potential inhibitor (usually screened across a range of concentrations) are mixed and the extent of cleavage of substrate determined.
  • Potentially useful inhibitors are those which decrease the amount of cleavage.
  • Inhibitors can be used in the diagnosis and treatment and/or prevention of Alzheimer's disease and conditions associated therewith, such as elevated levels of the forty-two amino acid peptide cleavage product, and the accumulation of the peptide in amyeloid plaques.
  • the substrate analogs can be used as reagents for specifically binding to memapsin 2 or memapsin 2 analogs and for aiding in memapsin 2 isolation and purification or characterization, as described in the examples.
  • the inhibitors and purified recombinant enzyme can be used in screens for those individuals more genetically prone to develop Alzheimer's disease.
  • Recombinant human memapsin 2 cleaves a substrate with the sequence LVNM/AEGD (SEQ ID NO:9).
  • This sequence is the in vivo processing site sequence of human presenilins.
  • Both presenilin 1 and presenilin 2 are integral membrane proteins. They are processed by protease cleavage, which removes the N terminal sequence from the unprocessed form. Once processed, presenilin forms a two-chain heterodimer (Capell et al., J. Biol. Chem. 273, 3205 (1998); Thinakaran et al., Neurobiol. Dis. 4, 438 (1998); Yu et al., Neurosci Lett.
  • presenilin therefore enhances the progression of Alzheimer's disease. This is supported by the observation that in the absence of presenilin gene, the production of alpha-beta42 peptide is lowered (De Strooper et al., Nature 391, 387 (1998)). Since unprocessed presenilin is degraded quickly, the processed, heterodimeric presenilin must be responsible for the accumulation of alpha-beta42 leading to Alzheimer's disease. The processing of presenilin by memapsin 2 would enhance the production of alpha-beta42 and therefore, further the progress of Alzheimer's disease.
  • memapsin 2 inhibitor that crosses the blood brain barrier can be used to decrease the likelihood of developing or slow the progression of Alzheimer's disease which is mediated by deposition of alpha-beta42. Since memapsin 2 cleaves APP at the beta cleavage site, prevention of APP cleavage at the beta cleavage site will prevent the build up of alpha-beta42.
  • the catalytically active memapsin 2 or fragments thereof including the active site defined by the presence of two catalytic aspartic residues and substrate binding cleft can be used to induce an immune response to the memapsin 2.
  • the memapsin 2 is administered in an amount effective to elicit blocking antibodies, i.e., antibodies which prevent cleavage of the naturally occurring substrate of memapsin 2 in the brain.
  • An unmodified vaccine may be useful in the prevention and treatment of Alzheimer's disease.
  • the response to the vaccine may be influenced by its composition, such as inclusion of an adjuvant, viral proteins from production of the recombinant enzyme, and/or mode of administration (amount, site of administration, frequency of administration, etc).
  • the inhibitors will typically be administered orally or by injection. Oral administration is preferred. Alternatively, other formulations can be used for delivery by pulmonary, mucosal or transdermal routes.
  • the inhibitor will usually be administered in combination with a pharmaceutically acceptable carrier.
  • Pharmaceutical carriers are known to those skilled in the art. The appropriate carrier will typically be selected based on the mode of administration.
  • Pharmaceutical compositions may also include one or more active ingredients such as antimicrobial agents, antiinflammatory agents, and analgesics.
  • Preparations for parenteral administration or administration by injection include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
  • non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
  • Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
  • Preferred parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils.
  • Intravenous vehicles include fluid and nutrient replenishers, and electrolyte replenishers (such as those based on Ringer's dextrose).
  • Formulations for topical (including application to a mucosal surface, including the mouth, pulmonary, nasal, vaginal or rectal) administration may include ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Formulations for these applications are known. For example, a number of pulmonary formulations have been developed, typically using spray drying to formulate a powder having particles with an aerodynanmic diameter of between one and three microns, consisting of drug or drug in combination with polymer and/or surfactant.
  • Peptides as described herein can also be administered as a pharmaceutically acceptable acid- or base- addition salt, formed by reaction with inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and phosphoric acid, and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, and fumaric acid, or by reaction with an inorganic base such as sodium hydroxide, ammonium hydroxide, potassium hydroxide, and organic bases such as mono-, di-, trialkyl and aryl amines and substituted ethanolamines.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and phosphoric acid
  • organic acids such as formic acid, acetic acid, prop
  • Dosing is dependent on severity and responsiveness of the condition to be treated, but will normally be one or more doses per day, with course of treatment lasting from several days to several months or until the attending physician determines no further benefit will be obtained. Persons of ordinary skill can determine optimum dosages, dosing methodologies and repetition rates.
  • the dosage ranges are those large enough to produce the desired effect in which the symptoms of the memapsin 2 mediated disorder are alleviated (typically characterized by a decrease in size and/or number of amyloid plaque, or by a failure to increase in size or quantity), or in which cleavage of the alpha-beta42 peptide is decreased.
  • the dosage can be adjusted by the individual physician in the event of any counterindications.
  • the Human Pancreas Marathon-Ready cDNA (Clontech), which is double-strand cDNA obtained by reverse-transcription, primer addition, and second strand synthesize of mRNA from human tissues, was used as template or PCR amplification.
  • An adapter primer (AP1) and a nested adapter primer (AP2) were used for 5′- and 3′-RACE PCR.
  • primers AP1 and NHASPR1 were used for PCR the 5′-region of the memapsin 2 cDNA.
  • Primers for the 3′-end of the cDNA are NHASPF2 and AP1.
  • the middle of the cDNA was amplified by primers NHASPF1 and NHASPR2.
  • NHASPF1 GGTAAGCATCCCCCATGGCCCCAACGTC (SEQ ID NO:10)
  • NHASPR1 GACGTTGGGGCCATGGGGGATGCTTACC
  • NHASPF2 ACGTTGTCTTGATCGGGCCCGAAAACGAATTGG
  • NHASPR2 CCAATTCGTTTTCGGGCCCGATCAAAGACAACG
  • AP1 CCATCCTAATACGACTCACTATAGGGC (SEQ ID NO:14)
  • AP2 ACTCACTATAGGGCTCGAGCGGC (SEQ ID NO:15)
  • Memapsin 2 was also cloned from a human pancreas library (Quick-Screen Human cDNA Library Panel) contained in lambda-gt10 and lambda-gt11 vectors.
  • the sequence of the primers used was: GT10FWD: CTTTTGAGCAAGTTCAGCCTGGTTAA (SEQ ID NO:16), GT10REV: GAGGTGGCTTATGAGTATTTCTTCCAGGGTA (SEQ ID NO:17), GT11FWD: TGGCGACGACTCCTGGAGCCCG (SEQ ID NO:18), GT11REV: TGACACCAGACCAACTGGTAATGG (SEQ ID NO:19).
  • memapsin 2 cDNA was amplified directly from the human pancreatic lambda-gt10 and lambda-gt11 libraries.
  • the sequence of the primers was: PASPN1: catatgGCGGGAGTGCTGCCTGCCCAC (SEQ ID NO:20) and NHASPC1: ggatccTCACTTCAGCAGGGAGATGTCATCAGCAAAGT (SEQ ID NO:21).
  • Pro-memapsin 2 is homologous to other human aspartic proteases. Based on the alignments, Pro-memapsin 2 contains a pro region, an aspartic protease region, and a trans-membrane region near the C-terminus. The active enzyme is memapsin 2 and its pro-enzyme is pro-memapsin 2.
  • the pro-memapsin 2 was PCR amplified and cloned into the BamHI site of a pET11a vector.
  • the resulting vector expresses pro-memapsin 2 having a sequence from Ala-8p to Ala 326.
  • FIG. 1 shows the construction of two expression vectors, pET11-memapsin 2-T1 (hereafter T1) and pET11 -memapsin 2-T2 (hereafter T2).
  • T1 pET11-memapsin 2-T1
  • T2 pET11 -memapsin 2-T2
  • the two recombinant pro-memapsin 2s have different C-terminal lengths.
  • Clone T1 ends at Thr-454 and clone T2 ends at Ala-419.
  • the T1 construct contains a C-terminal extension from the T2 construct but does not express any of the predicted transmembrane domain.
  • T1 and T2 expression vectors were separately transfected into E. coli strain BL21(DE3).
  • the procedures for the culture of transfected bacteria, induction for synthesis of recombinant proteins and the recovery and washing of inclusion bodies containing recombinant proteins are essentially as previously described (Lin et al., 1994).
  • Pro-memapsin 2 in 8 M urea/100 mM beta-mercaptoethanol with OD 280 nm ⁇ 5 was rapidly diluted into 20 volumes of 20 mM-Tris, pH 9.0. The solution was slowly adjusted into pH 8 with 1 M HCl. The refolding solution was then kept at 4° C. for 24 to 48 hours before proceeding with purification.
  • Inclusion bodies are dissolved in 8 M urea, 0.1 M Tris, 1 mM Glycine, 1 mM EDTA, 100 mM beta-mercaptoethanol, pH 10.0.
  • the OD 280 of the inclusion bodies are adjusted to 5.0 with the 8 M urea solution without beta-mercaptoethanol.
  • the final solution contains the following reducing reagents: 10 mM beta-mercaptoethanol, 10 mM DTT (Dithiothreitol), 1 mM reduced glutathion, and 0.1 M oxidized glutathion.
  • the final pH of the solution is 10.0.
  • the refolding procedures are critical to obtain an enzymically active preparation which can be used for studies of subsite specificity of M2, to analyze inhibition potency of M2 inhibitors, to screen for inhibitors using either random structural libraries or existing collections of compound libraries, to produce crystals for crystallography studies of M2 structures, and to produce monoclonal or polyclonal antibodies of M2.
  • the refolded material is concentrated by ultrafiltration, and separated on a SEPHACRYLTM S-300 column equilibrated with 20 mM Tris.HCl, 0.4 M urea, pH 8.0.
  • the refolded peak (second peak) from the S-300 column can be further purified with a FPLC RESOURCE-QTM column, which is equilibrated with 20 mM Tris-HCl, 0.4 M urea, pH 8.0.
  • the enzyme is eluted from the column with a linear gradient of NaCl.
  • the refolded peak from S-300 can also be activated before further purification.
  • the fractions are mixed with equal volume 0.2 M Sodium Acetate, 70% glycerol, pH 4.0. The mixture is incubated at 22° C. for 18 hr, and then dialyzed twice against 20 volumes of 20 mM Bis-Tris, 0.4 M urea, pH 6.0. The dialyzed materials are then further purified on a FPLC RESOURCE-QTM column equilibrated with 20 Bis-Tris, 0.4 M urea, pH 6.0. The enzyme is eluted with a linear gradient of NaCl.
  • fractions 6 and 7 contained most of the active proteins, which was consistent with the first FPLC peak containing the active protein.
  • the main peak was coupled to a shoulder peak, and was present with repeated purification with the same RESOURCETM Q column.
  • the main shoulder peaks were identified as active pro-memapsin 2 that exist in different conformations under these conditions.
  • oxidized ⁇ -chain of bovine insulin and two different synthetic peptides were used as substrates for memapsin 2 to determine the extent of other hydrolysis sites. These reactions were carried out by auto-activated pro-memapsin 2 in 0.1 M sodium acetate, pH 4.0, which was then incubated with the peptides. The hydrolytic products were subjected to HPLC on a reversed phase C-18 column and the eluent peaks were subjected to electrospray mass spectrometry for the determination of the molecular weight of the fragments. Two hydrolytic sites were identified on oxidized insulin B-chain (Table 1). Three hydrolytic sites were identified from peptide NCH-gamma.
  • K m and k cat values for presenilin 1 and Swedish APP peptides were measured by steady-state kinetics
  • the individual K m and k cat values for APP peptide could not be measured accurately by standard methods, so its k cat /K m value was measured by competitive hydrolysis of mixed substrates against presenilin 1 peptide (Fersht, A. “Enzyme Structure and Mechanism”, 2 nd Ed., W.H. Freeman and Company, New York. (1985)).
  • FIGS. 2A and 2B The results are shown in FIGS. 2A and 2B.
  • the conversion of pro-M pd at pH 4.0 to smaller fragments was shown by SDS-polyacrylamide electrophoresis.
  • the difference in migration between pro-M2 pd and converted enzyme is evident in a mixture of the two.
  • FIG. 2A is a graph of the initial rate of hydrolysis of synthetic peptide swAPP (see Table 1) by M2 pd at different pH.
  • FIG. 2B is a graph of the relative k cat /K m values for steady-state kinetic of hydrolysis of peptide substrates by M2 pd .
  • PM2 cDNA was cloned into the EcoRV site of vector pSecTag A (Invitrogen).
  • Human APP cDNA was PCR amplified from human placenta 8-gt11 library (Clontech) and cloned into the NheI and XbaI sites of pSecTag A.
  • the procedure for transfection into HeLa cells and vaccinia virus infection for T7-based expression are essentially the same as described by Lin, X., FASEB J. 7:1070-1080 (1993).
  • Transfected cells were metabolically labeled with 200 microCi 35 S methionine and cysteine (TransLabel; ICN) in 0.5 ml of serum-free/methionine-free media for 30 min, rinsed with 1 ml media, and replaced with 2 ml DMEM/10% FCS.
  • ICN microCi 35 S methionine and cysteine
  • Bafilomycin Al was included in the media (Perez, R. G., et al., J Biol Chem 271:9100-9107 (1996)).
  • HeLa cells transfected with APP or M2 in 4-well chamber slides were fixed with acetone for 10 min and permeabilized in 0.2% Triton X-100 in PBS for 6 min.
  • polyclonal goat anti-pro-M 2 pd antibodies were purified on DEAE-sepharose 6B and affinity purified against recombinant pro-M2 pd immobilized on Affigel (BioRad).
  • Purified anti-pro-M2 pd antibodies were conjugated to Alexa568 (Molecular Probes) according to the manufacturer's protocol. Fixed cells were incubated overnight with a 1:100 dilution of antibody in PBS containing 0.1% BSA and washed 4 times with PBS.
  • Antibody A ⁇ 1-17 (described above) and antibody A ⁇ 17-42 , which recognizes the first 26 residues following the beta-secretase cleavage site (Chemicon). After 4 PBS washes, the cells were incubated overnight with an anti-mouse FITC conjugate at a dilution of 1:200. Cells were mounted in Prolong anti-fade reagent (Molecular Probes) and visualized on a Leica TCS confocal laser scanning microscope.
  • Ala was selected for P1′ mainly because its hydophobicity over Ser and Asp is favored for the penetration of the blood-brain barrier, a requirement for the design of a memapsin 2 inhibitor drug for treating Alzheimer's disease. Therefore, inhibitors were designed to place a transition-state analogue isostere between Leu and Ala (shown as Leu*Ala, where * represents the transition-state isostere, —CH(OH)—CH 2 —) and the subsite P4, P3, P2, P2′, P3′ and P4′ are filled with the beta-secretase site sequence of the Swedish mutant from the beta-amyloid protein.
  • inhibitors OM99-1 Val-Asn-Leu*Ala-Ala-Glu-Phe (SEQ. ID NO.27)
  • OM99-2 Glu-Val-Asn-Leu*Ala-Ala-Glu-Phe (SEQ. ID NO.28)
  • Leu-Ala dipeptide isostere for the M 2 -inhibitor was prepared from L-leucine. As shown in Scheme 1, L-leucine was protected as its BOC-derivative 2 by treatment with BOC 2 0 in the presence of 10% NaOH in diethyl ether for 12 h. Boc-leucine 2 was then converted to Weinreb amide 3 by treatment with isobutyl chcloroformate and N-methylpiperidine followed by treatment of the resulting mixed anhydride with N 2 ,O-dimethylhydroxylamine
  • the epimeric cis-lactone was removed by column chromatography over silica gel using a mixture (3:1) of ethyl acetate and hexane as the solvent system.
  • the stereochemical assignment of alkylated lactone 8 was made based on extensive 1 H-NMR NOE experiments.
  • Aqueous lithium hydroxide promoted hydrolysis of the lactone 8 followed by protection of the gamma-hydroxyl group with tert-butyldimetlhylsilyl chloride in the presence of imidazole and dimethylaminopyridine in dimethylformamide afforded the acid 9 in 90% yield after standard work-up and chromatography.
  • N,O-dimetliylhydroxyamine hydrochloride 5.52 g, 56.6 mmol
  • -methylpiperidine 6.9 mL, 56.6 mmol
  • N-(tert-butyloxycarbonyl)-L-leucine (1) (11.9 g, 51.4 mmol) was dissolved in a mixture of THF (45 mL) and dichloromethane (180 mL) under N 2 atmosphere. The resulting solution was cooled to ⁇ 20° C.
  • Enzyme activity was measured as described above, but with the addition of either OM99-1 or OM99-2.
  • OM99-1 inhibited recombinant memapsin 2 as shown in FIG. 5A.
  • the Ki calculated is 3 ⁇ 10 ⁇ 8 M.
  • the substrate used was a synthetic fluorogenic peptide substrate.
  • the inhibition of OM99-2 on recombinant memapsin 2 was measured using the same fluorogenic substrate.
  • the Ki value was determined to be 9.58 ⁇ 10 ⁇ 9 M, as shown in FIG. 5B.
  • memapsin 2 About 50 mg was purified as described in Example 3. For optimal crystal growth, memapsin 2 must be highly purified. Memapsin 2 was over-expressed from vector pET11a-M2pd. This memapsin 2 is the zymogen domain which includes the pro and catalytic domains to the end of the C-terminal extension but does not include the transmembrane and the intracellular domains. The vector was transfected into E. coli BL21 (DE3) and plated onto ZB agar containing 50 mg/liter ampicillin.
  • a single colony was picked to inoculate 100 ml of liquid ZB containing 5 mg ampicillin and cultured at 30° C., for 18 hours, with shaking at 220 RPM. Aliquots of approximately 15 ml of the overnight culture were used to inoculate each 1 liter of LB containing 50 mg of ampicillin. Cultures were grown at 37° C., with shaking at 180 RPM, until an optical density at 600 nm near 0.8 was attained. At that time, expression was induced by addition of 119 mg of IPTG to each liter of culture. Incubation was continued for 3 additional hours post-induction.
  • Bacteria were harvested, suspended in 50 mM Tris, 150 mM NaCl, pH 7.5 (TN buffer), and lysed by incubation with 6 mg lysozyme for 30 minutes, followed by freezing for 18 hours at ⁇ 20° C. Lysate was thawed and made to 1 mM MgCl 2 then 1000 Kunitz units of DNAse were added with stirring, and incubated for 30 min. Volume was expanded to 500 ml with TN containing 0.1% Triton X-100 (TNT buffer) and lysate stirred for 30 minutes.
  • TNT buffer Triton X-100
  • Insoluble inclusion bodies containing greater than 90% memapsin 2 protein were pelleted by centrifugation, and washed by resuspension in TNT with stirring for 1-2 hours. Following three additional TNT washes, the memapsin 2 inclusion bodies were dissolved in 40 ml of 8 M urea, 1 mM EDTA, 1 mM glycine, 100 mM Tris base, 100 mM beta-mercaptoethanlol (8 M urea buffer). Optical density at 280 nm was measured, and volume expanded with 8 M urea buffer to achieve final O.D.
  • This memapsin 2 solution was allowed to stand at 4° C. for 2-3 weeks.
  • the total volume of approximately 16 liters was concentrated to 40 mls using ultra-filtration (Millipore) and stir-cells (Amicon), and centrifuged at 140,000 ⁇ g at 30 minutes in a rotor pre-equilbrated to 4° C.
  • the recovered supernatant was applied to a 2.5 ⁇ 100 cm column of S-300 equilibrated in 0.4 M urea, 20 mM Tris-HCl, pH 8.0, and eluted with the same buffer at 30 ml/hour.
  • the active fraction of memapsin 2 was pooled and further purified in a FPLC using a 1 ml Resource-Q (Pharmacia) column. Sample was filtered, and applied to the Resource-Q column equilibrated in 0.4 M urea, 50 mM Tris-HCl, pH 8.0. Sample was eluted with a gradient of 0-1 M NaCl in the same buffer, over 30 ml at 2 ml/min. The eluents containing memapsin 2 appeared near 0.4 M NaCl which was pooled for crystallization procedure at a concentration near 5 mg/ml.
  • OM99-2 is equivalent to eight amino-acid residues (including subsites S4, S3, S2, S1 S1′, S2′, S3′ and S4′ in a sequence EVNLAAEF) with the substitution of the peptide bond between the S1 and S1′ (L-A) by a transition-state isostere hydroxyethylene.
  • Purified M2 was concentrated and mixed with 10 fold excessive molar amount of inhibitor. The mixture was incubated at room temperature for 2-3 hours to optimize the inhibitor binding. The crystallization trial was conducted at 20° C. using the hanging drop vapor diffusion procedure.
  • a systemic search with various crystallization conditions was conducted to find the optimum crystallization conditions for memapsin 2/OM99-2 inhibitor complex.
  • a coarse screen aimed at covering a wide range of potential conditions were carried out using the Sparse Matrix Crystallization Screen Kits purchased from Hampton Research. Protein concentration and temperature were used as additional variables. Conditions giving promising (micro) crystals were subsequently used as starting points for optimization. using fine grids of pH, precipitants concentration etc.
  • the crystal structure obtained from these data has the potential to reach atomic solution, i.e., the three-dimensional positions of atoms and chemical bonds in the inhibitor and in memapsin 2 can be deduced.
  • memapsin 2 sequence is homologous with other mammalian aspartic proteases, e.g., pepsin or cathepsin D, it is predicted that the three dimensional structures of memapsin 2 will be similar (but not identical) to their structures. Therefore, in the determination of x-ray structure from the diffraction data obtained from the current crystal, it is likely the solution of the phase can be obtained from the molecular replacement method using the known crystal structure of aspartic proteases as the search model.
  • Diffraction data were measured on a Raxis-IV image plate with a Rigaku X-ray generator, processed with the HKL program package [Z. Otwinowski, W. Minor, Methods Enzymol. 276, 307 (1997)]
  • a single crystal of approximately 0.4 ⁇ 0.4 ⁇ 0.2 mm 3 in size was treated with a cryo-protection solution of 25% PEG8000, 20% glycerol, 0.1 M sodium-cacodylate pH 6.6, and 0.2 M (NH 14 ) 2 SO 4 and then flash-cooled with liquid nitrogen to about ⁇ 180° C. for data collection. Diffraction was observed to at least 1.9 ⁇ .
  • the crystal form belongs to space group P2 1 , with two memapsin 2/OM99-2 complexes per crystallographic asymmetric unit and 56% solvent content.
  • the bilobal structure of memapsin 2 (FIG. 7) is characteristic of aspartic proteases (Tang, J., et al., Nature 271, 618-621 (1978)) with the conserved folding of the globular core.
  • the substrate binding cleft, where the inhibitor is bound (FIG. 7), is located between the two lobes.
  • a pseudo two-fold symmetry between the N- (residues 1-180) and C- (residues 181-385) lobes (FIG. 7), which share 61 superimposable atoms with an overall 2.3 ⁇ rms deviation using a 4 ⁇ cutoff.
  • the corresponding numbers for pepsin are 67 atoms and 2.2 ⁇ .
  • Active-site Asp 32 and Asp28 and the surrounding hydrogen-bond network are located in the center of the cleft (FIG. 7) and are conserved with the typical active-site conformation (Davies, D. R., Annu. Rev. Biophys. Chem. 19, 189 (1990)).
  • the active site carboxyls are, however, not co-planar and the degree of which (50°) exceeds those observed previously.
  • the latter contains a beta-strand that paired with part of the C-terminal extension G.
  • a six-residue deletion occurs at position 329 on a loop facing the flap on the opposite side of the active-site cleft, resulting in an apparently more accessible cleft.
  • Most of the C-terminal extension (residues 359-393) is in highly ordered structure.
  • Residues 369-376 form a beta structure with 7 hydrogen bonds to strand 293-299, while residues 378-383 form a helix (FIGS. 7 and 8)
  • Two disulfide pairs (residues 155/359 and 217/382) unique to memapsin 2 fasten both ends of the extension region to the C-lobe.
  • the protease S 4 subsite is mostly hydrophilic and open to solvent.
  • the position of inhibitor P 4 Glu side chain is defined by hydrogen bonds to Gly 11 and to P 2 Asn (FIG. 9) and the nearby sidechains of Arg 235 and Arg 307 , which explains why the absence of this residue from OM99-2 cause a 10-fold increase in K i .
  • the protease S 2 subsite is relatively hydrophilic and open to solvent.
  • Inhibitor P 2 Asn side chain has hydrogen bonds to P 4 Glu and Arg 235 .
  • the relatively small S 2 residues Ser 325 and Ser 327 may fit a side chain larger than Asn.
  • Memapsin 2 S 1 and S 3 subsites which consist mostly of hydrophobic residues, have conformations very different from pepsin due to the deletion of pepsin helix h H2 (Dealwis, et al., (1994)).
  • the inhibitor side chains of P 3 Val and P 1 Leu are closely packed against each other and have substantial hydrophobic contacts with the enzyme (FIG. 9), especially P 3 interacts with Tyr 71 and Phe 108 .
  • the P 2 and P1 residues are Lys and Met respectively.
  • inhibitor drugs normally post a size limit under 800 daltons. In the case of memapsin 2 inhibitors, this requirement may even be more stringent due to the need for the drugs to penetrate the blood-brain barrier [Kearney and Aweeka, (1999)].
  • well defined subsite structures spending P 4 to P 2 ′ provide sufficient template areas for rational design of such drugs.
  • the spacial relationships of individual inhibitor side chain with the corresponding subsite of the enzyme as revealed in this crystal structure permits the design of new inhibitor structures in each of these positions. It is also possible to incorporate the unique conformation of subsites P 2 ′, P 3 ′ and P 4 ′ into the selectivity of memapsin 2 inhibitors.
  • the examples of inhibitor design based on the current crystal structure are given below.
  • the P1′ Ala side chain may be extended to add new hydrophobic, Van der Waals and H-bond interactions.
  • An example of such a design is diagramed in FIG. 13.
  • the polypeptide backbone in the region of P1, P2, and P3, and the side chain of P1-Leu can be bridged into rings by the addition of two atoms (A and B in FIG. 14). Also, a methyl group can be added to the beta-carbon of the P1 -Leu (FIG. 14).

Abstract

Methods for the production of purified, catalytically active, recombinant memapsin 2 have been developed. The substrate and subsite specificity of the catalytically active enzyme have been determined. The substrate and subsite specificity information was used to design substrate analogs of the natural memapsin 2 substrate that can inhibit the function of memapsin 2. The substrate analogs are based on peptide sequences, shown to be related to the natural peptide substrates for memapsin 2. The substrate analogs contain at least one analog of an amide bond which is not capable of being cleaved by memapsin 2. Processes for the synthesis of two substrate analogues including isosteres at the sites of the critical amino acid residues were developed and the substrate analogues, OMR99-1 and OM99-2, were synthesized. OM99-2 is based on an octapeptide Glu-Val-Asn-Leu-Ala-Ala-Glu-Phe (SEQ ID NO:28) with the Leu-Ala peptide bond substituted by a transition-state isostere hydroxyethylene group (FIG. 1). The inhibition constant of OM99-2 is 1.6×10−9 M against recombinant pro-memapsin 2. Crystallography of memapsin 2 bound to this inhibitor was used to determine the three dimensional structure of the protein, as well as the importance of the various residues in binding. This information can be used by those skilled in the art to design new inhibitors, using commercially available software programs and techniques familiar to those in organic chemistry and enzymology, to design new inhibitors to memapsin 2, useful in diagnostics and for the treatment and/or prevention of Alzheimer's disease.

Description

  • This application claims priority to U.S. Ser. No. 60/141,363 filed Jun. 28, 1999 by Lin, et al., U.S. Ser. No. 60/168,060 filed Nov. 30, 1999 by Lin, et al., U.S. Ser. No. 60/177,836 filed Jan. 25, 2000 by Lin, et al., U.S. Ser. No. 60/178,368 filed Jan. 27, 2000 by Lin, et a., and U.S. Ser. No. 60/210,292 filed Jun. 8, 2000 by Lin Hong, et al., the teachings of which are incorporated by reference herein.[0001]
    • BACKGROUND OF THE INVENTION
  • This invention is in the area of the expression of catalytically active Memapsin 2 (beta-secretase) and use thereof in the design and screening of specific inhibitors which are useful in the treatment and/or prevention of Alzheimer's Disease. [0002]
  • Alzheimer's disease (AD) is a degenerative disorder of the brain first described by Alios Alzheimer in 1907 after examining one of his patients who suffered drastic reduction in cognitive abilities and had generalized dementia ([0003] The early story of Alzheimer's Disease, edited by Bick et al. (Raven Press, New York 1987)). It is the leading cause of dementia in elderly persons. AD patients have increased problems with memory loss and intellectual functions which progress to the point where they cannot function as normal individuals. With the loss of intellectual skills the patients exhibit personality changes, socially inappropriate actions and schizophrenia (A Guide to the Understanding of Alzheimer's Disease and Related Disorders, edited by Jorm (New York University Press, New York 1987). AD is devastating for both victims and their families, for there is no effective palliative or preventive treatment for the inevitable neurodegeneration.
  • AD is associated with neuritic plaques measuring up to 200 οm in diameter in the cortex, hippocampus, subiculum, hippocampal gyrus, and amygdala. One of the principal constituents of neuritic plaques is amyloid, which is stained by Congo Red (Fisher (1983); Kelly Microbiol. Sci. 1(9):214-219 (1984)). Amyloid plaques stained by Congo Red are extracellular, pink or rust-colored in bright field, and birefringent in polarized light. The plaques are composed of polypeptide fibrils and are often present around blood vessels, reducing blood supply to various neurons in the brain. [0004]
  • Various factors such as genetic predisposition, infectious agents, toxins, metals, and head trauma have all been suggested as possible mechanisms of AD neuropathy. Available evidence strongly indicates that there are distinct types of genetic predispositions for AD. First, molecular analysis has provided evidence for mutations in the amyloid precursor protein (APP) gene in certain AD-stricken families (Goate et al. [0005] Nature 349:704-706 (1991); Murrell et al. Science 254:97-99 (1991); Chartier-Harlin et al. Nature 353:844-846 (1991); Mullan et al., Nature Genet. 1:345-347 (1992)). Additional genes for dominant forms of early onset AD reside on chromosome 14 and chromosome 1 (Rogaev et al., Nature 376:775-778 (1995); Levy-Lahad et al., Science 269:913-977 (1995); Sherrington et al., Nature 375:754-760 (1995)). Another loci associated with AD resides on chromosome 19 and encodes a variant form of apolipoprotein E (Corder, Science 261:921-923 (1993)).
  • Amyloid plaques are abundantly present in AD patients and in Down's Syndrome individuals surviving to the age of 40. The overexpression of APP in Down's Syndrome is recognized as a possible cause of the development of AD in Down's patients over thirty years of age (Rumble et al., [0006] New England J. Med. 20 320:1446-1452 (1989); Mann et al., Neurobiol. Aging 10:397-399 (1989)). The plaques are also present in the normal aging brain, although at a lower number. These plaques are made up primarily of the amyloid β peptide (Aβ; sometimes also referred to in the literature as β-amyloid peptide or β peptide) (Glenner and Wong, Biochem. Biophys. Res. Comm. 120:885-890 (1984)), which is also the primary protein constituent in cerebrovascular amyloid deposits. The amyloid is a filamentous material that is arranged in beta-pleated sheets. Aβ is a hydrophobic peptide comprising up to 43 amino acids.
  • The determination of its amino acid sequence led to the cloning of the APP cDNA (Kang el al., [0007] Nature 325:733-735 (1987); Goldgaber el al, Science 235:877-880 (1987); Robakis el al., Proc. Natl. Acad. Sci. 84:4190-4194 (1987); Tanzi et al., Nature 331:528-530 (1988)) and genomic APP DNA (Lemaire et al, Nucl. Acids Res. 17:517-522 (1989); Yoshikai et al., Gene 87, 257-263 (1990)). A number of forms of APP cDNA have been identified, including the three most abundant forms, APP695, APP751, and APP770. These forms arise from a single precursor RNA by alternate splicing. The gene spans more than 175 kb with 18 exons (Yoshikai et al. (1990)). APP contains an extracellular domain, a transmembrane region and a cytoplasmic domain. Aβ consists of up to 28 amino acids just outside the hydrophobic transmembrane domain and up to 15 residues of this transmembrane domain. Aβ is normally found in brain and other tissues such as heart, kidney and spleen. However, Aβ deposits are usually found in abundance only in the brain.
  • Van Broeckhaven et al., [0008] Science 248:1120-1122 (1990), have demonstrated that the APP gene is tightly linked to hereditary cerebral hemorrhage with amyloidosis (HCHWA-D) in two Dutch families. This was confirmed by the finding of a point mutation in the APP coding region in two Dutch patients (Levy et al., Science 248:1124-1128 (1990)). The mutation substituted a glutamine for glutamic acid at position 22 of the Aβ (position 618 of APP695, or position 693 of APP770). In addition, certain families are genetically predisposed to Alzheimer's disease, a condition referred to as familial Alzheimer's disease (FAD), through mutations resulting in an amino acid replacement at position 717 of the full length protein (Goate et al. (1991); Murrell et al. (1991); Chartier-Harlin et al. (1991)). These mutations co-segregate with the disease within the families and are absent in families with late-onset AD. This mutation at amino acid 717 increases the production of the Aβ1-42 form of Aβ from APP (Suzuki et al., Science 264:1336-1340 (1994)). Another mutant form contains a change in amino acids at positions 670 and 671 of the full length protein (Mullan et al. (1992)). This mutation to amino acids 670 and 671 increases the production of total Aβ from APP (Citron et al., Nature 360:622-674 (1992)).
  • APP is processed in vivo at three sites. The evidence suggests that cleavage at the β-secretase site by a membrane associated metalloprotease is a physiological event. This site is located in APP 12 residues away from the lumenal surface of the plasma membrane. Cleavage of the β-secretase site (28 residues from the plasma membrane's lumenal surface) and the β-secretase site (in the transmembrane region) results in the 40/42-residue β-amyloid peptide (Aβ), whose elevated production and accumulation in the brain are the central events in the pathogenesis of Alzheimer's disease (for review, see Selkoe, D. J. [0009] Nature 399:23-31 (1999)). Presenilin 1, another membrane protein found in human brain, controls the hydrolysis at the APP (β-secretase site and has been postulated to be itself the responsible protease (Wolfe, M. S. et al., Nature 398:513-517 (1999)). Presenilin 1 is expressed as a single chain molecule and its processing by a protease, presenilinase, is required to prevent it from rapid degradation (Thinakaran, G. et al., Neuron 17:181-190 (1996) and Podlisny, M. B., et al., Neurobiol. Dis. 3:325-37 (1997)). The identity of presenilinase is unknown. The in vivo processing of the β-secretase site is thought to be the rate-limiting step in A β production (Sinha, S. & Lieberburg, I., Proc. Natl. Acad. Sci., USA, 96:11049-11053 (1999)), and is therefore a strong therapeutic target.
  • The design of inhibitors effective in decreasing amyeloid plaque formation is dependent on the identification of the critical enzyme(s) in the cleavage of APP to yield the 42 amino acid peptide, the Aβ[0010] 1-42 form of Aβ. Although several enzymes have been identified, it has not been possible to produce active enzyme. Without active enzyme, one cannot confirm the substrate specificity, determine the subsite specificity, nor determine the kinetics or critical active site residues, all of which are essential for the design of inhibitors.
  • Memapsin 2 has been shown to be beta-secretase, a key protease involved in the production in human brain of beta-amyloid peptide from beta-amyloid precursor protein (for review, see Selkoe, D. J. [0011] Nature 399:23-31 (1999)). It is now generally accepted that the accumulation of beta-amyloid peptide in human brain is a major cause for the Alzheimer's disease. Inhibitors specifically designed for human memapsin 2 should inhibit or decrease the formation of beta-amyloid peptide and the progression of the Alzheimer's disease.
  • [0012] Memapsin 2 belongs to the aspartic protease family. It is homologous in amino acid sequence to other eukaryotic aspartic proteases and contains motifs specific to that family. These structural similarities predict that memapsin 2 and other eukaryotic aspartic proteases share common catalytic mechanism Davies, D. R., Annu. Rev. Biophys. Chem. 19, 189 (1990). The most successful inhibitors for aspartic proteases are mimics of the transition state of these enzymes. These inhibitors have substrate-like structure with the cleaved planar peptide bond between the carbonyl carbon and the amide nitrogen replaced by two tetrahedral atoms, such as hydroxyethylene [—CH(OH)—CH2—], which was originally discovered in the structure of pepstatin (Marciniszyn et al., 1976).
  • However, for clinical use, it is preferable to have small molecule inhibitors which will pass through the blood brain barrier and which can be readily synthesized. It is also desirable that the inhibitors are relatively inexpensive to manufacture and that they can be administered orally. [0013]
  • Screening of thousands of compounds for these properties would require an enormous effort. To rationally design [0014] memapsin 2 inhibitors for treating Alzheimer's disease, it will be important to know the three-dimensional structure of memapsin 2, especially the binding mode of an inhibitor in the active site of this protease.
  • It is therefore an object of the present invention to provide purified, recombinant, and [0015] active memapsin 2, as well as its substrate and subsite specificity and critical active site residues.
  • It is a further object of the present invention to provide compositions and methods for synthesis of inhibitors of [0016] memapsin 2.
  • It is a still further object of the present invention to provide compositions that interact with [0017] memapsin 2 or its substrate to inhibit cleavage by the memapsin 2 which can cross the blood brain barrier (BBB).
  • It is therefore an object of the present invention to provide means for rational design and screening of compounds for inhibition of [0018] mamapsin 2.
    • SUMMARY OF THE INVENTION
  • Methods for the production of purified, catalytically active, [0019] recombinant memapsin 2 have been developed. The substrate and subsite specificity of the catalytically active enzyme have been determined. The active enzyme and assays for catalytic activity are useful in screening libraries for inhibitors of the enzyme.
  • The substrate and subsite specificity information was used to design substrate analogs of the [0020] natural memapsin 2 substrate that can inhibit the function of memapsin 2. The substrate analogs are based on peptide sequences, shown to be related to the natural peptide substrates for memapsin 2. The substrate analogs contain at least one analog of an amide (peptide) bond which is not capable of being cleaved by memapsin 2. Processes for the synthesis of two substrate analogues including isosteres at the sites of the critical amino acid residues were developed and the substrate analogues, OMR99-1 and OM99-2, were synthesized. OM99-2 is based on an octapeptide Glu-Val-Asn-Leu-Ala-Ala-Glu-Phe (SEQ ID NO:28) with the Leu-Ala peptide bond substituted by a transition-state isostere hydroxyethylene group. The inhibition constant of OM99-2 is 1.6×10−9 M against recombinant pro-memapsin 2. Crystallography of memapsin 2 bound to this inhibitor was used to determine the three dimensional structure of the protein, as well as the importance of the various residues in binding.
  • This information can be used by those skilled in the art to design new inhibitors, using commercially available software programs and techniques familiar to those in organic chemistry and enzymology, to design new inhibitors. For example, the side chains of the inhibitors may be modified to produce stronger interactions (through hydrogen bonding, hydrophobic interaction, charge interaction and/or van der Waal interaction) in order to increase inhibition potency. Based on this type of information, the residues with minor interactions may be eliminated from the new inhibitor design to decrease the molecular weight of the inhibitor. The side chains with no structural hindrance from the enzyme may be cross-linked to lock in the effective inhibitor conformation. This type of structure also enables the design of peptide surrogates which may effectively fill the binding sites of [0021] memapsin 2 yet produce better pharmaceutical properties.
  • The examples demonstrate the production of catalytically active enzyme, design and synthesis of inhibitors, and how the crystal structure was obtained. The examples thereby demonstrate how the methods and materials described herein can be used to screen libraries of compounds for other inhibitors, as well as for design of inhibitors. These inhibitors are useful in the prevention and/or treatment of Alzheimer's disease as mediated by the action of the beta secretase [0022] memapsin 2, in cleaving APP.
    •  BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 depicts the plasmid construct of vector pET-11a-memapsin 2-T1 and pET-11a-memapsin 2-T2. The T7 promotor, amino acid sequence from the vector (T7 protein) (SEQ ID NO:3), and the beginning and ending of the [0023] memapsin 2 T1 and T2 construct are shown. Construct promemapsin 2-T1 was used in the preparation of protein for crystallization and includes residues 1v-15v which are derived from vector pET-11a. Residues 1p-48p are putative pro-peptide. Residues 1-393 correspond to the mature protease domain and C-terminal extension. The residue numbering of memapsin 2 starts at the aligned N-terminal position of pepsin (FIG. 3).
  • FIG. 2A is a graph of the initial rate of hydrolysis of synthetic peptide swAPP (see Table 1) by M2[0024] pd at different pH. FIG. 2B is a graph of the relative Kcat/Km values for steady-state kinetic of hydrolysis of peptide substrates by M2pd.
  • FIGS. 3A and 3B are the chemical structures of [0025] memapsin 2 inhibitors, OM99-2 and OM99-1.
  • FIG. 4A is a graph of the inhibition of [0026] recombinant memapsin 2 by OM99-1 FIG. 4B is a graph of the inhibition of recombinant memapsin 2 by OM99-2.
  • FIGS. [0027] 5A-E are photographs of crystals of recombinant memapsin 2-OM99-2 complex.
  • FIG. 6 is a stereo view of crystal structure of [0028] memapsin 2 protease domain with bound OM99-2.The polypeptide backbone of memapsin 2 is shown as a ribbon diagram. The N-lobe and C-lobe are blue and yellow, respectively, except the insertion loops (designated A to G, see FIG. 2) in the C-lobe are magenta and the C-terminal extension is green. The inhibitor bound between the lobes is shown in red.
  • FIG. 7 is a stereo view of comparison of the three-dimensional structures of [0029] memapsin 2 and pepsin. The molecular surface of the former is significantly larger by the insertion of surface loops and helix and the C-terminal extension. Chain tracing of human memapsin 2 is dark blue and is grey for human pepsin. The light blue balls represent identical residues which are topologically equivalent. The disulfide bonds are shown in red for memapsin 2 and orange for pepsin. The C-terminal extension is in green.
  • FIG. 8 is a schematic presentation of interaction between OM99-2 and [0030] memapsin 2 protease domain. The S3′ and S4′ subsites are not defined.
  • FIG. 9 is a stereo presentation of interactions between inhibitor OM99-2 (orange) and memapsin 2 (light blue). Nitrogen and oxygen atoms are marked blue and red, respectively. Hydrogen bonds are indicated in yellow dotted lines. [0031] Memapsin 2 residues which comprise the binding subsites are included. Residues P4, P3, P2, P1 and P1′ (defined in FIG. 8) of OM99-2 are in an extended conformation. Inhibitor chain turns at residue P2′ which makes a distinct kink at this position. The backbone of P3′ and P4′ directs the inhibitor to exit the active site.
  • FIG. 10 are schematics of the cross linking between P[0032] 3 Val and P1 Leu side chains in the design of new inhibitors for memapsin 2 based on the current crystal structure. R and R′ at positions P2 and P1′ indicate amino acid side chains. Other structural elements of inhibitor are omitted for clarity.
  • FIG. 11 are schematics of the cross linking between P[0033] 4 Glu and P2 Asn side chains in the design of new inhibitors for memapsin 2 based on the current crystal structure. R at position P3 indicates amino acid side chain. Other structural elements of inhibitor are omitted for clarity.
  • FIG. 12 is a schematic of the design for the side chain at the P[0034] 1′ subsite for the new memapsin 2 inhibitors based on the current crystal structure. Arrows indicate possible interactions between memapsin 2 and inhibitor. Other structural elements of inhibitor are omitted for clarity.
  • FIG. 13 is a schematic of the design of two six-membered rings in the inhibitor structure by the addition of atoms A and B. The ring formation involves the P[0035] 1-Leu side chain the the peptide backbone near P1, P2, and P3. The new bonds are in dotted lines. A methyl group can be added to the beta-carbon of P1-Leu. Other structural elements of inhibitor are omitted for clarity.
    • DETAILED DESCRIPTION OF THE INVENTION
  • I. Preparation of Catalytically Active [0036] Recombinant Memapsin 2 Cloning and Expression of Memapsin 2
  • [0037] Memapsin 2 was cloned and the nucleotide (SEQ ID NO. 1) and predicted amino acid (SEQ ID NO. 2) sequences were determined, as described in Example 1. The cDNA was assembled from the fragments. The nucleotide and the deduced protein sequence are shown in SEQ ID NOs. 1 and 2, respectively. The protein is the same as the aspartic proteinase 2 (ASP2) described in EP 0 855 444 A by SmithKline Beecham Pharmaceuticals, (published Jul. 29, 1998), and later reported by Sinha, et al., Nature 402, 537-540 (Dec. 1999) and Vassar, et al., Science 286, 735-741 (Oct. 22, 1999).
  • Pro-memapsin 2 is homologous to other human aspartic proteases. Based on the alignments, Pro-memapsin 2 contains a pro region, an aspartic protease region, and a trans-membrane region near the C-terminus. The C-terminal domain is over 80 residues long. The active enzyme is [0038] memapsin 2 and its pro-enzyme is pro-memapsin 2.
  • Refolding Catalytically Active Enzyme [0039]
  • In order to determine the substrate specificity and to design inhibitors. it is necessary to express catalytically active recombinant enzyme. No other known proteases contain a transmembrane domain. The presence of transmembrane domains makes the recombinant expression of these proteins less predictable and more difficult. The transmembrane region often needs to be removed so that secretion of the protein can take place. However, the removal of the transmembrane region can often alter the structure and/or function of the protein. [0040]
  • The starting assumption was that the region of [0041] memapsin 2 that is homologous with other aspartic proteases would independently fold in the absence of the transmembrane domain, and would retain protease activity in the absence of the C-terminal transmembrane region. The transmembrane region appears to serve as a membrane anchor. Since the active site is not in the transmembrane region and activity does not require membrane anchoring, memapsin 2 was expressed in E. coli in two different lengths, both without the transmembrane region, and purified, as described in Example 3. The procedures for the culture of transfected bacteria, induction of synthesis of recombinant proteins and the recovery and washing of inclusion bodies containing recombinant proteins are essentially as described by Lin et al., (1994). Refolding was not a simple matter, however. Two different refolding methods both produced satisfactory results. In both methods, the protein was dissolved in a strong denaturing/reducing solution such as 8 M urea/100 mM beta-mercaptoethanol. The rate at which the protein was refolded, and in what solution, was critical to activity. In one method, the protein is dissolved into 8 M urea/100 mM beta-mercaptoethanol then rapidly diluted into 20 volumes of 20 mM-Tris, pH 9.0, which is then slowly adjusted to pH 8 with 1 M HCl. The refolding solution was then kept at 4° C. for 24 to 48 hours before proceeding with purification. In the second method, an equal volume of 20 mM Tris, 0.5 mM oxidized/1.25 mM reduced glutathione, pH 9.0 is added to rapidly stirred pro-memapsin 2 in 8 M urea/10 mM beta-mercaptoethanol. The process is repeated three more times with 1 hour intervals. The resulting solution is then dialyzed against sufficient volume of 20 mM Tris base so that the final urea concentration is 0.4 M. The pH of the solution is then slowly adjusted to 8.0 with 1 M HCl.
  • The refolded protein is then further purified by column chromatography, based on molecular weight exclusion, and/or elution using a salt gradient, and analyzed by SDS-PAGE analysis under reduced and non-reduced conditions. [0042]
  • II. Substrate Specificity and Enzyme Kinetics of [0043] Memapsin 2 Substrate Specificity
  • The tissue distribution of the [0044] memapsin 2 was determined, as described in Example 2. The presence of memapsin 2 (M2) in the brain indicated that it might hydrolyze the β-amyloid precursor protein (APP). As described below, detailed enzymatic and cellular studies demonstrated that M2 fits all the criteria of the β-secretase.
  • The M2 three-dimensional structure modeled as a type I integral membrane protein. The model suggested that its globular protease unit can hydrolyze a membrane anchored polypeptide at a distance range of 20-30 residues from the membrane surface. As a transmembrane protein of the brain, APP is a potential substrate and its beta-secretase site, located about 28 residues from the plasma membrane surface, is within in the range for M2 proteolysis. [0045]
  • A synthetic peptide derived from this site (SEVKM/DAEFR) (SEQ ID NO:4) was hydrolyzed by M2[0046] pd (modified M2 containing amino acids from Ala−8P to Ala326) at the beta-secretase site (marked by /) A second peptide (SEVNL/DAEFR) (SEQ ID NO:5) derived from the APP beta-secretase site and containing the ‘Swedish mutation’ (Mullan, M. el al., Nature Genet. 2:340-342 (1992)), known to elevate the level of alpha-beta production in cells (Citron, M. et al., Nature 260:672-674 (1992)), was hydrolyzed by M2pd with much higher catalytic efficiency. Both substrates were optimally cleaved at pH 4.0. A peptide derived from the processing site of presenilin 1 (SVNM/AEGD) (SEQ ID NO:6) was also cleaved by M2 pd with less efficient kinetic parameters. A peptide derived from the APP gamma-secretase site (KGGVVIATVIVK) (SEQ ID NO:7) was not cleaved by M2pd. Pepstatin A inhibited M2pd poorly (IC50 approximately approximately 0.3 mM). The kinetic parameters indicate that both presenilin 1 (kcat, 0.67 s−1; Km, 15.2 mM; kcat/Km, 43.8 s−1M−1) and native APP peptides (kcat/Km, 39.9 s−1M−1) are not as good substrates as the Swedish APP peptide (kcat, 2.45 s−1,Km, 1 mM; kcat/Km, 2450 s−1M−1).
  • To determine if M2 possesses an APP beta-secretase function in mammalian cells, [0047] memapsin 2 was transiently expressed in HeLa cells (Lin, X., et al., FASEB J. 7:1070-1080 (1993)), metabolically pulse-labeled with 35S-Met, then immunoprecipitated with anti-APP antibodies for visualization of APP-generated fragments after SDS-polyacrylamide electrophoresis and imaging. SDS-PAGE patterns of immuno-precipitated APP Nβ-fragment (97 kD band) from the conditioned media (2 h) of pulse-chase experiments showed that APP was cleaved by M2. Controls transfected with APP alone and co-transfected with APP and M2 with Bafilomycin A1 added were performed. SDS-PAGE patterns of APP βC-fragment (12 kD) were immunoprecipitated from the conditioned media of the same experiment as discussed above. Controls transfected with APP alone; co-transfected with APP and M2; co-transfected with APP and M2 with Bafilomycin A1; transfections of Swedish APP; and co-transfections of Swedish APP and M2 were performed. SDS-PAGE gels were also run of immuno-precipitated M2 (70 kD), M2 transfected cells; untransfected HeLa cells after long time film exposure; and endogenous M2 from HEK 293 cells. SDS-PAGE patterns of APP fragments (100 kD betaN-fragment and 95 kD betaN-fragment) recovered from conditioned media after immuno-precipitation using antibodies specific for different APP regions indicated that memapsin 2 cleaved APP.
  • Cells expressing both APP and M2 produced the 97 kD APP beta N-fragment (from the-N-terminus to the beta-secretase site) in the conditioned media and the 12 kD betaC-fragment (from the beta-secretase site to the C-terminus) in the cell lystate. Controls transfected with APP alone produced little detectable betaN-fragment and no beta C-fragment. Bafilomycin A1, which is known to raise the intra-vesicle pH of lysosomes/endosomes and has been shown to inhibit APP cleavage by beta-secretase (Knops, J. et al, [0048] J. Biol. Chem. 30 270:2419-2422 (1995)), abolished the production of both APP fragments beta N- and beta C- in co-transfected cells. Cells transfected with Swedish APP alone did not produce the beta C-fragment band in the cell lysate but the co-transfection of Swedish APP and M2 did. This Swedish beta C-fragment band is more intense than that of wild-type APP. A 97-kD beta N-band is also seen in the conditioned media but is about equal intensity as the wild-type APP transfection.
  • These results indicate that M2 processes the beta-secretase site of APP in acidic compartments such as the endosomes. To establish the expression of transfected M2 gene, the pulse-labeled cells were lysed and immuno-precipitated by anti-M2 antibodies. A 70 kD M2 band was seen in cells transfected with M2 gene, which has the same mobility as the major band from HEK 293 cells known to express beta-secretase (Citron, M. et al., [0049] Nature 260:672-674 (1992)). A very faint band of M2 is also seen, after a long film exposure, in untransfected HeLa cells, indicating a very low level of endogenous M2, which is insufficient to produce betaN- or betaC-fragments without M2 transfection. Antibody alpha-beta1-17, which specifically recognizes residues 1-17 in alpha-beta peptide, was used to confirm the correct beta-secretase site cleavage. In cells transfected with APP and M2, both beta N- and beta N-fragments are visible using an antibody recognizing the N-terminal region of APP present in both fragments. Antibody Abeta1-17 recognize the beta N-fragment produced by endogenous beta-secretase in the untransfected cells. This antibody was, however, unable to recognize the beta N-fragment known to be present in cells co-transfected with APP and M2. These observations confirmed that betaN-fragment is the product of beta-secretase site cut by M2, which abolished the recognition epitope of alpha-beta1-17.
  • The processing of APP by M2 predicts the intracellular colocalization of the two proteins. HeLa cells co-expressing APP and M2 were stained with antibodies directed toward APP and M2 and visualized simultaneously by CSLM using a 100×objective. Areas of colocalization appeared in yellow. [0050]
  • Immunodetection observed by confocal microscopy of both APP and M2 revealed their colocalization in the superimposed scans. The distribution of both proteins is consistent with their residence in lysosomal/endosomal compartments. [0051]
  • In specificity studies, it was found that M2[0052] pd cleaved its pro peptide (2 sites) and the protease portion (2 sites) during a 16 h incubation after activation (Table 1). Besides the three peptides discussed above, M2pd also cleaved oxidized bovine insulin B chain and a synthetic peptide Nch. Native proteins were not cleaved by M2pd.
  • The data indicate that human M2 fulfills all the criteria of a beta-secretase which cleaves the beta-amyloid precursor protein (APP): (a) M2 and APP are both membrane proteins present in human brain and co-localize in mammalian cells, (b) M2 specifically cleaves the beta-secretase site of synthetic peptides and of APP in cells, (c) M2 preferentially cleaves the beta-secretase site from the Swedish over the wild-type APP, and (d) the acidic pH optimum for M2 activity and bafilomycin A1 inhibition of APP processing by M2 in the cells are consistent with the previous observations that beta-secretase cleavage occurs in acidic vesicles (Knops, J., et al., [0053] J. Biol. Chem. 270:2419-2422 (1995)). The spontaneous appearance of activity of recombinant pro-M2 in an acidic solution suggests that, intracellularly, this zymogen can by itself generate activity in an acidic vesicle like an endosome.
  • II. Design and Synthesis of Inhibitors [0054]
  • Design of Substrate Analogs for [0055] Memapsin 2.
  • The five human aspartic proteases have homologous amino acid sequences and have similar three-dimensional structures. There are two aspartic residues in the active site and each residue is found within the signature aspartic protease sequence motif, Asp-Thr/Ser-Gly- (SEQ ID NO:8). There are generally two homologous domains within an aspartic protease and the substrate binding site is positioned between these two domains, based on the three-dimensional structures. The substrate binding sites of aspartic proteases generally recognize eight amino acid residues. There are generally four residues on each side of the amide bond which is cleaved by the aspartic protease. [0056]
  • Typically the side chains of each amino acid are involved in the specificity of the substrate/aspartic protease interaction. The side chain of each substrate residue is recognized by regions of the enzyme which are collectively called sub-sites. The generally accepted nomenclature for the protease sub-sites and their corresponding substrate residues are shown below, where the double slash represents the position of bond cleavage. [0057]
    Protease sub-sites S4 S3 S2 S1 S1′ S2′ S3′ S4′
    Substrate residues P4 P3 P2 P1 // P1′ P2′ P3′ P4′
  • While there is a general motif for aspartic protease substrate recognition, each protease has a very different substrate specificity and breadth of specificity. Once the specificity of an aspartic protease is known, inhibitors can be designed based on that specificity, which interact with the aspartic protease in a way that prevents natural substrate from being efficiently cleaved. Some aspartic proteases have specificities which can accommodate many different residues in each of the sub-sites for successful hydrolysis. Pepsin and cathepsin D have this type of specificity and are said to have “broad” substrate specificity. When only a very few residues can be recognized at a sub-site, such as in renin, the aspartic protease is said to have a stringent or narrow specificity. [0058]
  • The information on the specificity of an aspartic protease can be used to design specific inhibitors in which the preferred residues are placed at specific sub-sites and the cleaved peptide bond is replaced by an analog of the transition-state. These analogs are called transition state isosteres. Aspartic proteases cleave amide bonds by a hydrolytic mechanism. This reaction mechanism involves the attack by a hydroxide ion on the β-carbon of the amino acid. Protonation must occur at the other atom attached to the β-carbon through the bond that is to be cleaved. If the β-carbon is insufficiently electrophilic or the atom attached to the bond to be cleaved is insufficiently nucleophilic the bond will not be cleaved by a hydrolytic mechanism. Analogs exist which do not mimic the transition state but which are non-hydrolyzable, but transition state isosteres mimic the transition state specifically and are non-hydrolyzable. [0059]
  • Transition state theory indicates that it is the transition state intermediate of the reaction which the enzyme catalyzes for which the enzyme has its highest affinity. It is the transition state structure, not the ground state structure, of the substrate which will have the highest affinity for its given enzyme. The transition state for the hydrolysis of an amide bond is tetrahedral while the ground state structure is planar. A typical transition-state isostere of aspartic protease is —CH(OH)—CH[0060] 2—, as was first discovered in pepstatin by Marciniszyn et al. (1976). The transition-state analogue principles have been successfully applied to inhibitor drugs for human immunodeficiency virus protease, an aspartic protease. Many of these are currently in clinical use. Information on the structure, specificity, and types of inhibitors can be found in Tang, Acid Proteases, Structure, Function and Biology, Adv. in Exptl. Med. Biol. vol. 95 (Plenum Press, NY 1977); Kostka, Aspartic Proteinases and their Inhibitors (Walter de Gruyter, Berlin 1985); Dunn, Structure and Functions of the Aspartic Proteinases, Adv. in Exptl. Med. Biol. 306 (Plenum Press, NY 1991); Takahashi, Aspartic Proteases, Structure, Function, Biology, Biomedical Implications, Adv. in Exptl. Med. Biol. 362 (Plenum Press, NY 1995); and James, Aspartic Proteinases, Retroviral and Cellular Enzymes, Adv. in Exptl. Med. Biol. 436 (Plenum Press, NY 1998)).
  • Substrate analog compositions are generally of the general formula X-L[0061] 4-P4-L3-P3-L2-P2-L1-P1-L0-P1′-L1′-P2′-L2′-P3′-L3′-P4′-L4′-Y. The substrate analog compositions are analogs of small peptide molecules. Their basic structure is derived from peptide sequences that were determined through structure/function studies. It is understood that positions represented by Pxrepresent the substrate specificity position relative to the cleavage site which is represented by an -L0-. The positions of the compositions represented by Lxrepresent the linking regions between each substrate specificity position, PX.
  • In a natural substrate for [0062] memapsin 2, a PX-Lxpair would represent a single amino acid of the peptide which is to be cleaved. In the present general formula, each Pxpart of the formula refers to the α-carbon and side chain functional group of each would be amino acid. Thus, the Pxportion of an PxLxpair for alanine represents HC—CH3. The general formula representing the Pxportion of the general composition is —R1CR3—.
  • In general R[0063] 1 can be either CH3 (side chain of alanine), CH(CH3)2 (side chain of valine), CH2CH(CH3)2 (side chain of leucine), (CH3)CH(CH2CH3) (side chain of isoleucine), CH2(Indole) (side chain of tryptophan), CH2(Benzene) (side chain of phenylalanine), CH2CH2SCH3 (side chain of methionine), H (side chain of glycine), CH2OH (side chain of serine), CHOHCH3 (side chain of threonine), CH2(Phenol) (side chain of tyrosine), CH2SH (side chain of cysteine), CH2CH2CONH2 (side chain of glutamine), CH2CONH2 (side chain of asparagine), CH2CH2CH2CH2NH2 (side chain of lysine), CH2CH2CH2NHC(NH)(NH2) (side chain of arginine), CH2(Imidazole) (side chain of histidine), CH2COOH (side chain of aspartic acid), CH2CH2COOH (side chain of glutamic acid), and functional natural and non-natural derivatives or synthetic substitutions of these.
  • It is most preferred that R[0064] 3 is a single H. In general, however, R3 can be alkenyl, alkynal, alkenyloxy, and alkynyloxy groups that allow binding to memapsin 2. Preferably, alkenyl, alkynyl, alkenyloxy and alkynyloxy groups have from 2 to 40 carbons, and more preferably from 2 to 20 carbons, from 2 to 10 carbons, or from 2 to 3 carbons., and functional natural and non-natural derivatives or synthetic substitutions of these.
  • The L[0065] xportion of the PX-Lxpair represents the atoms linking the Pxregions together. In a natural substrate the Lxrepresents the β-carbon attached to the amino portion of what would be the next amino acid in the chain. Thus, Lxwould be represented by —CO—NH—. The general formula for Lxis represented by R2. In general R2 can be CO—HN (amide), CH(OH)(CH2) (hydroxyethylene), CH(OH)CH(OH) (dihydroxyethylene), CH(OH)CH2NH (hydroxyethylamine), PO(OH)CH2 (phosphinate), CH2NH, (reduced amide). It is understood that more than one L- maybe an isostere as long as the substrate analog functions to inhibit aspartic protease function.
  • Ls which are not isosteres may either be an amide bond or mimetic of an amide bond that is non-hydrolyzable. [0066]
  • X and Y represent molecules which are not typically involved in the recognition by the aspartic protease recognition site, but which do not interfere with recognition. It is preferred that these molecules confer resistance to the degradation of the substrate analog. Preferred examples would be amino acids coupled to the substrate analog through a non-hydrolyzable bond. Other preferred compounds would be capping agents. Still other preferred compounds would be compounds which could be used in the purification of the substrate analogs such as biotin. [0067]
  • As used herein, alkyl refers to substituted or unsubstituted straight, branched or cyclic alkyl groups; and alkoxyl refers to substituted or unsubstituted straight, branched or cyclic alkoxy. Preferably, alkyl and alkoxy groups have from 1 to 40 carbons, and more preferably from 1 to 20 carbons, from 1 to 10 carbons, or from 1 to 3 carbons. [0068]
  • As used herein, atkenyl refers to substituted or unsubstituted straight chain or branched alkenyl groups; alkynyl refers to substituted or unsubstituted straight chain or branched alkynyl groups; alkenyloxy refers to substituted or unsubstituted straight chain or branched alkenyloxy; and alkynyloxy refers to substituted or unsubstituted straight chain or branched alkynyloxy. Preferably, alkenyl, alkynyl, alkenyloxy and alkynyloxy groups have from 2 to 40 carbons, and more preferably from 2 to 20 carbons, from 2 to 10 carbons, or from 2 to 3 carbons. [0069]
  • As used herein, alkaryl refers to an alkyl group that has an aryl substituent; aralkyl refers to an aryl group that has an alkyl substituent; heterocyclic-alkyl refers to a heterocyclic group with an alkyl substituent; alkyl-heterocyclic refers to an alkyl group that has a heterocyclic substituent. [0070]
  • The substituents for alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, and alkynyloxy groups can be halogen, cyano, amino, thio, carboxy, ester, ether, thioether, carboxamide, hydroxy, or mercapto Further, the groups can optionally have one or more methylene groups replaced with a heteroatom, such as O, NH or S. [0071]
  • A number of different substrates were tested and analyzed, and the cleavage rules for [0072] Memapsin 2 were determined. The results of the substrates which were analyzed are presented in Table 1 and the rules determined from these results are summarized below.
  • (1) The primary specificity site for a [0073] memapsin 2 substrate is subsite position, P1′. This means that the most important determinant for substrate specificity in memapsin 2 is the amino acid, S1′. P1′ must contain a small side chain for memapsin 2 to recognize the substrate. Preferred embodiments are substrate analogs where R1 of the P1′ position is either H (side chain of glycine), CH3 (side chain of alanine), CH2OH (side chain of serine), or CH2OOH (side chain of aspartic acid). Embodiments that have an R1 structurally smaller than CH3 (side chain of alanine) or CH2OH (side chain of serine) are also preferred.
  • (2) There are no specific sequence requirements at positions P[0074] 4, P3, P2, P1, P2′, P3′, and P3′, and P4′ Each site can accommodate any other amino acid residue in singularity as long as rule number 3 is met.
  • (3) At least two of the remaining seven positions, P[0075] 4, P3, P2, P1, P2′, P3′, and P4′, must have an R1 which is made up of a hydrophobic residue. It is preferred that there are at least three hydrophobic residues in the remaining seven positions, P4, P3, P2, P1, P2′, P3′, and P4′. Preferred R1 groups for the positions that contain a hydrophobic group are CH3 (side chain of alanine), CH(CH3)2 (side chain of valine), CH2CH(CH3)2 (side chain of leucine), (CH3)CH(CH2 CH3) (side chain of isoleucine), CH2(INDOLE) (side chain of tryptophan), CH2(Benzene) (side chain of phenylalanine), CH2CH2SCH3 (side chain of methionine) CH2(Phenol) (side chain of tyrosine). It is more preferred that the hydrophobic group be a large hydrophobic group. Preferred R1s which contain large hydrophobic groups are CH(CH3)2 (side chain of valine), CH2CH(CH3)2 (side chain of leucine), (CH3)CH(CH2CH3) (side chain of isoleucine), CH2(Indole) (side chain of tryptophan), CH2(Benzene) (side chain of phenylalanine), CH2CH2SCH3 (side chain of methionine) CH2(Phenol) (side chain of tyrosine). It is most preferred that positions with a hydrophobic R1 are CH(CH3)2 (side chain of valine), CH2CH(CH3)2 (side chain of leucine), CH2(Benzene) (side chain of phenylalanine), CH2CH2SCH3 (side chain of methionine), or CH2(Phenol) (side chain of tyrosine).
  • (4) None of the eight positions, P[0076] 4, P3, P2, P1, P1′, P2′, P3′, and P4′ may have a proline side chain at its R1 position.
  • (5) Not all subsites must have an P represented in the analog. For example, a substrate analog could have X-P[0077] 2-L1-P1-L0-P1′-L1′-P2′-L2′-P3′-L3′-Y or it could have X-L1-P1-L0-P1′-L1′-P2′-L2′ -P3′-L3′-P4′-L4′-Y.
  • Preferred substrate analogs are analogs having the sequences disclosed in Table 1, with the non-hydrolyzable analog between P1 and P1′. [0078]
  • Combinatorial Chemistry to Make Inhibitors [0079]
  • Combinatorial chemistry includes but is not limited to all methods for isolating molecules that are capable of binding either a small molecule or another macromolecule. Proteins, oligonucleotides, and polysaccharides are examples of macromolecules. For example, oligonucleotide molecules with a given function, catalytic or ligand-binding, can be isolated from a complex mixture of random oligonucleotides in what has been referred to as “in vitro genetics” (Szostak, [0080] TIBS 19:89, 1992). One synthesizes a large pool of molecules bearing random and defined sequences and subjects that complex mixture, for example, approximately 1015 individual sequences in 100 μg of a 100 nucleotide RNA, to some selection and enrichment process. Through repeated cycles of affinity chromatography and PCR amplification of the molecules bound to the ligand on the column, Ellington and Szostak (1990) estimated that 1 in 1010 RNA molecules folded in such a way as to bind a small molecule dyes. DNA molecules with such ligand-binding behavior have been isolated as well (Ellington and Szostak, 1992; Bock et al, 1992).
  • Techniques aimed at similar goals exist for small organic molecules, proteins and peptides and other molecules known to those of skill in the art. Screening sets of molecules for a desired activity whether based on libraries of small synthetic molecules, oligonucleotides, proteins or peptides is broadly referred to as combinatorial chemistry. [0081]
  • There are a number of methods for isolating proteins either have de novo activity or a modifed activity. For example, phage display libraries have been used for a number of years. A preferred method for isolating proteins that have a given function is described by Roberts and Szostak (Roberts R. W. and Szostak J. W. [0082] Proc. Natl. Acad. Sci. USA, 94(23)12997-302 (1997). Another preferred method for combinatorial methods designed to isolate peptides is described in Cohen et al. (Cohen B. A., et al., Proc. Natl. Acad. Sci. USA 95(24): 14272-7 (1998)). This method utilizes a modified two-hybrid technology. Yeast two-hybrid systems are useful for the detection and analysis of protein:protein interactions. The two-hybrid system, initially described in the yeast Saccharomyces cerevisiae, is a powerful molecular genetic technique for identifying new regulatory molecules, specific to the protein of interest (Fields and Song, Nature 340:245-6 (1989)). Cohen et al., modifed this technology so that novel interactions between synthetic or engineered peptide sequences could be identified which bind a molecule of choice. The benefit of this type of technology is that the selection is done in an intracellular environment. The method utilizes a library of peptide molecules that attach to an acidic activation domain. A peptide of choice, for example an extracellular portion of memapsin 2 is attached to a DNA binding domain of a transcriptional activation protein, such as Gal 4. By performing the Two-hybrid technique on this type of system, molecules that bind the extracellular portion of memapsin 2 can be identified.
  • Screening of Small Molecule Libraries [0083]
  • In addition to these more specialized techniques, methodology well known to those of skill in the art, in combination with various small molecule or combinatorial libraries, can be used to isolate and characterize those molecules which bind to or interact with the desired target, either [0084] memapsin 2 or its substrate. The relative binding affinity of these compounds can be compared and optimum inhibitors identified using competitive or non-competitive binding studies which are well known to those of skill in the art. Preferred competitive inhibitors are non-hydrolyzable analogs of memapsin 2. Another will cause allosteric rearrangements which prevent memapsin 2 from functioning or folding correctly.
  • Computer Assisted Rational Drug Design [0085]
  • Another way to isolate inhibitors is through rational design. This is achieved through structural information and computer modeling. Computer modeling technology allows visualization of the three-dimensional atomic structure of a selected molecule and the rational design of new compounds that will interact with the molecule. The three-dimensional construct typically depends on data from x-ray crystallographic analyses or NMR imaging of the selected molecule. The molecular dynamics require force field data. The computer graphics systems enable prediction of how a new compound will link to the target molecule and allow experimental manipulation of the structures of the compound and target molecule to perfect binding specificity. For example, using NMR spectroscopy, Inouye and coworkers were able to obtain the structural information of N-terminal truncated TSHK (transmembrane sensor histidine kinases) fragments which retain the structure of the individual sub-domains of the catalytic site of a TSHK. On the basis of the NMR study, they were able to identify potential TSHK inhibitors (U.S. Pat. No. 6,077,682 to Inouye). Another good example is based on the three-dimensional structure of a calcineurin/FKBP12/FK506 complex determined using high resolution X-ray crystallography to obtain the shape and structure of both the calcineurin active site binding pocket and the auxiliary FKBP12/FK506 binding pocket (U.S. Pat. No. 5,978,740 to Armistead). With this information in hand, researchers can have a good understanding of the association of natural ligands or substrates with the binding pockets of their corresponding receptors or enzymes and are thus able to design and make effective inhibitors. [0086]
  • Prediction of molecule-compound interaction when small changes are made in one or both requires molecular mechanics software and computationally intensive computers, usually coupled with user-friendly, menu-driven interfaces between the molecular design program and the user Examples of molecular modeling systems are the CHARMm and QUANTA programs, Polygen Corporation, Waltham, Mass. CHARMm performs the energy minimization and molecular dynamics functions. QUANTA performs the construction, graphic modeling and analysis of molecular structure. QUANTA allows interactive construction, modification, visualization, and analysis of the behavior of molecules with each other. [0087]
  • A number of articles review computer modeling of drugs interactive with specific proteins, such as Rotivinen, et al., 1988 [0088] Acta Pharmaceutica Fennica 37, 159-166; Ripka, New Scientist 54-57 (Jun. 16, 1988); McKinaly and Rossmann, 1989 Annu. Rev. Pharmacol Toxiciol. 29, 111-122; Perry and Davies, QSAR: Quantitative Structure-Activity Relationships in Drug Design pp. 189-193 (Alan R. Liss, Inc. 1989); Lewis and Dean, 1989 Proc. R. Soc. Lond. 236, 125-140 and 141-162; and, with respect to a model enzyme for nucleic acid components, Askew, et al., 1989 J. Am. Chem. Soc. 111, 1082-1090. Other computer programs that screen and graphically depict chemicals are available from companies such as BioDesign, Inc., Pasadena, Calif., Allelix, Inc, Mississauga, Ontario, Canada, and Hypercube, Inc., Cambridge, Ontario.
  • Although described above with reference to design and generation of compounds which could alter binding, one could also screen libraries of known compounds, including natural products or synthetic chemicals, and biologically active materials, including proteins, for compounds which alter substrate binding or enzymatic activity. [0089]
  • Screening of Libraries [0090]
  • Design of substrate analogs and rational drug design are based on knowledge of the active site and target, and utilize computer software programs that create detailed structures of the enzyme and its substrate, as well as ways they interact, alone or in the presence of inhibitor. These techniques are significantly enhanced with x-ray crystallographic data in hand. Inhibitors can also be obtained by screening libraries of existing compounds for those which inhibit the catalytically active enzyme. In contrast to reports in the literature relating to [0091] memapsin 2, the enzyme described herein has activity analogous to the naturally produced enzyme, providing a means for identifying compounds which inhibit the endogenous activity. These potential inhibitors are typically identified using high throughput assays, in which enzyme, substrate (preferably a chromogenic substrate) and potential inhibitor (usually screened across a range of concentrations) are mixed and the extent of cleavage of substrate determined. Potentially useful inhibitors are those which decrease the amount of cleavage.
  • III. Methods of Diagnosis and Treatment [0092]
  • Inhibitors can be used in the diagnosis and treatment and/or prevention of Alzheimer's disease and conditions associated therewith, such as elevated levels of the forty-two amino acid peptide cleavage product, and the accumulation of the peptide in amyeloid plaques. [0093]
  • Diagnostic Uses [0094]
  • The substrate analogs can be used as reagents for specifically binding to [0095] memapsin 2 or memapsin 2 analogs and for aiding in memapsin 2 isolation and purification or characterization, as described in the examples. The inhibitors and purified recombinant enzyme can be used in screens for those individuals more genetically prone to develop Alzheimer's disease.
  • Therapeutic Uses [0096]
  • Recombinant [0097] human memapsin 2 cleaves a substrate with the sequence LVNM/AEGD (SEQ ID NO:9). This sequence is the in vivo processing site sequence of human presenilins. Both presenilin 1 and presenilin 2 are integral membrane proteins. They are processed by protease cleavage, which removes the N terminal sequence from the unprocessed form. Once processed, presenilin forms a two-chain heterodimer (Capell et al., J. Biol. Chem. 273, 3205 (1998); Thinakaran et al., Neurobiol. Dis. 4, 438 (1998); Yu et al., Neurosci Lett. 2;254(3):125-8 (1998)), which is stable relative to the unprocessed presenilins. Unprocessed presenilines are quickly degraded (Thinakaran et al., J. Biol. Chem. 272, 28415 (1997); Steiner et al., J. Biol. Chem. 273, 32322 (1998)). It is known that presenilin controls the in vivo activity of beta-secretase, which in turn cleaves the amyloid precursor protein (APP) leading to the formation of alpha-beta42. The accumulation of alpha-beta42 in the brain cells is known to be a major cause of Alzheimer's disease (for review, see Selkoe, 1998). The activity of presenilin therefore enhances the progression of Alzheimer's disease. This is supported by the observation that in the absence of presenilin gene, the production of alpha-beta42 peptide is lowered (De Strooper et al., Nature 391, 387 (1998)). Since unprocessed presenilin is degraded quickly, the processed, heterodimeric presenilin must be responsible for the accumulation of alpha-beta42 leading to Alzheimer's disease. The processing of presenilin by memapsin 2 would enhance the production of alpha-beta42 and therefore, further the progress of Alzheimer's disease. Therefore a memapsin 2 inhibitor that crosses the blood brain barrier can be used to decrease the likelihood of developing or slow the progression of Alzheimer's disease which is mediated by deposition of alpha-beta42. Since memapsin 2 cleaves APP at the beta cleavage site, prevention of APP cleavage at the beta cleavage site will prevent the build up of alpha-beta42.
  • Vaccines [0098]
  • The catalytically [0099] active memapsin 2 or fragments thereof including the active site defined by the presence of two catalytic aspartic residues and substrate binding cleft can be used to induce an immune response to the memapsin 2. The memapsin 2 is administered in an amount effective to elicit blocking antibodies, i.e., antibodies which prevent cleavage of the naturally occurring substrate of memapsin 2 in the brain. An unmodified vaccine may be useful in the prevention and treatment of Alzheimer's disease. The response to the vaccine may be influenced by its composition, such as inclusion of an adjuvant, viral proteins from production of the recombinant enzyme, and/or mode of administration (amount, site of administration, frequency of administration, etc). Since it is clear that the enzyme must be properly folded in order to be active, antibody should be elicited that is active against the endogenous memapsin 2. Antibodies that are effective against the endogenous enzyme are less likely to be produced against the enzyme that is not properly refolded.
  • Pharmaceutically Acceptable Carriers [0100]
  • The inhibitors will typically be administered orally or by injection. Oral administration is preferred. Alternatively, other formulations can be used for delivery by pulmonary, mucosal or transdermal routes. The inhibitor will usually be administered in combination with a pharmaceutically acceptable carrier. Pharmaceutical carriers are known to those skilled in the art. The appropriate carrier will typically be selected based on the mode of administration. Pharmaceutical compositions may also include one or more active ingredients such as antimicrobial agents, antiinflammatory agents, and analgesics. [0101]
  • Preparations for parenteral administration or administration by injection include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Preferred parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, and electrolyte replenishers (such as those based on Ringer's dextrose). [0102]
  • Formulations for topical (including application to a mucosal surface, including the mouth, pulmonary, nasal, vaginal or rectal) administration may include ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Formulations for these applications are known. For example, a number of pulmonary formulations have been developed, typically using spray drying to formulate a powder having particles with an aerodynanmic diameter of between one and three microns, consisting of drug or drug in combination with polymer and/or surfactant. [0103]
  • Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets, or tablets. Thickeners, flavorings. diluents, emulsifiers, dispersing aids or binders may be desirable. [0104]
  • Peptides as described herein can also be administered as a pharmaceutically acceptable acid- or base- addition salt, formed by reaction with inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and phosphoric acid, and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, and fumaric acid, or by reaction with an inorganic base such as sodium hydroxide, ammonium hydroxide, potassium hydroxide, and organic bases such as mono-, di-, trialkyl and aryl amines and substituted ethanolamines. [0105]
  • Dosages [0106]
  • Dosing is dependent on severity and responsiveness of the condition to be treated, but will normally be one or more doses per day, with course of treatment lasting from several days to several months or until the attending physician determines no further benefit will be obtained. Persons of ordinary skill can determine optimum dosages, dosing methodologies and repetition rates. [0107]
  • The dosage ranges are those large enough to produce the desired effect in which the symptoms of the [0108] memapsin 2 mediated disorder are alleviated (typically characterized by a decrease in size and/or number of amyloid plaque, or by a failure to increase in size or quantity), or in which cleavage of the alpha-beta42 peptide is decreased. The dosage can be adjusted by the individual physician in the event of any counterindications.
  • The present invention will be further understood by reference to the following non-limiting examples. [0109]
    • EXAMPLE 1 Cloning of Memapsin 2
  • 1. Cloning and Nucleotide Sequence of [0110] Pro-Memapsin 2
  • New sequences homologous to human aspartic proteases were found in the following entries in the EST IMAGE database: AA136368 pregnant uterus ATCC 947471, AA207232 neurepithelium ATCC 214526, and R55398 human breast ATCC 392689. The corresponding bacterial strains: #947471, #214526, and #392689 containing the EST sequences were obtained from the ATCC (Rockville, Md.). The sequencing of these clones obtained from ATCC confirmed that they contained sequences not identical to known human aspartic proteases. The completed sequences of these clones assembled into about 80% of prepro-M2 cDNA. Full length cDNAs of these clones were obtained using the following methods. [0111]
  • The Human Pancreas Marathon-Ready cDNA (Clontech), which is double-strand cDNA obtained by reverse-transcription, primer addition, and second strand synthesize of mRNA from human tissues, was used as template or PCR amplification. An adapter primer (AP1) and a nested adapter primer (AP2) were used for 5′- and 3′-RACE PCR. For PCR the 5′-region of the [0112] memapsin 2 cDNA, primers AP1 and NHASPR1 were used. Primers for the 3′-end of the cDNA are NHASPF2 and AP1. The middle of the cDNA was amplified by primers NHASPF1 and NHASPR2. The sequence for the primers is as follows: NHASPF1: GGTAAGCATCCCCCATGGCCCCAACGTC (SEQ ID NO:10), NHASPR1: GACGTTGGGGCCATGGGGGATGCTTACC (SEQ ID NO:11), NHASPF2: ACGTTGTCTTGATCGGGCCCGAAAACGAATTGG (SEQ ID NO:12), NHASPR2: CCAATTCGTTTTCGGGCCCGATCAAAGACAACG (SEQ ID NO:13), AP1: CCATCCTAATACGACTCACTATAGGGC (SEQ ID NO:14), and AP2: ACTCACTATAGGGCTCGAGCGGC (SEQ ID NO:15)
  • [0113] Memapsin 2 was also cloned from a human pancreas library (Quick-Screen Human cDNA Library Panel) contained in lambda-gt10 and lambda-gt11 vectors. The primers from the vectors, GT10FWD, GT10REV, GT11FWD, and GT11REV, were used as outside primers. The sequence of the primers used was:
    GT10FWD: CTTTTGAGCAAGTTCAGCCTGGTTAA (SEQ ID NO:16),
    GT10REV: GAGGTGGCTTATGAGTATTTCTTCCAGGGTA (SEQ ID NO:17),
    GT11FWD: TGGCGACGACTCCTGGAGCCCG (SEQ ID NO:18),
    GT11REV: TGACACCAGACCAACTGGTAATGG (SEQ ID NO:19).
  • In addition, [0114] memapsin 2 cDNA was amplified directly from the human pancreatic lambda-gt10 and lambda-gt11 libraries. The sequence of the primers was: PASPN1: catatgGCGGGAGTGCTGCCTGCCCAC (SEQ ID NO:20) and NHASPC1: ggatccTCACTTCAGCAGGGAGATGTCATCAGCAAAGT (SEQ ID NO:21).
  • The amplified [0115] memapsin 2 fragments were cloned into an intermediate PCR vector (Invitrogen) and sequenced.
  • The assembled cDNA from the fragments, the nucleotide and the deduced protein sequence are shown in [0116] SEQ ID NO 1 and SEQ ID NO 2.
  • Pro-memapsin 2 is homologous to other human aspartic proteases. Based on the alignments, Pro-memapsin 2 contains a pro region, an aspartic protease region, and a trans-membrane region near the C-terminus. The active enzyme is [0117] memapsin 2 and its pro-enzyme is pro-memapsin 2.
    • EXAMPLE 2 Distribution of Memapsin 2 in Human Tissues
  • Multiple tissue cDNA panels from Clontech were used as templates for PCR amplification of a 0.82 kb fragment of [0118] memapsin 2 cDNA. The primers used for memapsin 2 were NHASPF1 and NHASPR2. Tissues that contain memapsin 2 or fragments of memapsin 2 yielded amplified PCR products The amount of amplified product indicated that memapsin 2 is present in the following organs from most abundant to least abundant: pancreas, brain, lung, kidney, liver, placenta, and heart. Memapsin 2 is also present in spleen, prostate, testis, ovary, small intestine, and colon cells.
    • EXAMPLE 3 Expression of Pro-memapsin 2 cDNA in E. coli, Refolding and Purification of Pro-Memapsin 2
  • The [0119] pro-memapsin 2 was PCR amplified and cloned into the BamHI site of a pET11a vector. The resulting vector expresses pro-memapsin 2 having a sequence from Ala-8p to Ala 326. FIG. 1 shows the construction of two expression vectors, pET11-memapsin 2-T1 (hereafter T1) and pET11 -memapsin 2-T2 (hereafter T2). In both vectors, the N-terminal 15 residues of the expressed recombinant proteins are derived from the expression vector. Pro-memapsin memapsin 2 residues start at residue Ala-1 6. The two recombinant pro-memapsin 2s have different C-terminal lengths. Clone T1 ends at Thr-454 and clone T2 ends at Ala-419. The T1 construct contains a C-terminal extension from the T2 construct but does not express any of the predicted transmembrane domain.
  • Expression of Recombinant Proteins and Recovery of Inclusion Bodies [0120]
  • The T1 and T2 expression vectors were separately transfected into [0121] E. coli strain BL21(DE3). The procedures for the culture of transfected bacteria, induction for synthesis of recombinant proteins and the recovery and washing of inclusion bodies containing recombinant proteins are essentially as previously described (Lin et al., 1994).
  • Three different refolding methods have produced satisfactory results. [0122]
  • (i) The Rapid Dilution Method [0123]
  • Pro-memapsin 2 in 8 M urea/100 mM beta-mercaptoethanol with OD[0124] 280 nm−5 was rapidly diluted into 20 volumes of 20 mM-Tris, pH 9.0. The solution was slowly adjusted into pH 8 with 1 M HCl. The refolding solution was then kept at 4° C. for 24 to 48 hours before proceeding with purification.
  • (ii) The Reverse Dialysis Method [0125]
  • An equal volume of 20 mM Tris, 0.5 mM oxidized/1.25 mM reduced glutathione, pH 9.0 is added to rapidly stirred [0126] pro-memapsin 2 in 8 M urea/10 mM beta-mercaptoethanol with OD280 nm=5. The process is repeated three more times with 1 hour intervals. The resulting solution is then dialyzed against sufficient volume of 20 mM Tris base so that the final urea concentration is 0.4 M. The pH of the solution is then slowly adjusted to 8.0 with 1 M HCl.
  • (iii) The Preferred Method for Refolding [0127]
  • Inclusion bodies are dissolved in 8 M urea, 0.1 M Tris, 1 mM Glycine, 1 mM EDTA, 100 mM beta-mercaptoethanol, pH 10.0. The OD[0128] 280 of the inclusion bodies are adjusted to 5.0 with the 8 M urea solution without beta-mercaptoethanol. The final solution contains the following reducing reagents: 10 mM beta-mercaptoethanol, 10 mM DTT (Dithiothreitol), 1 mM reduced glutathion, and 0.1 M oxidized glutathion. The final pH of the solution is 10.0.
  • The above solution is rapidly diluted into 20 volumes of 20 mM Tris base, the pH is adjusted to 9.0, and the resulting solution is kept at 4° C. for 16 hr. The solution is equilibrated to room temperature in 6 hr, and the pH is adjusted to 8.5. The solution is returned to 4° C. again for 18 hr. [0129]
  • The solution is again equilibrated to room temperature in 6 hr, and the pH is adjusted to 8.0. The solution is returned to 4° C. again for 4 to 7 days. [0130]
  • The refolding procedures are critical to obtain an enzymically active preparation which can be used for studies of subsite specificity of M2, to analyze inhibition potency of M2 inhibitors, to screen for inhibitors using either random structural libraries or existing collections of compound libraries, to produce crystals for crystallography studies of M2 structures, and to produce monoclonal or polyclonal antibodies of M2. [0131]
  • Purification of Recombinant Pro-memapsin 2-T2 [0132]
  • The refolded material is concentrated by ultrafiltration, and separated on a SEPHACRYL™ S-300 column equilibrated with 20 mM Tris.HCl, 0.4 M urea, pH 8.0. The refolded peak (second peak) from the S-300 column can be further purified with a FPLC RESOURCE-Q™ column, which is equilibrated with 20 mM Tris-HCl, 0.4 M urea, pH 8.0. The enzyme is eluted from the column with a linear gradient of NaCl. The refolded peak from S-300 can also be activated before further purification. For activation, the fractions are mixed with equal volume 0.2 M Sodium Acetate, 70% glycerol, pH 4.0. The mixture is incubated at 22° C. for 18 hr, and then dialyzed twice against 20 volumes of 20 mM Bis-Tris, 0.4 M urea, pH 6.0. The dialyzed materials are then further purified on a FPLC RESOURCE-Q™ column equilibrated with 20 Bis-Tris, 0.4 M urea, pH 6.0. The enzyme is eluted with a linear gradient of NaCl. [0133]
  • SDS-PAGE analysis of the S-300 fractions under reduced and non-reduced conditions indicated that [0134] Pro-memapsin 2 first elutes as a very high molecular weight band (greater than about 42 kD) under non-reduced conditions. This indicates that the protein is not folded properly in these fractions, due to disulfide cross linking of proteins. Subsequent fractions contain a protein of predicted pro-memapsin 2-T12 size (about 42 kDa). The pro-enzyme obtained in these fractions is also proteolytically active for auto-catalyzed activation. These fractions were pooled and subjected to chromatography on the FPLC RESOURCE™ column eluted with a linear gradient of NaCl. Some fractions were analyzed using SDS-PAGE under non-reducing conditions. The analysis showed that fractions 6 and 7 contained most of the active proteins, which was consistent with the first FPLC peak containing the active protein. The main peak was coupled to a shoulder peak, and was present with repeated purification with the same RESOURCE™ Q column. The main shoulder peaks were identified as active pro-memapsin 2 that exist in different conformations under these conditions.
    • EXAMPLE 4 Proteolytic Activity and Cleavage-site Preferences of Recombinant Memapsin 2
  • The amino acid sequence around the proteolytic cleavage sites was determined in order to establish the specificity of [0135] memapsin 2. Recombinant pro-memapsin 2-T1 was incubated in 0.1 M sodium acetate, pH 4.0, for 16 hours at room temperature in order to create autocatalyzed cleavages The products were analyzed using SDS-polyacrylamide gel electrophoresis. Several bands which corresponded to molecular weights smaller than that of pro-memapsin 2 were observed. The electrophoretic bands were trans-blotted onto a PVDF membrane. Four bands were chosen and subjected to N-terminal sequence determination in a Protein Sequencer. The N-terminal sequence of these bands established the positions of proteolytic cleavage sites on pro-memapsin 2.
  • In addition, the oxidized β-chain of bovine insulin and two different synthetic peptides were used as substrates for [0136] memapsin 2 to determine the extent of other hydrolysis sites. These reactions were carried out by auto-activated pro-memapsin 2 in 0.1 M sodium acetate, pH 4.0, which was then incubated with the peptides. The hydrolytic products were subjected to HPLC on a reversed phase C-18 column and the eluent peaks were subjected to electrospray mass spectrometry for the determination of the molecular weight of the fragments. Two hydrolytic sites were identified on oxidized insulin B-chain (Table 1). Three hydrolytic sites were identified from peptide NCH-gamma. A single cleavage site was observed in synthetic peptide PS1-gamma, whose sequence (LVNMAEGD) (SEQ ID NO:9) is derived from the beta-processing site of human presenilin 1 (Table 1).
    TABLE 1
    Substrate Specificity of Memapsin 2
    Site # Substrate P4 P3 P2 P1 P1′ P2′ P3′ P4′
     1 Pro- R G S M A G V L aa 12-18 of SEQ ID No. 3
     2 memapsin 2 G T Q H G I R L aa 23-30 of SEQ ID No. 3
     3 S S N F A V G A aa 98-105 of SEQ ID No. 3
     4 G L A Y A E I A aa 183-190 of SEQ ID No. 3
     5 Oxidized H L C{circumflex over ( )} G S H L V C{circumflex over ( )} is cysteic acid;
    insulin B- C{circumflex over ( )} G E R G F F Y SEQ ID No. 22
     6 chain SEQ ID No. 23
     7 Synthetic V G S G V Three sites cleaved in a peptide:
     8 peptide* V G S G V L L VGSGVLLSRK (SEQ ID
     9 G V L L S R K NO:30)
    SEQ ID No. 24
    SEQ ID No. 25
    SEQ ID No. 26
    10 Peptide** L V N M A E G D SEQ ID No.9
    • EXAMPLE 5 Activation of Pro-memapsin 2 and Enzyme Kinetics
  • Incubation in 0.1 M sodium acetate, pH 4.0, for 16 h at 22° C. auto-catalytically converted pro-M2[0137] pd to M2pd. For initial hydrolysis tests, two synthetic peptides were separately incubated with pro-M2pd in 0.1 M Na acetate, pH 4.0 for different periods ranging from 2 to 18 h. The incubated samples were subjected to LC/MS for the identification of the hydrolytic products. For kinetic studies, the identified HPLC (Beckman System Gold) product peaks were integrated for quantitation. The Km and kcat values for presenilin 1 and Swedish APP peptides (Table 1) were measured by steady-state kinetics The individual Km and kcat values for APP peptide could not be measured accurately by standard methods, so its kcat/Km value was measured by competitive hydrolysis of mixed substrates against presenilin 1 peptide (Fersht, A. “Enzyme Structure and Mechanism”, 2nd Ed., W.H. Freeman and Company, New York. (1985)).
  • The results are shown in FIGS. 2A and 2B. The conversion of pro-M[0138] pd at pH 4.0 to smaller fragments was shown by SDS-polyacrylamide electrophoresis. The difference in migration between pro-M2pd and converted enzyme is evident in a mixture of the two. FIG. 2A is a graph of the initial rate of hydrolysis of synthetic peptide swAPP (see Table 1) by M2pd at different pH. FIG. 2B is a graph of the relative kcat /Km values for steady-state kinetic of hydrolysis of peptide substrates by M2pd.
    • EXAMPLE 6 Expression in Mammalian Cells
  • Methods [0139]
  • PM2 cDNA was cloned into the EcoRV site of vector pSecTag A (Invitrogen). Human APP cDNA was PCR amplified from human placenta 8-gt11 library (Clontech) and cloned into the NheI and XbaI sites of pSecTag A. The procedure for transfection into HeLa cells and vaccinia virus infection for T7-based expression are essentially the same as described by Lin, X., [0140] FASEB J. 7:1070-1080 (1993).
  • Transfected cells were metabolically labeled with 200 microCi[0141] 35S methionine and cysteine (TransLabel; ICN) in 0.5 ml of serum-free/methionine-free media for 30 min, rinsed with 1 ml media, and replaced with 2 ml DMEM/10% FCS. In order to block vesicle acidification, Bafilomycin Al was included in the media (Perez, R. G., et al., J Biol Chem 271:9100-9107 (1996)). At different time points (chase), media was removed and the cells were harvested and lysed in 50 mM Tris, 0.3 M NaCl, 5 mM EDTA, 1% Triton X-100, ph 7.4, containing 10 mM iodoacetamide, 10:M TPCK, 10:M TLCK, and 2 microg/ml leupeptin. The supernatant (14,000×g) of cell lysates and media were immunoadsorbed onto antibody bound to protein G sepharose (Sigma) Anti-APP N-terminal domain antibody (Chemicon) was used to recover the betaN-fragment of APP and anti-alpha-beta1-17 antibody (Chemicon, recognizing the N-terminal 17 residues of alpha-beta) was used to recover the 12 kDa β C-fragment. The former antibody recognized only denatured protein, so media was first incubated in 2 mM dithiothrietol 0.1% SDS at 55° C. for 30 min before immunoabsorption. Samples were cooled and diluted with an equal volume of cell lysis buffer before addition of anti-APP N-terminal domain (Chemicon). Beads were washed, eluted with loading buffer, subjected to SDS-PAGE (NOVEX™) and visualized by autoradiogram or phosphorimaging Molecular Dynamics) on gels enhanced with Amplify (Amersham). immunodetection of the betaN-fragment was accomplished by transblotting onto a PVDF membrane and detecting with anti-alpha-beta1-7 and chemiluminescent substrate (Amersham).
  • Results [0142]
  • HeLa cells transfected with APP or M2 in 4-well chamber slides were fixed with acetone for 10 min and permeabilized in 0.2% Triton X-100 in PBS for 6 min. For localizing M2, polyclonal goat anti-pro-M[0143] 2pd antibodies were purified on DEAE-sepharose 6B and affinity purified against recombinant pro-M2pd immobilized on Affigel (BioRad). Purified anti-pro-M2pd antibodies were conjugated to Alexa568 (Molecular Probes) according to the manufacturer's protocol. Fixed cells were incubated overnight with a 1:100 dilution of antibody in PBS containing 0.1% BSA and washed 4 times with PBS. For APP, two antibodies were used. Antibody Aβ1-17 (described above) and antibody Aβ17-42, which recognizes the first 26 residues following the beta-secretase cleavage site (Chemicon). After 4 PBS washes, the cells were incubated overnight with an anti-mouse FITC conjugate at a dilution of 1:200. Cells were mounted in Prolong anti-fade reagent (Molecular Probes) and visualized on a Leica TCS confocal laser scanning microscope.
    • EXAMPLE 7 Design and Synthesis of OM99-1 and OM99-2
  • Based on the results of specificity studies of [0144] memapsin 2, it was predicted that good residues for positions P1 and P1′ would be Leu and Ala. It was subsequently determined from the specificity data that P1′ preferred small residues, such as Ala and Ser. However, the crystal structure (determined below in Example 9) indicates that this site can accommodate a lot of larger residues. It was demonstrated that P1′ of memapsin 2 is the position with the most stringent specificity requirement where residues of small side chains, such as Ala, Ser, and Asp, are preferred. Ala was selected for P1′ mainly because its hydophobicity over Ser and Asp is favored for the penetration of the blood-brain barrier, a requirement for the design of a memapsin 2 inhibitor drug for treating Alzheimer's disease. Therefore, inhibitors were designed to place a transition-state analogue isostere between Leu and Ala (shown as Leu*Ala, where * represents the transition-state isostere, —CH(OH)—CH2—) and the subsite P4, P3, P2, P2′, P3′ and P4′ are filled with the beta-secretase site sequence of the Swedish mutant from the beta-amyloid protein. The structures of inhibitors
    OM99-1:     Val-Asn-Leu*Ala-Ala-Glu-Phe (SEQ. ID NO.27)
    OM99-2: Glu-Val-Asn-Leu*Ala-Ala-Glu-Phe (SEQ. ID NO.28)
  • The Leu*Ala dipeptide isostere was synthesized as follows: [0145]
  • The Leu-Ala dipeptide isostere for the M[0146] 2-inhibitor was prepared from L-leucine. As shown in Scheme 1, L-leucine was protected as its BOC-derivative 2 by treatment with BOC20 in the presence of 10% NaOH in diethyl ether for 12 h. Boc-leucine 2 was then converted to Weinreb amide 3 by treatment with isobutyl chcloroformate and N-methylpiperidine followed by treatment of the resulting mixed anhydride with N2,O-dimethylhydroxylamine
    Figure US20020164760A1-20021107-C00001
  • (Nahm and Weinreb, [0147] Tetrahedron Letters 191, 32, 3815) Reduction of 3 with lithium aluminum hydride in diethyl ether provided the aldehyde 4. Reaction of the aldehyde 4 with lithium propiolate derived from the treatment of ethyl propiolate and lithium diisopropylamide afforded the acetylenic alcohol 5 as an inseparable mixture of diastereomers (5.8:1) in 42% isolated yield (Fray, Kaye and Kleinman, J. Org. Chem. 1986, 51, 4828-33). Catalytic hydrogenation of 5 over Pd/BaSO4 followed by acid-catalyzed lactonization of the resulting gamma-hydroxy ester with a catalytic amount of acetic acid in toluene at reflux, furnished the gamma-lactone 6 and 7 in 73% yield. The isomers were separated by silica gel chromatography by using 40% ethyl acetate in hexane as the eluent.
    Figure US20020164760A1-20021107-C00002
  • Introduction of the methyl group at C-2 was accomplished by stereoselective alkylation of 7 with methyl iodide (Scheme 2). Thus, generation of the dianion of lactone 7 with lithium hexamethyldisilazide (2.2 equivalents) in tetrahydrofuran at −78° C. (30 min) and alkylation with methyl iodide (1.1 equivalents) for 30 min at −78° C., followed by quenching with propionic acid (5 equivalents), provided the desired alkylated lactone 8 (76% yield) along with a small amount (less than 5%) of the corresponding epimer (Ghosh and Fidanze, 1998 J. Org. Chem. 1998, 63, 6146-54). The epimeric cis-lactone was removed by column chromatography over silica gel using a mixture (3:1) of ethyl acetate and hexane as the solvent system. The stereochemical assignment of alkylated [0148] lactone 8 was made based on extensive 1H-NMR NOE experiments. Aqueous lithium hydroxide promoted hydrolysis of the lactone 8 followed by protection of the gamma-hydroxyl group with tert-butyldimetlhylsilyl chloride in the presence of imidazole and dimethylaminopyridine in dimethylformamide afforded the acid 9 in 90% yield after standard work-up and chromatography. Selective removal of the BOC-group was effected by treatment with trifluoroacetic acid in dichloromethane at 0° C. for 1 h. The resulting amine salt was then reacted with commercial (Aldrich, Milwaukee) Fmoc-succinimide derivative in dioxane in the presence of aqueous NaHCO3 to provide the Fmoc-protected L*A isostere 10 in 65% yield after chromatography. Protected isostere 10 was utilized in the preparation of a random sequence inhibitor library.
    • Experimental Procedure N-(tert-Butoxycarbonyl)-L-Leucine (2)
  • To the suspension of 10 g (76.2 mmol ) of L-leucine in 140 mL of diethyl ether was added 80 mL of 10% NaOH. After all solid dissolves, 20 mL (87.1 mmol) of BOC[0149] 2O was added to the reaction mixture. The resulting reaction mixture was stirred at 23° C. for 12 h. After this period, the layers were separated and the aqueous layer was acidified to pH 1 by careful addition of 1 N aqueous HCl at 0° C. The resulting mixture was extracted with ethyl acetate (3×100 mL). The organic layers were combined and washed with brine and dried over anhydrous Na2SO4. The solvent was removed under reduced pressure to provide title product which was used directly for next reaction without further purification (yield, 97%). 1H NMR (400 MHz, CDCl3) δ4.89 (broad d, 1H, J=8.3 Hz), 4.31 (m, 1H), 1.74-1.49 (m, 3H), 1.44 (s, 9H), 0.95 (d, 6H, J=6.5 Hz).
    • N-(tert-Butoxycarbonyl)-L-leucine-N′-methoxy-N′-methyla-mide (3)
  • To a stirred solution of N,O-dimetliylhydroxyamine hydrochloride (5.52 g, 56.6 mmol) in dry dichloromethane (25 mL) under N[0150] 2 atmosphere at 0° C., -methylpiperidine (6.9 mL, 56.6 mmol) was added dropwise The resulting mixture was stirred at 0° C. for 30 min. In a separate flask, N-(tert-butyloxycarbonyl)-L-leucine (1) (11.9 g, 51.4 mmol) was dissolved in a mixture of THF (45 mL) and dichloromethane (180 mL) under N2 atmosphere. The resulting solution was cooled to −20° C. To this solution was added 1-methylpiperidine (6.9 mL, 56.6 mmol) followed by isobutyl chloroformate (7.3 mL, 56.6 mmol). The resulting mixture was stirred for 5 minutes at −20° C. and the above solution of N,O-dimethylhydroxyamine was added to it. The reaction mixture was kept −20° C. for 30 minutes and then warmed to 23° C. The reaction was quenched with water and the layers were seperated. The aqueous layer was extracted with dichloromethane (3×100 mL). The combined organic layers were washed with 10% citric acid, saturated sodium bicarbonate, and brine. The organic layer was dried over anhydrous Na2SO4 and concentrated under the reduced pressure. The residue was purified by flash silica gel chromatography (25% ethyl acetate/hexane) to yield the title compound 3 (13.8 g, 97%) as a pale yellow oil. 1H NMR (400 MHz, CDCl3) δ5.06 (broad d, 1H, J=9.1 Hz), 4.70 (m, 1H), 3.82 (s, 3H), 3.13 (s, 3H), 1.70 (m, 1H), 1.46-1.36 (m, 2H) 1.41 (s, 9H), 0.93 (dd, 6H, J=6.5, 14.2 Hz).
    • N-(tert-Butoxycarbonyl)-L-leucinal (4)
  • To a stirred suspension of lithium aluminum hydride (770 mg, 20.3 mmol) in dry diethyl ether (60 mL) at -40° C. under N[0151] 2 atmosphere, was added N-tert-butyloxycarbonyl-L-leucine-N′-methoxy-N′-methylamide (5.05 g, 18.4 mmol) in diethyl ether (20 mL). The resulting reaction mixture was stirred for 30 min. After this period, the reaction was quenched with 10% NaHSO4 solution (30 mL). The resulting reaction mixture was then warmed to 23° C. and stirred at that temperature for 30 min. The resulting solution was filtered and the filter cake was washed by two portions of diethyl ether. The combined organic layers were washed with saturated sodium bicarbonate, brine and dried over anhydrous MgSO4. Evaporation of the solvent under reduced pressure afforded the title aldehyde 4 (3.41 g) as a pale yellow oil. The resulting aldehyde was used immediately without further purification. 1H NMR (400 MHz, CDC13) δ9.5 (s, 1H), 4.9 (s, 1H), 4.2 (broad m, 1H), 1.8-1.6 (m, 2H), 1.44 (s, 9H), 1.49-1.39 (m, 1H), 0.96 (dd, 6H, J=2.7,6.5 Hz).
    • Ethyl (4S,5S)- and (4R,5S) -5-[(tert-Butoxycarbonyl)amino]-4-hydroxy 7-methyloct-2-ynoate (5)
  • To a stirred solution of diisopropylamine (1.1 mL, 7.9 mmol) in dry THF (60 mL) at 0° C. under N[0152] 2 atmosphere, was added n-BuLi (1.6 M in hexane, 4.95 mL, 7.9 mmol) dropwise. The resulting solution was stirred at 0° C. for 5 min and then warmed to 23° C. and stirred for 15 min. The mixture was cooled to −78° C. and ethyl propiolate (801 μL) in THF (2 mL) was added dropwise over a period of 5 min. The mixture was stirred for 30 min, after which N-Boc-L-leucinal 4 (1.55 g, 7.2 mmol) in 8 mL of dry THF was added. The resulting mixture was stirred at −78° C. for 1 h. After this period, the reaction was quenched with acetic acid (5 mL) in THF (20 mL). The reaction mixture was warmed up to 23° C. and brine solution was added. The layers were separated and the organic layer was washed with saturated sodium bicarbonate and dried over Na2SO4. Evaporation of the solvent under reduced pressure provided a residue which was purified by flash silica gel chromatography (15% ethyl acetate/hexane) to afford a mixture (3:1) of acetylenic alcohols 5 (0.96 g, 42%). 1H NMR (300 MHz, CDCl3) δ4.64 (d, 1H, J=9.0 Hz), 4.44 (broad s, 1H), 4.18 (m, 2H), 3.76 (m, 1H), 1.63 (m, 1H), 1.43-1.31 (m, 2H), 1.39 (s, 9H), 1.29-1.18 (m, 3H), 0.89 (m, 6H).
    • (5S,1′S)-5-[1′-[(tert-Butoxycarbonyl)amino]-3′-methylbutyl]-dihydrofuran-2(3H)-one (7)
  • To a stirred solution of the above mixture of acetylenic alcohols (1.73 g, 5.5 mmol ) in ethyl acetate (20 mL) was added 5% Pd/BaSO[0153] 4 (1 g). The resulting mixture was hydrogenated at 50 psi for 1.5 h. After this period, the catalyst was filtered off through a plug of Celite and the filtrate was concentrated under reduced pressure. The residue was dissolved in toluene (20 mL) and acetic acid (100 μL). The reaction mixture was refluxed for 6 h. After this period, the reaction was cooled to 23° C. and the solvent was evaporated to give a residue which was purified by flash silica gel chromatography (40% diethyl ether/hexane) to yield the (5S, 1S′)-gamma-lactone 7 (0.94 g, 62.8 and the (5R, 1S′)-gamma-lactone 6 (0.16 g, 10.7%). Lactone 7: 1H NMR (400 MHz, CDCl3) δ4.50-4.44 (m, 2H), 3.84-3.82 (m, 1H), 2.50 (t, 6H, J=7.8 Hz) 2.22-2.10 (m, 2H), 1.64-1.31 (m, 3H), 1.41 (s, 9H), 0.91 (dd, 6H, J=2.2, 6.7 Hz); 13C NMR (75 MHz, CDCl3) δ177.2, 156.0, 82.5, 79.8, 51.0,42.2, 28,6, 28.2, 24.7, 24.2, 23.0, 21.9.
    • (3R,5S,1′S)-5-[1′-[(tert-Butoxycarbonyl)amino)]-3′-methylbut-yl]-3-methyldihydrofuran-2(3H)-one (8)
  • To a stirred solution of the lactone 7 (451.8 mg, 1.67 mmol) in [0154] dry THF 8 mL) at −78° C. under N2 atmosphere, was added lithium hexamnethyldisilazane (3.67 mL, 1.0 M in THF) over a period of 3 min. The resulting mixture was stirred at −78° C. for 30 min to generate the lithium enolate. After this period, Mel (228 μL) was added dropwise and the resulting mixture was stirred at −78° C. for 20 min. The reaction was quenched with saturated aqueous NH4Cl solution and was allowed to warm to 23° C. The reaction mixture was concentrated under reduced pressure and the residue was extracted with ethyl acetate (3×100 mL). The combined organic layers were washed with brine and dried over anhydrous Na2SO4. Evaporation of the solvent afforded a residue which was purified by silica gel chromatography (15% ethyl acetate/hexane) to furnish the alkylated lactone 8 (0.36 g, 76%) as an amorphous solid. 1H NMR (300 MHz, CDCl3) δ4.43 (broad t, 1H, J=6.3 Hz), 4.33 (d, 1H, J=9.6 Hz), 3.78 (m, 1H), 2.62 (m, 1H), 2.35 (m, 1H), 1.86 (m, 1H), 1.63-1.24 (m, 3H), 1.37 (s, 9H), 1.21 (d, 3H, J=7.5 Hz), 0.87 (dd, 6H, J=2.6, 6.7 Hz); 13NMR (75 MHz, CDCl3) δ180.4, 156.0, 80.3, 79.8, 51.6, 41.9, 34.3, 32.5, 28.3, 24.7,23.0, 21.8, 16.6.
    • (2R,4S,5S)-5-[(tert-Butoxycarbonyl)amino]-4-[(tert-butyldimethylsilyl)oxy]-2,7-dimethyloctanoic acid (9)
  • To a stirred solution of lactone 8 (0.33 g, 1.17 mmol) in THF (2 mL) was added 1 N aqueous LiOH solution (5.8 mL). The resulting mixture was stirred at 23° C. for 10 h. After this period, the reaction mixture was concentrated under reduced pressure and the remaining aqueous residue was cooled to 0° C. and acidified with 25% citric acid solution to [0155] pH 4. The resulting acidic solution was extracted with ethyl acetate (3×50 mL). The combined organic layers were washed with brine, dried over Na2SO4 and concentrated to yield the corresponding hydroxy acid (330 mg) as a white foam. This hydroxy acid was used directly for the next reaction without further purification.
  • To the above hydroxy acid (330 mg, 1.1 mmol) in anhydrous DMF was added imidazole (1.59 g, 23.34 mmol) and tert-butyldimethylchlorosilane (1.76 g, 11.67 mmol). The resulting mixture was stirred at 23° C. for 24 h. After this period, MeOH (4 mL) was added and the mixture was stirred for 1 h. The mixture was diluted with 25% citric acid (20 mL) and was extracted with ethyl acetate (3×20 mL). The combined extracts were washed with water, brine and dried over anhydrous Na[0156] 2SO4. Evaporation of the solvent gave a viscous oil which was purified by flash chromatography over silica gel (35% ethyl acetate/hexane) to afford the silyl protected acid 9 (0.44 g, 90%). IR (neat) 3300-3000 (broad), 2955,2932,2859,1711 cm−1; 1H NMR (400 MHz, DMSO-d6, 343 K) delta 6.20 (broad s, 1H), 3.68 (m, 1H), 3.51 (broad s, 1H), 2.49-2.42 (m, 1H), 1.83 (t, 1H, J=10.1 Hz), 1.56 (m, 1H), 1.37 (s, 9H), 1.28-1.12 (m, 3H), 1.08 (d, 3H, J=7.1 Hz), 0.87 (d, 3H, J=6.1 Hz) 0.86 (s, 9H), 0.82 (d, 3H, J=6.5 Hz), 0.084 (s, 3H), 0.052 (s, 3H).
    • (2R,4S,5S)-5-[(fluorenylmethyloxycarbonyl)amino]-4-[(tert-butyldi-methylsilyl)oxy]-2,7-dimethyloctanoic acid (10)
  • To a stirred solution of the acid 9 (0.17 g, 0.41 mmol) in dichloromethane (2 mL) at 0° C. was added trifluoroacetic acid (500 μL). The resulting mixture was stirred at 0° C. for 1 h and an additional portion (500 μL) of trifluoroacetic acid was added to the reaction mixture. The mixture was stirred for an additional 30 min and the progress of the reaction was monitored by TLC. After this period, the solvents were carefully removed under reduced pressure at a bath temperature not exceeding 5° C. The residue was dissolved in dioxane (3 mL) and NaHCO[0157] 3 (300 mg) in 5 mL of H2O. To this solution was added Fmoc-succinimide (166.5 mg, 0.49 mmol) in 5 mL of dioxane. The resulting mixture was stirred at 23° C. for 8 h. The mixture was then diluted with H2O (5 mL) and acidified with 25% aqueous citric acid to pH 4. The acidic solution was extracted with ethyl acetate (3×50 mL). The combined extracts were washed with brine, dried over Na2SO4 and concentrated under reduced pressure to give a viscous oil residue. Purification of the residue by flash chromatography over silica gel afforded the Fmoc-protected acid 10 (137 mg, 61%) as a white foam. 1H NMR (400 MHz, DMSO-d6, 343 K) δ7.84 (d, 2H, J=7.4 Hz), 7.66 (d, 2H, J=8 Hz), 7.39 (t, 2H, J=7.4 Hz), 7.29 (m, 2H), 6.8 (s, 1H), 4.29-4.19 (m, 3H), 3.74-3.59 (m, 2H), 2.49 (m, 1H), 1.88 (m, 1H), 1.58 (m, 1H), 1.31-1.17 (m, 3H), 1.10 (d, 3H, J=7.1 Hz), 0.88 (s, 9H), 0.82 (d, 6H, J=6.2 Hz), 0.089 (s, 3H), 0.057 (s, 3H).
  • The synthesis of OM99-1 and OM99-2 were accomplished using solid state peptide synthesis procedure in which Leu*Ala was incorporated in the fourth step. The synthesized inhibitors were purified by reverse phase HPLC and their structure confirmed by mass spectrometry. [0158]
    • EXAMPLE 8 Inhibition of Memapsin 2 by OM99-1 and OM99-2
  • Enzyme activity was measured as described above, but with the addition of either OM99-1 or OM99-2. OM99-1 inhibited [0159] recombinant memapsin 2 as shown in FIG. 5A. The Ki calculated is 3×10−8 M. The substrate used was a synthetic fluorogenic peptide substrate. The inhibition of OM99-2 on recombinant memapsin 2 was measured using the same fluorogenic substrate. The Ki value was determined to be 9.58×10−9 M, as shown in FIG. 5B.
  • These results demonstrate that the predicted subsite specificity is accurate and that inhibitors can be designed based on the predicted specificity. [0160]
  • The residues in P1 and P1′ are very important since the M2 inhibitor must penetrate the blood-brain barrier (BBB). The choice of Ala in P1′ facilitates the penetration of BBB. Analogues of Ala side chains will also work. For example, in addition to the methyl side chain of Ala, substituted methyl groups and groups about the same size like methyl or ethyl groups can be substituted for the Ala side chain. Leu at P1 can also be substituted by groups of similar sizes or with substitutions on Leu side chain. For penetrating the BBB, it is desirable to make the inhibitors smaller. One can therefore use OM99-1 as a starting point and discard the outside subsites P4, P3, P3′ and P4′. The retained structure Asn-Leu*Ala-Ala (SEQ ID NO:29) is then further evolved with substitutions for a tight-binding M2 inhibitor which can also penetrate the BBB. [0161]
    • EXAMPLE 9 Crystallization and X-ray Diffraction Study of the Protease Domain of Human Memapsin 2 Complexed to a Specifically Designed Inhibitor, OM99-2
  • The crystallization condition and preliminary x-ray diffraction data on recombinant [0162] human memapsin 2 complexed to OM99-2 were determined.
  • Production of [0163] Recombinant Memapsin 2
  • About 50 mg of [0164] recombinant memapsin 2 was purified as described in Example 3. For optimal crystal growth, memapsin 2 must be highly purified. Memapsin 2 was over-expressed from vector pET11a-M2pd. This memapsin 2 is the zymogen domain which includes the pro and catalytic domains to the end of the C-terminal extension but does not include the transmembrane and the intracellular domains. The vector was transfected into E. coli BL21 (DE3) and plated onto ZB agar containing 50 mg/liter ampicillin. A single colony was picked to inoculate 100 ml of liquid ZB containing 5 mg ampicillin and cultured at 30° C., for 18 hours, with shaking at 220 RPM. Aliquots of approximately 15 ml of the overnight culture were used to inoculate each 1 liter of LB containing 50 mg of ampicillin. Cultures were grown at 37° C., with shaking at 180 RPM, until an optical density at 600 nm near 0.8 was attained. At that time, expression was induced by addition of 119 mg of IPTG to each liter of culture. Incubation was continued for 3 additional hours post-induction.
  • Bacteria were harvested, suspended in 50 mM Tris, 150 mM NaCl, pH 7.5 (TN buffer), and lysed by incubation with 6 mg lysozyme for 30 minutes, followed by freezing for 18 hours at −20° C. Lysate was thawed and made to 1 mM MgCl[0165] 2 then 1000 Kunitz units of DNAse were added with stirring, and incubated for 30 min. Volume was expanded to 500 ml with TN containing 0.1% Triton X-100 (TNT buffer) and lysate stirred for 30 minutes. Insoluble inclusion bodies containing greater than 90% memapsin 2 protein were pelleted by centrifugation, and washed by resuspension in TNT with stirring for 1-2 hours. Following three additional TNT washes, the memapsin 2 inclusion bodies were dissolved in 40 ml of 8 M urea, 1 mM EDTA, 1 mM glycine, 100 mM Tris base, 100 mM beta-mercaptoethanlol (8 M urea buffer). Optical density at 280 nm was measured, and volume expanded with 8 M urea buffer to achieve final O.D. near 0.5, with addition of sufficient quantity of beta-mercaptoethanol to attain 10 mM total, and 10 mM DTT, 1 mM reduced glutathione, 0.1 mM oxidized glutathione. The pH of the solution was adjusted to 10.0 or greater, and divided into four aliquots of 200 ml each. Each 200 ml was rapidly-diluted into 4 liters of 20 mM Tris base, with rapid stirring. The pH was adjusted immediately to 9.0, with 1 M HCl, and stored at 4° C. overnight. The following morning the diluted memapsin 2 solution was maintained at room temperature for 4-6 hours followed by adjusting pH to 8.5 and replacing the flasks to the 4° C. room. The same procedure was followed the next day with adjustment of pH to 8.0.
  • This [0166] memapsin 2 solution was allowed to stand at 4° C. for 2-3 weeks. The total volume of approximately 16 liters was concentrated to 40 mls using ultra-filtration (Millipore) and stir-cells (Amicon), and centrifuged at 140,000×g at 30 minutes in a rotor pre-equilbrated to 4° C. The recovered supernatant was applied to a 2.5×100 cm column of S-300 equilibrated in 0.4 M urea, 20 mM Tris-HCl, pH 8.0, and eluted with the same buffer at 30 ml/hour. The active fraction of memapsin 2 was pooled and further purified in a FPLC using a 1 ml Resource-Q (Pharmacia) column. Sample was filtered, and applied to the Resource-Q column equilibrated in 0.4 M urea, 50 mM Tris-HCl, pH 8.0. Sample was eluted with a gradient of 0-1 M NaCl in the same buffer, over 30 ml at 2 ml/min. The eluents containing memapsin 2 appeared near 0.4 M NaCl which was pooled for crystallization procedure at a concentration near 5 mg/ml.
  • The amino-terminal sequence of the protein before crystallization showed two sequences starting respectively at residues 28p and 30p. Apparently, the pro peptide of [0167] recombinant pro-memapsin 2 had been cleaved during the preparation by a yet unidentified proteolytic activity.
  • The activation of the folded pro-enzyme to mature enzyme, [0168] memapsin 2, was carried out as described above, i.e., incubation in 0.1 M sodium acetate pH 4.0 for 16 hours at 22° C. Activated enzyme was further purified using anion-exchange column chromatography on Resource-Q anion exchange column. The purity of the enzyme was demonstrated by SDS-gel electrophoresis. At each step of the purification, the specific activity of the enzyme was assayed as described above to ensure the activity of the enzyme.
    • Preliminary Crystallization with OM99-2
  • Crystal trials were performed on purified [0169] memapsin 2 in complex with a substrate based transition-state inhibitor OM99-2 with a Ki=10 nM. OM99-2 is equivalent to eight amino-acid residues (including subsites S4, S3, S2, S1 S1′, S2′, S3′ and S4′ in a sequence EVNLAAEF) with the substitution of the peptide bond between the S1 and S1′ (L-A) by a transition-state isostere hydroxyethylene. Purified M2 was concentrated and mixed with 10 fold excessive molar amount of inhibitor. The mixture was incubated at room temperature for 2-3 hours to optimize the inhibitor binding. The crystallization trial was conducted at 20° C. using the hanging drop vapor diffusion procedure. A systemic search with various crystallization conditions was conducted to find the optimum crystallization conditions for memapsin 2/OM99-2 inhibitor complex. For the first step, a coarse screen aimed at covering a wide range of potential conditions were carried out using the Sparse Matrix Crystallization Screen Kits purchased from Hampton Research. Protein concentration and temperature were used as additional variables. Conditions giving promising (micro) crystals were subsequently used as starting points for optimization. using fine grids of pH, precipitants concentration etc.
  • Crystals of memapsin-inhibitor complex were obtained at 30% PEG 8000, 0.1 M NaCocadylate, pH 6.4. SDS gel electrophoresis of a dissolved crystal verified that the content of the crystal to be [0170] memapsin 2. Several single crystals (with the sizes about 0.3 mm×0.2 mm×0.1 mm) were carefully removed from the cluster for data collection on a Raxis IV image plate. These results showed that the crystals diffract to 2.6 Å. A typical protein diffraction pattern is shown in FIG. 6. An X-ray image visualization and integration software-Denzo, was used to visualize and index the diffraction data Denzo identified that the primitive orthorhombic lattice has the highest symmetry with a significantly low distortion index. The unit cell parameters were determined as: a=89.1 Å, b=96.6 Å, c=134.1 Å, α=β=γ=90°. There are two memapsin 2/OM99-2 complexes per crystallographic asymmetric unit, the Vm of the crystal is 2.9 Å3/Da. Diffraction extinctions suggested that the space group is P2 12121.
  • With diffraction of the current crystal to 2.6 Å, the crystal structure obtained from these data has the potential to reach atomic solution, i.e., the three-dimensional positions of atoms and chemical bonds in the inhibitor and in [0171] memapsin 2 can be deduced. Since memapsin 2 sequence is homologous with other mammalian aspartic proteases, e.g., pepsin or cathepsin D, it is predicted that the three dimensional structures of memapsin 2 will be similar (but not identical) to their structures. Therefore, in the determination of x-ray structure from the diffraction data obtained from the current crystal, it is likely the solution of the phase can be obtained from the molecular replacement method using the known crystal structure of aspartic proteases as the search model.
  • Further Crystallization Studies [0172]
  • [0173] Concentrated memapsin 2 was mixed with 10-fold molar excessive of the inhibitor. The mixture was incubated at room temperature for 2-3 hours to optimize inhibitor binding, and then clarified with a 0.2 micron filter using centrifugation. Crystals of memapsin 2-inhibitor complex were grown at 20° C. by hanging drop vapor diffusion method using equal volumes of enzyme-inhibitor and well solution. Crystals of quality suitable for diffraction studies were obtained in two weeks in 0.1 M sodium cacodylate, pH 7.4, 0.2 M (NH4)2SO4, and 22.5% PEG8000. The typical size of the crystals was about 0.4×0.4×0.2mm3.
  • Diffraction data were measured on a Raxis-IV image plate with a Rigaku X-ray generator, processed with the HKL program package [Z. Otwinowski, W. Minor, Methods Enzymol. 276, 307 (1997)] A single crystal of approximately 0.4×0.4×0.2 mm[0174] 3 in size was treated with a cryo-protection solution of 25% PEG8000, 20% glycerol, 0.1 M sodium-cacodylate pH 6.6, and 0.2 M (NH14)2SO4 and then flash-cooled with liquid nitrogen to about −180° C. for data collection. Diffraction was observed to at least 1.9 Å. The crystal form belongs to space group P21, with two memapsin 2/OM99-2 complexes per crystallographic asymmetric unit and 56% solvent content.
  • Molecular replacement was performed with data in the range of 15.0-3.5 Å using program AmoRe, CCP4 package [Navaza, J., Acta Crystallog. Sect. A. 50, 157 (1994)]. Pepsin, a human aspartic protease with 22% sequence identity, was used as the search model([0175] PDB id 1 psn). Rotation and translation search, followed by rigid body refinement, identified a top solution and positioned both molecules in the asymmetric unit. The initial solution had a correlation coefficient of 22% and an R-factor of 0.51. The refinement was carried out using the program CNS [Brunger et al., Acta Crystallogr. Sect. D, 54, 905 (1998)]. 10% of reflections were randomly selected prior to refinement for Rfree monitoring [Bruger, A. T., X-PLOR Version 3.1: A system for X-ray Crystallography and NMR, Yale University Press, New Haven, Conn. (1992)]. Molecular graphics program [Jones, T. A., et al., Improved methods for building protein models in electron denisty maps and location of errors in these models. Acta Crystallogr. Sect. A 47, 110 (1991)] was used for map display and model building. From the initial pepsin model, corresponding amino acid residues were changed to that of memapsin 2 according to sequence alignment. The side chain conformations were decided by the initial electron density map and a rotomer library. This model was refined using molecular dynamics and energy minimization function of CNS [Bruger, A. T., et al., Acta Crystallogr. Sect. D, 54, 905 (1998)]. The first cycle of refinement dropped the Rworking to 41% and the Rfree to 45%. At this stage, electron densities in the omit map clearly showed the inhibitor configuration in the active site cleft. Structural features unique to memapsin 2 in chain tracing, secondary structure, insertions, deletions and extensions (as compared to the search model) are identified and constructed in subsequent iterations of crystallographic refinement and map fitting. The inhibitor was built into the corresponding electron density.
  • About 440 solvent molecules were then gradually added to the structure as identified in the |F|-|Fc| map contoured at the 3 sigma level Non-crystallographic symmetry restriction and averaging were used in early stages of refinement and model building. Bulk solvent and anisotropic over-all B factor corrections were applied through the refinement. The final structure was validated by the program PROCHECK Laskowski, R. A. et al., J. Appl. Crystallog. 26, 283 (1993) which showed that 95% of the residues are located in the most favored region of the Ramachandran plot. All the main chain and side chain parameters are within or better than the standard criteria. The final R[0176] working and Rfree are 18% and 22% respectively. Refinement statistics are listed in Table 2.
    TABLE 2
    Data Collection and Refinement Statistics
    A. Data Statistics
    Space group P21
    Unit Cell (a, b, and c in ) 53.7, 85.9, 109.2
    ( , , and in degrees) 90.0, 101.4, 90.0
    Resolution ( ) 25.0-1.9
    Number of observed reflections 144, 164
    Number of unique reflections  69,056
    Rmerge a 0.061 (0.25)
    Data completeness (%) (25.0-1.9)  90.0 (68.5)
    <I/(I)>  13.7 (3.0)
    B. Refinement Statistics
    Rworking b 0.186
    Rfree b 0.228
    RMS deviation from ideal values
    Bond length ( ) 0.014
    Bond angle (Deg) 1.7
    Number of water molecules 445
    Average B-factor (2)
    Protein 28.5
    Solvent 32.2
  • Memapsin 2 Crystal Structure [0177]
  • The bilobal structure of memapsin 2 (FIG. 7) is characteristic of aspartic proteases (Tang, J., et al., Nature 271, 618-621 (1978)) with the conserved folding of the globular core. The substrate binding cleft, where the inhibitor is bound (FIG. 7), is located between the two lobes. A pseudo two-fold symmetry between the N- (residues 1-180) and C- (residues 181-385) lobes (FIG. 7), which share 61 superimposable atoms with an overall 2.3 Å rms deviation using a 4 Å cutoff. The corresponding numbers for pepsin are 67 atoms and 2.2 Å. Active-site Asp[0178] 32 and Asp28 and the surrounding hydrogen-bond network are located in the center of the cleft (FIG. 7) and are conserved with the typical active-site conformation (Davies, D. R., Annu. Rev. Biophys. Chem. 19, 189 (1990)). The active site carboxyls are, however, not co-planar and the degree of which (50°) exceeds those observed previously.
  • Compared to pepsin, the conformation of the N-lobe is essentially conserved (Sielecki et al., 1990). The most significant structural differences are the insertions and a C-terminal extension in the C-lobe. Four insertions in helices and loops (FIG. 7) are located on the adjacent molecular surface. Insertion F, which contains four acidic residues, is the most negatively charged surface on the molecule. Together, these insertions enlarged significantly the molecular boundary of [0179] memapsin 2 as compared to pepsin (FIG. 8). These surface structural changes may have function in the association of memapsin 2 with other cell surface components. Insertions B and E are located on the other side of the molecule (FIG. 7). The latter contains a beta-strand that paired with part of the C-terminal extension G. A six-residue deletion occurs at position 329 on a loop facing the flap on the opposite side of the active-site cleft, resulting in an apparently more accessible cleft. Most of the C-terminal extension (residues 359-393) is in highly ordered structure. Residues 369-376 form a beta structure with 7 hydrogen bonds to strand 293-299, while residues 378-383 form a helix (FIGS. 7 and 8) Two disulfide pairs (residues 155/359 and 217/382) unique to memapsin 2 fasten both ends of the extension region to the C-lobe. This C-terminal extension is much longer than those observed previously and is conformationally different [Cutfield, S. M., et al., Structure 3, 1261 (1995); Abad-Zapatero, C., et al., Protein Sci. 5, 640 (1996); Symersky, J. et al., Biochemistry 36, 12700 (1997); Yang, J., et al., Acta Crystallogr. D 55, 625 (1999)]. The last eight residues (386-393) are not seen in the electron density map; they may form a connecting stem between the globular catalytic domain and the membrane anchoring domain.
  • Of the 21 putative pro residues only the last six, 43p-48p, are visible in the electron density map. The remainders are likely mobile. Pro-memapsin expressed in mammalian cell culture has an N-terminus position at Glu[0180] 33p. However, an Arg-Arg sequence present at residues 43p-44p is a frequent signal for pro-protein processing, e.g., in prorenin (Corvol, P. et al., Hypertension 5, 13-9 (1983)). Recombinant memapsin 2 derived from this cleavage is fully active. The mobility of residues 28p-42p suggests that they are not part of the structure of mature memapsin 2.
  • Memapsin 2-OM99-2 Interaction [0181]
  • The binding of the eight-residue inhibitor OM99-2 in the active-site cleft shares some structural features with other aspartic protease-inhibitor complexes [Davies, D. R., Annu. Rev. Biophys. Chem. 19, 189 (1990); Bailey and Cooper, (1994); Dealwis et al., (1994)]. These include four hydrogen bonds between the two active-site aspartics to the hydroxyl of the transition-state isostere, the covering of the flap (residues 69-75) over the central part of the inhibitor and ten hydrogen bonds to inhibitor backbone (FIG. 9). Most of the latter are highly conserved among aspartic proteases [Davies, D. R Annu. Rev. Biophys. Chem. 19, 189 (1990); Bailey and Cooper, (1994); Dealwis et al., (1994)] except that hydrogen bonds to Gly[0182] 11 and Tyr198 are unique to memapsin 2. These observations illustrate that the manner by which memapsin 2 transition-state template for substrate peptide backbone and mechanism of catalysis are similar to other aspartic proteases. These common features are, however, not the decisive factors in the design of specific memapsin 2 inhibitors with high selectivity.
  • The observation important for the design of inhibitor drugs is that the [0183] memapsin 2 residues in contact with individual inhibitor side chains (FIG. 9) ace quite different from those for other aspartic proteases. These side chain contacts are important for the design of tight binding inhibitor with high selectivity. Five N-terminal residues of OM99-2 are in extended conformation and, with the exception of P1′ Ala, all have clearly defined contacts (within 4 Å of an inhibitor side chain) with enzyme residues in the active-site cleft (FIG. 9).
  • The protease S[0184] 4 subsite is mostly hydrophilic and open to solvent. The position of inhibitor P4 Glu side chain is defined by hydrogen bonds to Gly11 and to P2 Asn (FIG. 9) and the nearby sidechains of Arg235 and Arg307, which explains why the absence of this residue from OM99-2 cause a 10-fold increase in Ki. Likewise, the protease S2 subsite is relatively hydrophilic and open to solvent. Inhibitor P2 Asn side chain has hydrogen bonds to P4 Glu and Arg235. The relatively small S2 residues Ser325 and Ser327 (Gln and Met respectively in pepsin) may fit a side chain larger than Asn. Memapsin 2 S1 and S3 subsites, which consist mostly of hydrophobic residues, have conformations very different from pepsin due to the deletion of pepsin helix hH2 (Dealwis, et al., (1994)). The inhibitor side chains of P3 Val and P1 Leu are closely packed against each other and have substantial hydrophobic contacts with the enzyme (FIG. 9), especially P3 interacts with Tyr71 and Phe108. In the beta-secretase site of native APP, the P2 and P1 residues are Lys and Met respectively. Swedish mutant APP has Asn and Leu in these positions respectively, resulting in a 60-fold increase of kcat/Km over that for native APP and an early onset of AD described by Mullan, M., et al. [Nat. Genet. 2, 340 (1992)]. The current structure suggests that inhibitor P2 Lys would place its positively charge in an unfavorable interaction with Arg235 with a loss of hydrogen bond to Arg235, while P1 Met would have less favorable contact with memapsin 2 than does leucine in this site (FIG. 10) No close contact with memapsin 2 was seen for P1′ Ala and an aspartic at this position, as in APP, may be accommodated by interacting with Arg228.
  • The direction of inhibitor chain turns at P[0185] 2′ and leads P3′ and P4′ toward he protein surface (FIG. 10). As a result, the side chain position of P2′ Ala eviates from the regular extended conformation. The side chains of P3′ Glu and P4′ Phe are both pointed toward molecular surface with little significant interaction with the protease (FIG. 10). The relatively high B-factors (58.2 Å2 for Glu and 75.6 Å2 for Phe) and less well-defined electron density suggests that these two residues are relatively mobile, in contrast to the defined structure of the S3′ and S4′ subsites in renin-inhibitor (CH-66) complex (Dealwis et al., 1994). The topologically equivalent region of these renin subsites (residues 292-297 in pepsin numbering) is deleted in memapsin 2. These observations suggest that the conformation of three C-terminal residues of OM99-2 may be a functional feature of memapsin 2, possibly a way to lead a long protein substrate out of the active-site cleft.
    • EXAMPLE 10 Using the Crystal Structure to Design Inhibitors
  • Pharmaceutically acceptable inhibitor drugs normally post a size limit under 800 daltons. In the case of [0186] memapsin 2 inhibitors, this requirement may even be more stringent due to the need for the drugs to penetrate the blood-brain barrier [Kearney and Aweeka, (1999)]. In the current model, well defined subsite structures spending P4 to P2′ provide sufficient template areas for rational design of such drugs. The spacial relationships of individual inhibitor side chain with the corresponding subsite of the enzyme as revealed in this crystal structure permits the design of new inhibitor structures in each of these positions. It is also possible to incorporate the unique conformation of subsites P2′, P3′ and P4′ into the selectivity of memapsin 2 inhibitors. The examples of inhibitor design based on the current crystal structure are given below.
    • Example A
  • Since the side chains of P[0187] 3 Val and P1 Leu are packed against each other and there is no enzyme structure between them, cross-linking these side chains would increase the binding strength of inhibitor to memaspin 2. This is because when binding to the enzyme, the cross-linked inhibitors would have less entropy difference between the free and bound forms than their non-cross-linked counterparts [Khan, A. R., et al., Biochemistry, 37, 16839 (1998)]. Possible structures of the cross-linked side chains include those shown in FIG. 11.
    • Example B
  • The same situation exits between the P4 Glu and P2 Asn. The current crystal structure shows that these side chains are already hydrogen bonded to each other so the cross linking between them would also derive binding benefit as described in the Example A. The cross-linked structures include those shown in FIG. 12. [0188]
    • Example C
  • Based on the current crystal structure, the P1′ Ala side chain may be extended to add new hydrophobic, Van der Waals and H-bond interactions. An example of such a design is diagramed in FIG. 13. [0189]
    • Example D
  • Based on the current crystal structure, the polypeptide backbone in the region of P1, P2, and P3, and the side chain of P1-Leu can be bridged into rings by the addition of two atoms (A and B in FIG. 14). Also, a methyl group can be added to the beta-carbon of the P1 -Leu (FIG. 14). [0190]
  • Modifications and variations of the methods and materials described herein will be obvious to those skilled in the art and are intended to come within the scope of the appended claims. [0191]
  • 1 31 1 3252 DNA Homo sapiens 1 gcgggagtgc tgcctgccca cggcacccag cacggcatcc ggctgcccct gcgcagcggc 60 ctggggggcg cccccctggg gctgcggctg ccccgggaga ccgacgaaga gcccgaggag 120 cccggccgga ggggcagctt tgtggagatg gtggacaacc tgaggggcaa gtcggggcag 180 ggctactacg tggagatgac cgtgggcagc cccccgcaga cgctcaacat cctggtggat 240 acaggcagca gtaactttgc agtgggtgct gccccccacc ccttcctgca tcgctactac 300 cagaggcagc tgtccagcac ataccgggac ctccggaagg gtgtgtatgt gccctacacc 360 cagggcaagt gggaagggga gctgggcacc gacctggtaa gcatccccca tggccccaac 420 gtcactgtgc gtgccaacat tgctgccatc actgaatcag acaagttctt catcaacggc 480 tccaactggg aaggcatcct ggggctggcc tatgctgaga ttgccaggcc tgacgactcc 540 ctggagcctt tctttgactc tctggtaaag cagacccacg ttcccaacct cttctccctg 600 cagctttgtg gtgctggctt ccccctcaac cagtctgaag tgctggcctc tgtcggaggg 660 agcatgatca ttggaggtat cgaccactcg ctgtacacag gcagtctctg gtatacaccc 720 atccggcggg agtggtatta tgaggtgatc attgtgcggg tggagatcaa tggacaggat 780 ctgaaaatgg actgcaagga gtacaactat gacaagagca ttgtggacag tggcaccacc 840 aaccttcgtt tgcccaagaa agtgtttgaa gctgcagtca aatccatcaa ggcagcctcc 900 tccacggaga agttccctga tggtttctgg ctaggagagc agctggtgtg ctggcaagca 960 ggcaccaccc cttggaacat tttcccagtc atctcactct acctaatggg tgaggttacc 1020 aaccagtcct tccgcatcac catccttccg cagcaatacc tgcggccagt ggaagatgtg 1080 gccacgtccc aagacgactg ttacaagttt gccatctcac agtcatccac gggcactgtt 1140 atgggagctg ttatcatgga gggcttctac gttgtctttg atcgggcccg aaaacgaatt 1200 ggctttgctg tcagcgcttg ccatgtgcac gatgagttca ggacggcagc ggtggaaggc 1260 ccttttgtca ccttggacat ggaagactgt ggctacaaca ttccacagac agatgagtca 1320 accctcatga ccatagccta tgtcatggct gccatctgcg ccctcttcat gctgccactc 1380 tgcctcatgg tgtgtcagtg gcgctgcctc cgctgcctgc gccagcagca tgatgacttt 1440 gctgatgaca tctccctgct gaagtgagga ggcccatggg cagaagatag agattcccct 1500 ggaccacacc tccgtggttc actttggtca caagtaggag acacagatgg cacctgtggc 1560 cagagcacct caggaccctc cccacccacc aaatgcctct gccttgatgg agaaggaaaa 1620 ggctggcaag gtgggttcca gggactgtac ctgtaggaaa cagaaaagag aagaaagaag 1680 cactctgctg gcgggaatac tcttggtcac ctcaaattta agtcgggaaa ttctgctgct 1740 tgaaacttca gccctgaacc tttgtccacc attcctttaa attctccaac ccaaagtatt 1800 cttcttttct tagtttcaga agtactggca tcacacgcag gttaccttgg cgtgtgtccc 1860 tgtggtaccc tggcagagaa gagaccaagc ttgtttccct gctggccaaa gtcagtagga 1920 gaggatgcac agtttgctat ttgctttaga gacagggact gtataaacaa gcctaacatt 1980 ggtgcaaaga ttgcctcttg aattaaaaaa aaactagatt gactatttat acaaatgggg 2040 gcggctggaa agaggagaag gagagggagt acaaagacag ggaatagtgg gatcaaagct 2100 aggaaaggca gaaacacaac cactcaccag tcctagtttt agacctcatc tccaagatag 2160 catcccatct cagaagatgg gtgttgtttt caatgttttc ttttctgtgg ttgcagcctg 2220 accaaaagtg agatgggaag ggcttatcta gccaaagagc tcttttttag ctctcttaaa 2280 tgaagtgccc actaagaagt tccacttaac acatgaattt ctgccatatt aatttcattg 2340 tctctatctg aaccaccctt tattctacat atgataggca gcactgaaat atcctaaccc 2400 cctaagctcc aggtgccctg tgggagagca actggactat agcagggctg ggctctgtct 2460 tcctggtcat aggctcactc tttcccccaa atcttcctct ggagctttgc agccaaggtg 2520 ctaaaaggaa taggtaggag acctcttcta tctaatcctt aaaagcataa tgttgaacat 2580 tcattcaaca gctgatgccc tataacccct gcctggattt cttcctatta ggctataaga 2640 agtagcaaga tctttacata attcagagtg gtttcattgc cttcctaccc tctctaatgg 2700 cccctccatt tatttgacta aagcatcrca cagtggcact agcattatac caagagtatg 2760 agaaatacag tgctttatgg ctctaacatt actgccttca gtatcaaggc tgcctggaga 2820 aaggatggca gcctcagggc ttccttatgt cctccaccac aagagctcct tgatgaaggt 2880 catctttttc ccctatcctg ttcttcccct ccccgctcct aatggtacgt gggtacccag 2940 gctggttctt gggctaggta gtggggacca agttcattac ctccctatca gttctagcat 3000 agtaaactac ggtaccagtg ttagtgggaa gagctgggtt ttcctagtat acccactgca 3060 tcctactcct acctggtcaa cccgctgctt ccaggtatgg gacctgctaa gtgtggaatt 3120 acctgataag ggagagggaa atacaaggag ggcctctggt gttcctggcc tcagccagct 3180 gcccmcaagc cataaaccaa taaamcaaga atactgagtc taaaaaaaaa aaaaaaaaaa 3240 aaaaaaaaaa aa 3252 2 488 PRT Homo sapiens Purified Memapsin 2 2 Ala Gly Val Leu Pro Ala His Gly Thr Gln His Gly Ile Arg Leu Pro 1 5 10 15 Leu Arg Ser Gly Leu Gly Gly Ala Pro Leu Gly Leu Arg Leu Pro Arg 20 25 30 Glu Thr Asp Glu Glu Pro Glu Glu Pro Gly Arg Arg Gly Ser Phe Val 35 40 45 Glu Met Val Asp Asn Leu Arg Gly Lys Ser Gly Gln Gly Tyr Tyr Val 50 55 60 Glu Met Thr Val Gly Ser Pro Pro Gln Thr Leu Asn Ile Leu Val Asp 65 70 75 80 Thr Gly Ser Ser Asn Phe Ala Val Gly Ala Ala Pro His Pro Phe Leu 85 90 95 His Arg Tyr Tyr Gln Arg Gln Leu Ser Ser Thr Tyr Arg Asp Leu Arg 100 105 110 Lys Gly Val Tyr Val Pro Tyr Thr Gln Gly Lys Trp Glu Gly Glu Leu 115 120 125 Gly Thr Asp Leu Val Ser Ile Pro His Gly Pro Asn Val Thr Val Arg 130 135 140 Ala Asn Ile Ala Ala Ile Thr Glu Ser Asp Lys Phe Phe Ile Asn Gly 145 150 155 160 Ser Asn Trp Glu Gly Ile Leu Gly Leu Ala Tyr Ala Glu Ile Ala Arg 165 170 175 Pro Asp Asp Ser Leu Glu Pro Phe Phe Asp Ser Leu Val Lys Gln Thr 180 185 190 His Val Pro Asn Leu Phe Ser Leu Gln Leu Cys Gly Ala Gly Phe Pro 195 200 205 Leu Asn Gln Ser Glu Val Leu Ala Ser Val Gly Gly Ser Met Ile Ile 210 215 220 Gly Gly Ile Asp His Ser Leu Tyr Thr Gly Ser Leu Trp Tyr Thr Pro 225 230 235 240 Ile Arg Arg Glu Trp Tyr Tyr Glu Val Ile Ile Val Arg Val Glu Ile 245 250 255 Asn Gly Gln Asp Leu Lys Met Asp Cys Lys Glu Tyr Asn Tyr Asp Lys 260 265 270 Ser Ile Val Asp Ser Gly Thr Thr Asn Leu Arg Leu Pro Lys Lys Val 275 280 285 Phe Glu Ala Ala Val Lys Ser Ile Lys Ala Ala Ser Ser Thr Glu Lys 290 295 300 Phe Pro Asp Gly Phe Trp Leu Gly Glu Gln Leu Val Cys Trp Gln Ala 305 310 315 320 Gly Thr Thr Pro Trp Asn Ile Phe Pro Val Ile Ser Leu Tyr Leu Met 325 330 335 Gly Glu Val Thr Asn Gln Ser Phe Arg Ile Thr Ile Leu Pro Gln Gln 340 345 350 Tyr Leu Arg Pro Val Glu Asp Val Ala Thr Ser Gln Asp Asp Cys Tyr 355 360 365 Lys Phe Ala Ile Ser Gln Ser Ser Thr Gly Thr Val Met Gly Ala Val 370 375 380 Ile Met Glu Gly Phe Tyr Val Val Phe Asp Arg Ala Arg Lys Arg Ile 385 390 395 400 Gly Phe Ala Val Ser Ala Cys His Val His Asp Glu Phe Arg Thr Ala 405 410 415 Ala Val Glu Gly Pro Phe Val Thr Leu Asp Met Glu Asp Cys Gly Tyr 420 425 430 Asn Ile Pro Gln Thr Asp Glu Ser Thr Leu Met Thr Ile Ala Tyr Val 435 440 445 Met Ala Ala Ile Cys Ala Leu Phe Met Leu Pro Leu Cys Leu Met Val 450 455 460 Cys Gln Trp Arg Cys Leu Arg Cys Leu Arg Gln Gln His Asp Asp Phe 465 470 475 480 Ala Asp Asp Ile Ser Leu Leu Lys 485 3 503 PRT Homo sapiens Pro-memapsin 2 3 Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg Gly Ser Met Ala 1 5 10 15 Gly Val Leu Pro Ala His Gly Thr Gln His Gly Ile Arg Leu Pro Leu 20 25 30 Arg Ser Gly Leu Gly Gly Ala Pro Leu Gly Leu Arg Leu Pro Arg Glu 35 40 45 Thr Asp Glu Glu Pro Glu Glu Pro Gly Arg Arg Gly Ser Phe Val Glu 50 55 60 Met Val Asp Asn Leu Arg Gly Lys Ser Gly Gln Gly Tyr Tyr Val Glu 65 70 75 80 Met Thr Val Gly Ser Pro Pro Gln Thr Leu Asn Ile Leu Val Asp Thr 85 90 95 Gly Ser Ser Asn Phe Ala Val Gly Ala Ala Pro His Pro Phe Leu His 100 105 110 Arg Tyr Tyr Gln Arg Gln Leu Ser Ser Thr Tyr Arg Asp Leu Arg Lys 115 120 125 Gly Val Tyr Val Pro Tyr Thr Gln Gly Lys Trp Glu Gly Glu Leu Gly 130 135 140 Thr Asp Leu Val Ser Ile Pro His Gly Pro Asn Val Thr Val Arg Ala 145 150 155 160 Asn Ile Ala Ala Ile Thr Glu Ser Asp Lys Phe Phe Ile Asn Gly Ser 165 170 175 Asn Trp Glu Gly Ile Leu Gly Leu Ala Tyr Ala Glu Ile Ala Arg Pro 180 185 190 Asp Asp Ser Leu Glu Pro Phe Phe Asp Ser Leu Val Lys Gln Thr His 195 200 205 Val Pro Asn Leu Phe Ser Leu Gln Leu Cys Gly Ala Gly Phe Pro Leu 210 215 220 Asn Gln Ser Glu Val Leu Ala Ser Val Gly Gly Ser Met Ile Ile Gly 225 230 235 240 Gly Ile Asp His Ser Leu Tyr Thr Gly Ser Leu Trp Tyr Thr Pro Ile 245 250 255 Arg Arg Glu Trp Tyr Tyr Glu Val Ile Ile Val Arg Val Glu Ile Asn 260 265 270 Gly Gln Asp Leu Lys Met Asp Cys Lys Glu Tyr Asn Tyr Asp Lys Ser 275 280 285 Ile Val Asp Ser Gly Thr Thr Asn Leu Arg Leu Pro Lys Lys Val Phe 290 295 300 Glu Ala Ala Val Lys Ser Ile Lys Ala Ala Ser Ser Thr Glu Lys Phe 305 310 315 320 Pro Asp Gly Phe Trp Leu Gly Glu Gln Leu Val Cys Trp Gln Ala Gly 325 330 335 Thr Thr Pro Trp Asn Ile Phe Pro Val Ile Ser Leu Tyr Leu Met Gly 340 345 350 Glu Val Thr Asn Gln Ser Phe Arg Ile Thr Ile Leu Pro Gln Gln Tyr 355 360 365 Leu Arg Pro Val Glu Asp Val Ala Thr Ser Gln Asp Asp Cys Tyr Lys 370 375 380 Phe Ala Ile Ser Gln Ser Ser Thr Gly Thr Val Met Gly Ala Val Ile 385 390 395 400 Met Glu Gly Phe Tyr Val Val Phe Asp Arg Ala Arg Lys Arg Ile Gly 405 410 415 Phe Ala Val Ser Ala Cys His Val His Asp Glu Phe Arg Thr Ala Ala 420 425 430 Val Glu Gly Pro Phe Val Thr Leu Asp Met Glu Asp Cys Gly Tyr Asn 435 440 445 Ile Pro Gln Thr Asp Glu Ser Thr Leu Met Thr Ile Ala Tyr Val Met 450 455 460 Ala Ala Ile Cys Ala Leu Phe Met Leu Pro Leu Cys Leu Met Val Cys 465 470 475 480 Gln Trp Arg Cys Leu Arg Cys Leu Arg Gln Gln His Asp Asp Phe Ala 485 490 495 Asp Asp Ile Ser Leu Leu Lys 500 4 10 PRT Artificial Sequence Description of Artificial Sequence Primer 4 Ser Glu Val Lys Met Asp Ala Glu Phe Arg 1 5 10 5 10 PRT Artificial Sequence Description of Artificial Sequence Synthetic Peptide 5 Ser Glu Val Asn Leu Asp Ala Glu Phe Arg 1 5 10 6 8 PRT Artificial Sequence Description of Artificial Sequence Synthetic Peptide 6 Ser Val Asn Met Ala Glu Gly Asp 1 5 7 12 PRT Artificial Sequence Description of Artificial Sequence Synthetic Peptide 7 Lys Gly Gly Val Val Ile Ala Thr Val Ile Val Lys 1 5 10 8 4 PRT Homo sapiens 8 Asp Thr Ser Gly 1 9 8 PRT Homo sapiens 9 Leu Val Asn Met Ala Glu Gly Asp 1 5 10 28 DNA Artificial Sequence Description of Artificial Sequence Primer 10 ggtaagcatc ccccatggcc ccaacgtc 28 11 28 DNA Artificial Sequence Description of Artificial Sequence Primer 11 gacgttgggg ccatggggga tgcttacc 28 12 34 DNA Artificial Sequence Description of Artificial Sequence Primer 12 acgttgtctt tgatcgggcc cgaaaacgaa ttgg 34 13 33 DNA Artificial Sequence Description of Artificial Sequence Primer 13 ccaattcgtt ttcgggcccg atcaaagaca acg 33 14 27 DNA Artificial Sequence Description of Artificial Sequence Primer 14 ccatcctaat acgactcact atagggc 27 15 23 DNA Artificial Sequence Description of Artificial Sequence Primer 15 actcactata gggctcgagc ggc 23 16 26 DNA Artificial Sequence Description of Artificial Sequence Primer 16 cttttgagca agttcagcct ggttaa 26 17 31 DNA Artificial Sequence Description of Artificial Sequence Primer 17 gaggtggctt atgagtattt cttccagggt a 31 18 22 DNA Artificial Sequence Description of Artificial Sequence Primer 18 tggcgacgac tcctggagcc cg 22 19 24 DNA Artificial Sequence Description of Artificial Sequence Primer 19 tgacaccaga ccaactggta atgg 24 20 27 DNA Artificial Sequence Description of Artificial Sequence Primer 20 catatggcgg gagtgctgcc tgcccac 27 21 38 DNA Artificial Sequence Description of Artificial Sequence Primer 21 ggatcctcac ttcagcaggg agatgtcatc agcaaagt 38 22 8 PRT Artificial Sequence Description of Artificial Sequence Oxidized Insulin B-chain 22 His Leu Xaa Gly Ser His Leu Val 1 5 23 8 PRT Artificial Sequence Description of Artificial Sequence Oxidized Insulin B-chain 23 Xaa Gly Glu Arg Gly Phe Phe Tyr 1 5 24 5 PRT Artificial Sequence Description of Artificial Sequence Synthetic Peptide 24 Val Gly Ser Gly Val 1 5 25 7 PRT Artificial Sequence Description of Artificial Sequence Synthetic Peptide 25 Val Gly Ser Gly Val Leu Leu 1 5 26 7 PRT Artificial Sequence Description of Artificial Sequence Synthetic Peptide 26 Gly Val Leu Leu Ser Arg Lys 1 5 27 7 PRT Artificial Sequence Description of Artificial Sequence Inhibitors 27 Val Asn Leu Ala Ala Glu Phe 1 5 28 8 PRT Artificial Sequence Description of Artificial Sequence Inhibitors 28 Glu Val Asn Leu Ala Ala Glu Phe 1 5 29 4 PRT Artificial Sequence Description of Artificial Sequence Synthetic Peptide 29 Asn Leu Ala Ala 1 30 10 PRT Artificial Sequence Description of Artificial Sequence Synthetic Peptide 30 Val Gly Ser Gly Val Leu Leu Ser Arg Lys 1 5 10 31 326 PRT Homo sapiens Amino acids 2-5, 6-9, 13-20, 25-32, 65-67, 69-74, 79-87, 89-91, 99-106, 119-122, 150-154, 164-167, 180-183, 191-194, 196-199, 201-204, 210-214, 221-223, 258-262, 265-269, and 275-278 are Beta Strands 31 Val Asp Glu Gln Pro Leu Glu Asn Tyr Leu Asp Met Glu Tyr Phe Gly 1 5 10 15 Thr Ile Gly Ile Gly Thr Pro Ala Gln Asp Phe Thr Val Val Phe Asp 20 25 30 Thr Gly Ser Ser Asn Leu Trp Val Pro Ser Val Tyr Cys Ser Ser Leu 35 40 45 Ala Cys Thr Asn His Asn Arg Phe Asn Pro Glu Asp Ser Ser Thr Tyr 50 55 60 Gln Ser Thr Ser Glu Thr Val Ser Ile Thr Tyr Gly Thr Gly Ser Met 65 70 75 80 Thr Gly Ile Leu Gly Tyr Asp Thr Val Gln Val Gly Gly Ile Ser Asp 85 90 95 Thr Asn Gln Ile Phe Gly Leu Ser Glu Thr Glu Pro Gly Ser Phe Leu 100 105 110 Tyr Tyr Ala Pro Phe Asp Gly Ile Leu Gly Leu Ala Tyr Pro Ser Ile 115 120 125 Ser Ser Ser Gly Ala Thr Pro Val Phe Asp Asn Ile Trp Asn Gln Gly 130 135 140 Leu Val Ser Gln Asp Leu Phe Ser Val Tyr Leu Ser Ala Asp Asp Gln 145 150 155 160 Ser Gly Ser Val Val Ile Phe Gly Gly Ile Asp Ser Ser Tyr Tyr Thr 165 170 175 Gly Ser Leu Asn Trp Val Pro Val Thr Val Glu Gly Tyr Trp Gln Ile 180 185 190 Thr Val Asp Ser Ile Thr Met Asn Gly Glu Ala Ile Ala Cys Ala Glu 195 200 205 Gly Cys Gln Ala Ile Val Asp Thr Gly Thr Ser Leu Leu Thr Gly Pro 210 215 220 Thr Ser Pro Ile Ala Asn Ile Gln Ser Asp Ile Gly Ala Ser Glu Asn 225 230 235 240 Ser Asp Gly Asp Met Val Val Ser Cys Ser Ala Ile Ser Ser Leu Pro 245 250 255 Asp Ile Val Phe Thr Ile Asn Gly Val Gln Tyr Pro Val Pro Pro Ser 260 265 270 Ala Tyr Ile Leu Gln Ser Glu Gly Ser Cys Ile Ser Gly Phe Gln Gly 275 280 285 Met Asn Leu Pro Thr Glu Ser Gly Glu Leu Trp Ile Leu Gly Asp Val 290 295 300 Phe Ile Arg Gln Tyr Phe Thr Val Phe Asp Arg Ala Asn Asn Gln Val 305 310 315 320 Gly Leu Ala Pro Val Ala 325

Claims (33)

We claim:
1. Purified recombinant catalytically active memapsin 2.
2. The memapsin 2 of claim 1 having the amino acid sequence of SEQ ID NO. 2 or the sequence present in a homologous species.
3. The memapsin 2 claim 2 of human origin and having the amino acid sequence of SEQ ID NO. 2.
4. The memapsin 2 of claim 1 not including the transmembrane domain.
5. The memapsin 2 of claim 1 expressed in a bacteria.
6. The memapsin 2 of claim 1 cleaving SEVKM/DAEFR (SEQ ID NO:4) and SEVNL/DAEFR (SEQ ID NO:5) at pH 4.0 with kcat/Km of less than or equal to 39.9 s−1M−1 and less than or equal to kcat, 2.45 s−1, Km, 1 mM; kcat/Km, 2450 s−1M−1, respectively.
7. A method for producing catalytically active recombinant memapsin 2 comprising refolding the recombinant memapsin 2 under conditions which dissociate and then slowly refold the enzyme into a catalytically active form.
8. The method of claim 7 wherein the memapsin 2 is first dissolved in 8 M urea solution including one or more reducing agents at a pH of greater than 8.0.
9. The method of claim 8 wherein the memapsin 2 is then diluted into an aqueous buffer like 20 mM-Tris, pH 9.0, the pH slowly adjusted to approximately 8 with 1 M HCl, and the solution maintained at low temperature for approximately 24 to 48 hours before proceeding with purification.
10. The method of claim 8 wherein the memapsin 2 is then rapidly mixed with an aqueous buffer like 20 mM-Tris, pH 9.0, containing oxidized and reduced glutathione, the process repeated, then the urea concentration decreased to approximately 0.4 M and the pH of the solution slowly adjusted to 8.0.
11. The method of claim 8 wherein the memapsin 2 is dissolved in 8 M urea, pH 10.0, then rapidly diluted into an aqueous buffer like 20 mM Tris base, pH 9.0, and maintained at low temperature several hours, maintained at room temperature for several hours, and then the process repeated at decreasing pH.
12. A method of isolating inhibitors of cleavage by memapsin 2 comprising
adding to one or more potential inhibitors catalytically active recombinant memapsin 2 cleaving SEVKM/DAEFR (SEQ ID NO:4) and SEVNL/DAEFR (SEQ ID NO:5) at pH 4.0 with kcat/Km of less than or equal to 39.9 s−1M−1 and less than or equal to kcat, 2.45 s−1, Km, 1 mM; kcat/Km, 2450 s−1M−1, respectively, and a substrate for memapsin 2, and
screening for decreased cleavage of the substrate by the inhibitors.
13. The method of claim 12 wherein the inhibitors are in a library of small synthetic molecules.
14. The method of claim 12 wherein the inhibitors are compounds selected from the group consisting of proteins and peptides.
15. The method of claim 12 wherein the recombinant memapsin 2 is expressed in genetically engineered cells and the inhibitors and substrate are added to the cells.
16. The method of claim 15 wherein the inhibitors are oligonucleotides preventing or decreasing expression of catalytically active memapsin 2.
17. The method of claim 14 wherein the compounds are isosteres of the memapsin 2 active site defined by the presence of two catalytic aspartic residues and substrate binding cleft.
18. The method of claim 12 further comprising identifying the inhibitors maximally decreasing cleavage of substrate by the memapsin 2.
19. A method for designing or obtaining inhibitors of catalytically active memapsin 2 comprising modeling an inhibitor based on the crystallization coordinates of memapsin 2 or parameters of Table 2.
20. The method of claim 19 comprising using a computer program to model a compound to determine its binding to the memapsin 2 active site defined by the presence of two catalytic aspartic residues and substrate binding cleft.
21. The method of claim 19 comprising using a computer program to design a compound which binds to the memapsin 2 active site defined by the presence of two catalytic aspartic residues and substrate binding cleft.
22. The method of claim 19 further comprising screening compounds which bind to the active site defined by the presence of two catalytic aspartic residues and substrate binding cleft for inhibition of memapsin 2 catalytic activity.
23. A data base comprising binding properties and chemical structures of compounds designed or screened by modeling an inhibitor based on the crystallization coordinates of memapsin 2 or parameters of Table 2.
24. A method of treating or preventing Alzheimer's disease comprising administering administering to a patient in need thereof an inhibitor of memapsin 2 which binds to the active site of the memapsin 2 defined by the presence of two catalytic aspartic residues and substrate binding cleft.
25. The method of claim 24 wherein the inhibitor has an Ki of less than or equal to 10−7 M.
26. The method of claim 24 wherein the inhibitor is selected from the group consisting of proteins, peptides, oligonucleotides, and small synthetic molecules.
27. The method of claim 24 wherein the inhibitor is modeled based on the crystallization coordinates of memapsin 2 or parameters of Table 2.
28. A crystallized memapsin 2 comprising the active site defined by the presence of two catalytic aspartic residues and substrate binding cleft.
29. The memapsin 2 of claim 28 not including the transmembrane and/or intracellular domains.
30. The memapsin 2 of claim 28 having the parameters defined in Table 2.
31. The memapsin 2 of claim 28 having a diffraction to at least 3.5 Å or less.
32. The memapsin 2 of claim 31 having a diffraction to at least 2 Å or less.
33. A method for treatment or preventing Alzheimer's disease comprising immunizing an individual in need thereof with catalytically active memapsin 2 cleaving SEVKM/DAEFR (SEQ ID NO:4) and SEVNL/DAEFR (SEQ ID NO:5) at pH 4.0 with kcat/Km of less than or equal to 39.9 s−1M−1 and less than or equal to kcat, 2.45 s−1, Km, 1 mM; kcat/Km, 2450 s−1M−1, respectively, to elicit an effective amount of antibodies to reduce cleavage by endogenous memapsin 2.
US09/795,903 1999-06-28 2001-02-28 Catalytically active recombinant memapsin and methods of use thereof Abandoned US20020164760A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/795,903 US20020164760A1 (en) 1999-06-28 2001-02-28 Catalytically active recombinant memapsin and methods of use thereof

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US14136399P 1999-06-28 1999-06-28
US16806099P 1999-11-30 1999-11-30
US17783600P 2000-01-25 2000-01-25
US17836800P 2000-01-27 2000-01-27
US21029200P 2000-06-08 2000-06-08
US09/604,608 US6545127B1 (en) 1999-06-28 2000-06-27 Catalytically active recombinant memapsin and methods of use thereof
US09/795,903 US20020164760A1 (en) 1999-06-28 2001-02-28 Catalytically active recombinant memapsin and methods of use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/604,608 Division US6545127B1 (en) 1999-06-28 2000-06-27 Catalytically active recombinant memapsin and methods of use thereof

Publications (1)

Publication Number Publication Date
US20020164760A1 true US20020164760A1 (en) 2002-11-07

Family

ID=27538142

Family Applications (7)

Application Number Title Priority Date Filing Date
US09/604,608 Expired - Lifetime US6545127B1 (en) 1999-06-28 2000-06-27 Catalytically active recombinant memapsin and methods of use thereof
US09/795,903 Abandoned US20020164760A1 (en) 1999-06-28 2001-02-28 Catalytically active recombinant memapsin and methods of use thereof
US09/845,226 Abandoned US20020115600A1 (en) 1999-06-28 2001-04-30 Inhibitors of memapsin 2 and use thereof
US10/773,754 Abandoned US20040220079A1 (en) 1999-06-28 2004-02-06 Inhibitors of Memapsin 2 and use thereof
US10/820,953 Expired - Fee Related US7244708B2 (en) 1999-06-28 2004-04-08 Inhibitors of memapsin 2 and use thereof
US11/763,342 Expired - Fee Related US7678760B2 (en) 1999-06-28 2007-06-14 Inhibitors of Memapsin 2 and use thereof
US11/888,920 Expired - Fee Related US7829669B2 (en) 1999-06-28 2007-08-03 Catalytically active recombinant memapsin and methods of use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/604,608 Expired - Lifetime US6545127B1 (en) 1999-06-28 2000-06-27 Catalytically active recombinant memapsin and methods of use thereof

Family Applications After (5)

Application Number Title Priority Date Filing Date
US09/845,226 Abandoned US20020115600A1 (en) 1999-06-28 2001-04-30 Inhibitors of memapsin 2 and use thereof
US10/773,754 Abandoned US20040220079A1 (en) 1999-06-28 2004-02-06 Inhibitors of Memapsin 2 and use thereof
US10/820,953 Expired - Fee Related US7244708B2 (en) 1999-06-28 2004-04-08 Inhibitors of memapsin 2 and use thereof
US11/763,342 Expired - Fee Related US7678760B2 (en) 1999-06-28 2007-06-14 Inhibitors of Memapsin 2 and use thereof
US11/888,920 Expired - Fee Related US7829669B2 (en) 1999-06-28 2007-08-03 Catalytically active recombinant memapsin and methods of use thereof

Country Status (9)

Country Link
US (7) US6545127B1 (en)
EP (2) EP1196609A2 (en)
JP (2) JP5138851B2 (en)
CN (1) CN1379819A (en)
AT (1) ATE482233T1 (en)
AU (2) AU5771500A (en)
CA (2) CA2374610A1 (en)
DE (1) DE60045005D1 (en)
WO (2) WO2001000663A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030199676A1 (en) * 2000-01-25 2003-10-23 Oklahoma Medical Research Foundation Universal procedure for refolding recombinant proteins
US6790610B2 (en) * 1998-09-24 2004-09-14 Pharmacia & Upjohn Company Alzheimer's disease, secretase, APP substrates therefor, and uses therefor
US20070092517A1 (en) * 2005-08-10 2007-04-26 Oklahoma Medical Research Foundation Truncated memapsin 2 compositions and treatments
US20080021196A1 (en) * 1999-06-28 2008-01-24 The Board Of Trustees Of The University Of Illinois Inhibitors of memapsin 2 and use thereof

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9701684D0 (en) 1997-01-28 1997-03-19 Smithkline Beecham Plc Novel compounds
US20040234976A1 (en) * 1998-09-24 2004-11-25 Gurney Mark E. Alzheimer's disease secretase, app substrates therefor, and uses therefor
US6844148B1 (en) 1998-09-24 2005-01-18 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
CN1300320C (en) 1998-09-24 2007-02-14 法玛西雅厄普约翰美国公司 Alzhimer's disease secretase
US7115410B1 (en) 1999-02-10 2006-10-03 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
US7456007B1 (en) 1998-12-31 2008-11-25 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
EP1165609A2 (en) 1999-02-10 2002-01-02 Elan Pharmaceuticals, Inc. Human beta-secretase enzyme, inhibitors and their compositions and uses
US20090162883A1 (en) * 1999-09-23 2009-06-25 Pharmacia & Upjohn Company Alzheimer's Disease Secretase, APP Substrates Thereof, and Uses Thereof
GB9924957D0 (en) * 1999-10-21 1999-12-22 Smithkline Beecham Plc Novel treatment
GB9925136D0 (en) * 1999-10-22 1999-12-22 Smithkline Beecham Plc Novel treatment
US7514408B1 (en) 1999-12-02 2009-04-07 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
AU779875B2 (en) * 2000-01-24 2005-02-17 Merck Sharp & Dohme Limited Gamma-secretase inhibitors
ES2275675T3 (en) 2000-03-23 2007-06-16 Elan Pharmaceuticals, Inc. COMPOUNDS AND METHODS TO TREAT ALZHEIMER'S DISEASE.
EP1666452A2 (en) 2000-06-30 2006-06-07 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
US7205120B2 (en) * 2000-07-19 2007-04-17 Pharmacia & Upjohn Company Substrates and assays for β-secretase activity
ATE355520T1 (en) * 2000-09-22 2006-03-15 Wyeth Corp CRYSTAL STRUCTURE OF BACE AND USES THEREOF
US7601528B1 (en) 2000-12-23 2009-10-13 Elan Pharmaceuticals, Inc. Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in alzheimer's disease
US7217556B1 (en) 2000-12-23 2007-05-15 Pfizer Inc Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in Alzheimer's disease
US7806980B2 (en) 2000-12-23 2010-10-05 Elan Pharmaceuticals, Inc. Method for crystallizing human beta secretase in complex with an inhibitor
US20040121947A1 (en) * 2000-12-28 2004-06-24 Oklahoma Medical Research Foundation Compounds which inhibit beta-secretase activity and methods of use thereof
EP1233021A3 (en) * 2001-02-20 2002-11-20 Pfizer Products Inc. An inhibitor of Beta amyloid cleavage enzyme
CN100582226C (en) * 2001-02-23 2010-01-20 Dsmip资产有限公司 Genes encoding proteolytic enzymes from aspargilli
US7524668B1 (en) 2001-05-10 2009-04-28 Elan Pharmaceuticals, Inc. Crystal of human beta secretase having monoclinic space group symmetry C2 and methods for crystallization thereof
US7384773B1 (en) * 2001-05-10 2008-06-10 Pfizer Inc Crystal of HIV protease-cleaved human beta secretase and method for crystallization thereof
US7196163B2 (en) 2001-05-22 2007-03-27 Merk & Co., Inc. Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity
IL159015A0 (en) 2001-05-25 2004-05-12 Genset Sa Polypeptides, their preparation and use
MXPA03011502A (en) * 2001-06-11 2004-03-26 Upjohn Co Substituted aminoalcohols useful in treatment of alzheimer's disease.
AU2002345247A1 (en) * 2001-07-26 2003-02-17 Astex Technology Ltd Crystal structure of beta-site app cleaving enzyme (bace) and use thereof
US7186539B1 (en) 2001-08-31 2007-03-06 Pharmacia & Upjohn Company Method for refolding enzymes
US20060234944A1 (en) * 2001-10-23 2006-10-19 Oklahoma Medical Reseach Foundation Beta-secretase inhibitors and methods of use
WO2003039454A2 (en) 2001-10-23 2003-05-15 Oklahoma Medical Research Foundation Beta-secretase inhibitors and methods of use
AU2002351009A1 (en) * 2001-11-06 2003-05-19 Decode Genetics Ehf. Nucleic acids encoding proteases
CH698246B1 (en) * 2001-12-20 2009-06-30 Hoffmann La Roche Test to identify inhibitors of beta secretases.
US7273743B2 (en) 2002-02-21 2007-09-25 Elan Pharmaceuticals, Inc. Modified BACE
AU2003211261A1 (en) 2002-03-01 2003-09-16 Takeda Chemical Industries, Ltd. Antidepressant
US7442537B1 (en) 2002-05-10 2008-10-28 Elan Pharmaceuticals, Inc. Crystals of unliganded beta secretase and/or beta secretase-like proteins and the use thereof
AU2003230392A1 (en) 2002-05-17 2003-12-12 Merck And Co., Inc. Beta-secretase inhibitors
US7166454B1 (en) 2002-05-24 2007-01-23 Schering Corporation Codon-optimized β-secretase and methods of refolding and processing
US6746303B2 (en) 2002-05-31 2004-06-08 Mattel, Inc. Flexible toy figure with wire armature
EP1527170A2 (en) * 2002-07-26 2005-05-04 Astex Technology Limited Crystal structure of beta-site app-cleaving enzyme (bace) mutants and uses thereof
US20050074456A1 (en) * 2002-12-04 2005-04-07 Marcus Ballinger Constructs for homogenously processed preparations of beta site APP-cleaving enzyme
EP1583750B1 (en) 2003-01-07 2013-02-27 Merck Sharp & Dohme Corp. Macrocyclic beta-secretase inhibitors for treatment of Alzheimer's disease
EP1473362A1 (en) 2003-05-02 2004-11-03 Elan Pharmaceuticals, Inc. Glycosylation variants of BACE
AU2004255183A1 (en) 2003-06-30 2005-01-20 Merck & Co., Inc. N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of Alzheimer's disease
US7348448B2 (en) 2003-07-01 2008-03-25 Merck & Co., Inc. Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
DE602004014170D1 (en) 2003-10-03 2008-07-10 Merck & Co Inc BENZYL ETHER AND BENZYLAMINO BETA SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
FR2860796B1 (en) * 2003-10-14 2006-02-10 Centre Nat Rech Scient PROCESS FOR DISSOCIATION OF ARENICOLA MARINA EXTRACELLULAR HEMOGLOBIN MOLECULE, PROTEIN CHAINS COMPRISING SAID MOLECULE AND NUCLEOTIDE SEQUENCES ENCODING THE SAME
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US20060019368A1 (en) * 2004-07-20 2006-01-26 Marcus Ballinger Constructs for homogenously processed preparations of beta site APP-cleaving enzyme
EP1841455A1 (en) * 2005-01-24 2007-10-10 Amgen Inc. Humanized anti-amyloid antibody
CA2600570C (en) * 2005-03-14 2011-12-06 Transtech Pharma, Inc. Benzazole derivatives, compositions, and methods of use as .beta.-secretase inhibitors
JP2008534541A (en) 2005-03-30 2008-08-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Substituted 1,2-ethylenediamine, drugs containing said compounds, their use and methods for their production
CA2618653A1 (en) 2005-08-12 2007-02-22 Takeda Pharmaceutical Company Limited Brain/neuronal cell-protecting agent and therapeutic agent for sleep disorder
EP1942101A4 (en) 2005-09-05 2010-08-25 Yoshiaki Kiso Secretase inhibitor
WO2007081534A2 (en) * 2005-12-22 2007-07-19 Pfizer Products Inc Method of producing catalytically active bace2 enzymes
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
EP2168947A4 (en) 2007-06-22 2010-07-28 Yoshiaki Kiso Novel compound having secretase inhibitory activity
EP2164834A2 (en) 2007-07-06 2010-03-24 Boehringer Ingelheim International GmbH Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture
MX2010002938A (en) * 2007-09-24 2010-04-01 Comentis Inc (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1- carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating.
US8414893B2 (en) 2007-12-21 2013-04-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
US7989597B2 (en) 2008-06-20 2011-08-02 Oklahoma Medical Research Foundation Immunogenic memapsin 2 β-secretase peptides and methods of use
TW201020244A (en) 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
EP2281824A1 (en) 2009-08-07 2011-02-09 Noscira, S.A. Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
WO2012064836A1 (en) 2010-11-10 2012-05-18 Genentech, Inc. Methods and compositions for neural disease immunotherapy
WO2012069428A1 (en) 2010-11-22 2012-05-31 Noscira, S.A. Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions
US9193709B2 (en) 2011-10-07 2015-11-24 Takeda Pharmaceutical Company Limited 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
CA2873678A1 (en) 2012-05-30 2013-12-05 Comentis, Inc. Chromane compounds
WO2014061676A1 (en) 2012-10-16 2014-04-24 武田薬品工業株式会社 Heterocyclic compound
CR20150364A (en) 2012-12-11 2016-09-20 Takeda Pharmaceuticals Co HETEROCICLICAL COMPOUND
EP2982666B1 (en) 2013-04-04 2019-08-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2014163162A1 (en) 2013-04-04 2014-10-09 武田薬品工業株式会社 Heterocyclic compound
JP6533799B2 (en) 2014-06-09 2019-06-19 武田薬品工業株式会社 Radiolabeled compounds
JP6993228B2 (en) 2014-11-19 2022-03-03 ジェネンテック， インコーポレイテッド Anti-transferrin receptor / anti-BACE1 multispecific antibody and usage
CN107108745B (en) 2014-11-19 2021-01-12 基因泰克公司 Antibodies against BACE1 and their use for immunotherapy of neurological diseases
US20180268321A1 (en) * 2015-09-03 2018-09-20 Contact Effect, Inc. Management of tenant locations in multi-tenant environments
AU2017215021B2 (en) 2016-02-04 2020-07-23 Takeda Pharmaceutical Company Limited Substituted piperidine compound and use thereof
US9919021B2 (en) * 2016-04-15 2018-03-20 Ibet—Instituto De Biologia Experimental E Tecnológica Brain permeant peptidomimetic beta-secretase 1 inhibitors for the treatment or prophylaxis of neurological disorders or conditions
US11034700B2 (en) 2017-03-08 2021-06-15 Takeda Pharmaceutical Company Limited Substituted pyrrolidine compound and use thereof
JP6957598B2 (en) 2017-03-08 2021-11-02 武田薬品工業株式会社 Substituted pyrrolidine compounds and their uses
JP7114594B2 (en) 2017-07-28 2022-08-08 武田薬品工業株式会社 heterocyclic compound
WO2019027003A1 (en) 2017-08-03 2019-02-07 武田薬品工業株式会社 Heterocyclic compound and application thereof
TWI790264B (en) 2017-08-03 2023-01-21 日商武田藥品工業股份有限公司 Heterocyclic compound and use thereof
EP3774800A1 (en) 2018-03-28 2021-02-17 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
CN108588040B (en) * 2018-06-08 2021-06-15 中国医学科学院病原生物学研究所 Recombinant MtMetRS, crystals thereof and application of recombinant MtMetRS and crystals thereof in preparation of anti-tuberculosis drugs
EP3816154A4 (en) 2018-06-29 2022-03-30 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
US11655241B2 (en) 2018-06-29 2023-05-23 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
EP3895707B1 (en) 2018-12-12 2023-10-04 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2020122093A1 (en) 2018-12-12 2020-06-18 武田薬品工業株式会社 Heterocyclic compound
EP3915638A4 (en) 2019-01-24 2022-10-19 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
AU2020215380A1 (en) 2019-01-31 2021-08-19 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
AU2020346456A1 (en) 2019-09-13 2022-04-14 Takeda Pharmaceutical Company Limited TAK-925 for use in treating narcolepsy
BR112022004576A2 (en) 2019-09-13 2022-06-14 Takeda Pharmaceuticals Co Methods to decrease or treat excessive sleepiness, treat type 2 narcolepsy or idiopathic hypersomnia, treat shift work disorder, increase sleep latency in insomnia test maintenance, improve karolinska sleepiness escape score, decrease or improve subjective sleepiness, increase insomnia or decrease excessive sleepiness, improve Epworth sleepiness scale score, treat type 2 narcolepsy, decrease or treat excessive daytime sleepiness, and, pharmaceutical composition
JP2021080177A (en) 2019-11-14 2021-05-27 武田薬品工業株式会社 Heterocyclic compounds and uses thereof
WO2021106975A1 (en) 2019-11-27 2021-06-03 武田薬品工業株式会社 Heterocyclic compound
JP2021183587A (en) 2020-05-22 2021-12-02 武田薬品工業株式会社 Heterocyclic compounds
JP2021183586A (en) 2020-05-22 2021-12-02 武田薬品工業株式会社 Heterocyclic compounds
WO2022190060A1 (en) 2021-03-12 2022-09-15 Takeda Pharmaceutical Company Limited An orexin 2 receptor agonist for the treatment of an orexin-mediated disease or disorder
WO2023199091A1 (en) 2022-04-12 2023-10-19 Takeda Pharmaceutical Company Limited Heterocyclic compound

Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US55459A (en) * 1866-06-12 Improvement in artificial legs
US72050A (en) * 1867-12-10 Improvement in horse hiy-foeks
US81634A (en) * 1868-09-01 Improved kailway-switch
US4923967A (en) * 1988-09-26 1990-05-08 Eli Lilly And Company Purification and refolding of recombinant proteins
US5200339A (en) * 1990-08-17 1993-04-06 Abraham Carmela R Proteases causing abnormal degradation of amyloid β-protein precursor
US5221607A (en) * 1989-09-18 1993-06-22 Scios Nova Inc. Assays and reagents for amyloid deposition
US5235043A (en) * 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins
US5252463A (en) * 1990-06-22 1993-10-12 The Du Pont Merck Pharmaceutical Company Clipsin, a chymotrypsin-like protease and method of using same
US5733768A (en) * 1992-05-28 1998-03-31 Eli Lilly And Company Amyloid precursor protein protease
US5744346A (en) * 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
US5942400A (en) * 1995-06-07 1999-08-24 Elan Pharmaceuticals, Inc. Assays for detecting β-secretase
US5978740A (en) * 1995-08-09 1999-11-02 Vertex Pharmaceuticals Incorporated Molecules comprising a calcineurin-like binding pocket and encoded data storage medium capable of graphically displaying them
US5986054A (en) * 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
US6077682A (en) * 1998-03-19 2000-06-20 University Of Medicine And Dentistry Of New Jersey Methods of identifying inhibitors of sensor histidine kinases through rational drug design
US6207710B1 (en) * 1996-11-22 2001-03-27 Elan Pharmaceuticals, Inc. Compounds for inhibiting β-amyloid peptide release and/or its synthesis
US6245884B1 (en) * 1998-10-16 2001-06-12 Vivian Y. H. Hook Secretases related to alzheimer's dementia
US6291223B1 (en) * 1999-11-23 2001-09-18 Smithkline Beecham Corporation Mouse aspartic secretase-1 (mASP1)
US6313268B1 (en) * 1998-10-16 2001-11-06 Vivian Y. H. Hook Secretases related to Alzheimer's dementia
US6319689B1 (en) * 1997-01-28 2001-11-20 Smithkline Beecham Corporation Asp2
US6329163B1 (en) * 1995-06-07 2001-12-11 Elan Pharmaceuticals, Inc. Assays for detecting β-secretase inhibition
US6361975B1 (en) * 1999-11-16 2002-03-26 Smithkline Beecham Corporation Mouse aspartic secretase-2(mASP-2)
US6420534B1 (en) * 1998-09-24 2002-07-16 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses thereof

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US111365A (en) * 1871-01-31 Improvement in combined rocking sofas and bedsteads
US159991A (en) * 1875-02-16 Improvement in shoe-tips
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4235877A (en) * 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4391904A (en) * 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) * 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5036006A (en) * 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) * 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) * 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4985544A (en) 1987-08-04 1991-01-15 Kyowa Hakko Kogyo Co., Ltd. Process for renaturing fish growth hormone
DE10399032I1 (en) 1987-08-28 2004-01-29 Health Research Inc Recombinant viruses.
US5591624A (en) * 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JP4041535B2 (en) 1989-08-18 2008-01-30 オックスフォード バイオメディカ（ユーケー）リミテッド Recombinant retroviruses that carry vector constructs to target cells
US5286634A (en) * 1989-09-28 1994-02-15 Stadler Joan K Synergistic method for host cell transformation
CA2044593C (en) 1989-11-03 2004-04-20 Kenneth L. Brigham Method of in vivo delivery of functioning foreign genes
FR2658432B1 (en) 1990-02-22 1994-07-01 Medgenix Group Sa MICROSPHERES FOR THE CONTROLLED RELEASE OF WATER-SOLUBLE SUBSTANCES AND PREPARATION METHOD.
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) * 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US5308854A (en) * 1990-06-18 1994-05-03 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
AU8200191A (en) 1990-07-09 1992-02-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The High efficiency packaging of mutant adeno-associated virus using amber suppressions
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
ES2108048T3 (en) * 1990-08-29 1997-12-16 Genpharm Int PRODUCTION AND USE OF LOWER TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGICAL ANTIBODIES.
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5192668A (en) * 1990-10-11 1993-03-09 Merck & Co., Inc. Synthesis of protease inhibitor
US5187074A (en) * 1990-10-11 1993-02-16 Merck & Co., Inc. Method of hydroxylation with ATCC 55086
US5173414A (en) * 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
ATE237694T1 (en) 1991-08-20 2003-05-15 Us Gov Health & Human Serv ADENOVIRUS-MEDIATED GENE TRANSFER INTO THE GASTROINTESTINAL TRACT
WO1993008184A1 (en) * 1991-10-23 1993-04-29 Merck & Co., Inc. Hiv protease inhibitors
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
US5519021A (en) * 1992-08-07 1996-05-21 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
WO1994026877A1 (en) 1993-05-17 1994-11-24 The Regents Of The University Of California Ribozyme gene therapy for hiv infection and aids
US5679647A (en) * 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) * 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
WO1995010281A1 (en) * 1993-10-13 1995-04-20 Merck & Co., Inc. Combination therapy for hiv infection
US5739118A (en) * 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5476874A (en) * 1994-06-22 1995-12-19 Merck & Co., Inc. New HIV protease inhibitors
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) * 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
US6221645B1 (en) * 1995-06-07 2001-04-24 Elan Pharmaceuticals, Inc. β-secretase antibody
JP2000506375A (en) 1996-01-26 2000-05-30 エイチエスシー リサーチ アンド デベロップメント リミテッド パートナーシップ Nucleic acids and proteins associated with Alzheimer's disease and uses thereof
US5846978A (en) * 1996-05-02 1998-12-08 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
EP0812916A3 (en) 1996-06-14 1998-12-09 Smithkline Beecham Corporation Cathepsin k gene
DE19641180A1 (en) 1996-09-24 1998-03-26 Schering Ag A method of displaying APP secretase modulation and its use as an agent for the treatment of Alzheimer's disease
WO1998015828A1 (en) 1996-10-07 1998-04-16 Scios Inc. Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase
WO1998021589A1 (en) 1996-11-15 1998-05-22 The Trustees Of The University Of Pennsylvania Screening for modulators of amyloid processing
WO1998026059A1 (en) 1996-12-11 1998-06-18 Athena Neurosciences, Inc. Beta-secretase isolated from human 293 cells
AU3054899A (en) 1998-03-31 1999-10-25 Chugai Seiyaku Kabushiki Kaisha Cell line not expressing beta-secretase activity
KR20010052499A (en) 1998-06-05 2001-06-25 아방티 파르마 소시에테 아노님 Polypeptides with beta-secretase type activity
US6844148B1 (en) * 1998-09-24 2005-01-18 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
CN1300320C (en) 1998-09-24 2007-02-14 法玛西雅厄普约翰美国公司 Alzhimer's disease secretase
US20040234976A1 (en) * 1998-09-24 2004-11-25 Gurney Mark E. Alzheimer's disease secretase, app substrates therefor, and uses therefor
US7115410B1 (en) * 1999-02-10 2006-10-03 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
EP1165609A2 (en) * 1999-02-10 2002-01-02 Elan Pharmaceuticals, Inc. Human beta-secretase enzyme, inhibitors and their compositions and uses
WO2000058479A1 (en) * 1999-03-26 2000-10-05 Amgen Inc. Beta secretase genes and polypeptides
EP1192177A1 (en) 1999-06-15 2002-04-03 Elan Pharmaceuticals, Inc. Statine-derived tetrapeptide inhibitors of beta-secretase
JP5138851B2 (en) * 1999-06-28 2013-02-06 オクラホマ メディカル リサーチ ファウンデーション Catalytically active recombinant memapsin and methods of use thereof
EP1496124A1 (en) 1999-06-28 2005-01-12 Oklahoma Medical Research Foundation Catalytically active recombinant memapsin and methods of use thereof
CO5770112A1 (en) 1999-09-23 2007-06-29 Upjohn Co SECRETASE OF ALZHEIMER'S DISEASE, SUBSTRATES OF THE APP AND ITS USES
WO2001055174A2 (en) * 2000-01-25 2001-08-02 Oklahoma Medical Research Foundation Universal procedure for refolding recombinant proteins
ES2275675T3 (en) 2000-03-23 2007-06-16 Elan Pharmaceuticals, Inc. COMPOUNDS AND METHODS TO TREAT ALZHEIMER'S DISEASE.
US6713276B2 (en) * 2000-06-28 2004-03-30 Scios, Inc. Modulation of Aβ levels by β-secretase BACE2
WO2002006511A2 (en) 2000-07-19 2002-01-24 Genisphere Inc Methods for detecting and assaying nucleic acid sequences
US6696488B2 (en) 2000-08-11 2004-02-24 The Brigham And Women's Hospital, Inc. (Hydroxyethyl)ureas as inhibitors of alzheimer's β-amyloid production
ATE355520T1 (en) * 2000-09-22 2006-03-15 Wyeth Corp CRYSTAL STRUCTURE OF BACE AND USES THEREOF
AU2002243391A1 (en) 2000-10-27 2002-06-24 The Johns Hopkins University School Of Medicine Beta-secretase transgenic organisms, anti-beta-secretase antibodies, and methods of use thereof
JP4344518B2 (en) 2000-12-28 2009-10-14 オクラホマ メディカル リサーチ ファウンデーション Inhibitors of memapsin 2 and uses thereof
US20040121947A1 (en) 2000-12-28 2004-06-24 Oklahoma Medical Research Foundation Compounds which inhibit beta-secretase activity and methods of use thereof
EP1922083A2 (en) 2005-08-10 2008-05-21 Oklahoma Medical Research Foundation Truncated memapsin 2 for use for treating alzheimer's disease

Patent Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US55459A (en) * 1866-06-12 Improvement in artificial legs
US72050A (en) * 1867-12-10 Improvement in horse hiy-foeks
US81634A (en) * 1868-09-01 Improved kailway-switch
US4923967A (en) * 1988-09-26 1990-05-08 Eli Lilly And Company Purification and refolding of recombinant proteins
US5221607A (en) * 1989-09-18 1993-06-22 Scios Nova Inc. Assays and reagents for amyloid deposition
US5235043A (en) * 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins
US5252463A (en) * 1990-06-22 1993-10-12 The Du Pont Merck Pharmaceutical Company Clipsin, a chymotrypsin-like protease and method of using same
US5200339A (en) * 1990-08-17 1993-04-06 Abraham Carmela R Proteases causing abnormal degradation of amyloid β-protein precursor
US5733768A (en) * 1992-05-28 1998-03-31 Eli Lilly And Company Amyloid precursor protein protease
US5986054A (en) * 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
US5942400A (en) * 1995-06-07 1999-08-24 Elan Pharmaceuticals, Inc. Assays for detecting β-secretase
US5744346A (en) * 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
US6329163B1 (en) * 1995-06-07 2001-12-11 Elan Pharmaceuticals, Inc. Assays for detecting β-secretase inhibition
US5978740A (en) * 1995-08-09 1999-11-02 Vertex Pharmaceuticals Incorporated Molecules comprising a calcineurin-like binding pocket and encoded data storage medium capable of graphically displaying them
US6207710B1 (en) * 1996-11-22 2001-03-27 Elan Pharmaceuticals, Inc. Compounds for inhibiting β-amyloid peptide release and/or its synthesis
US6319689B1 (en) * 1997-01-28 2001-11-20 Smithkline Beecham Corporation Asp2
US6077682A (en) * 1998-03-19 2000-06-20 University Of Medicine And Dentistry Of New Jersey Methods of identifying inhibitors of sensor histidine kinases through rational drug design
US6420534B1 (en) * 1998-09-24 2002-07-16 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses thereof
US6245884B1 (en) * 1998-10-16 2001-06-12 Vivian Y. H. Hook Secretases related to alzheimer's dementia
US6313268B1 (en) * 1998-10-16 2001-11-06 Vivian Y. H. Hook Secretases related to Alzheimer's dementia
US6361975B1 (en) * 1999-11-16 2002-03-26 Smithkline Beecham Corporation Mouse aspartic secretase-2(mASP-2)
US6291223B1 (en) * 1999-11-23 2001-09-18 Smithkline Beecham Corporation Mouse aspartic secretase-1 (mASP1)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790610B2 (en) * 1998-09-24 2004-09-14 Pharmacia & Upjohn Company Alzheimer's disease, secretase, APP substrates therefor, and uses therefor
US20080021196A1 (en) * 1999-06-28 2008-01-24 The Board Of Trustees Of The University Of Illinois Inhibitors of memapsin 2 and use thereof
US20080112946A1 (en) * 1999-06-28 2008-05-15 Gerald Koelsch Catalytically active recombinant memapsin and methods of use thereof
US7678760B2 (en) 1999-06-28 2010-03-16 The Board Of Trustees Of The University Of Illinois Inhibitors of Memapsin 2 and use thereof
US7829669B2 (en) 1999-06-28 2010-11-09 Oklahoma Medical Research Foundation Catalytically active recombinant memapsin and methods of use thereof
US20030199676A1 (en) * 2000-01-25 2003-10-23 Oklahoma Medical Research Foundation Universal procedure for refolding recombinant proteins
US7119166B2 (en) 2000-01-25 2006-10-10 Oklahoma Medical Research Foundation Universal procedure for refolding recombinant proteins
US20060287504A1 (en) * 2000-01-25 2006-12-21 Oklahoma Medical Research Foundation Universal procedure for refolding recombinant proteins
US20070092517A1 (en) * 2005-08-10 2007-04-26 Oklahoma Medical Research Foundation Truncated memapsin 2 compositions and treatments
US20090214554A1 (en) * 2005-08-10 2009-08-27 Oklahoma Medical Research Foundation Truncated memapsin 2 compositions and treatments

Also Published As

Publication number Publication date
JP4484410B2 (en) 2010-06-16
EP1196609A2 (en) 2002-04-17
CA2374610A1 (en) 2001-01-04
CN1379819A (en) 2002-11-13
US6545127B1 (en) 2003-04-08
US20020115600A1 (en) 2002-08-22
US20040220079A1 (en) 2004-11-04
EP1194449B1 (en) 2010-09-22
JP2003506322A (en) 2003-02-18
JP5138851B2 (en) 2013-02-06
US7829669B2 (en) 2010-11-09
WO2001000665A2 (en) 2001-01-04
US20080021196A1 (en) 2008-01-24
US20080112946A1 (en) 2008-05-15
WO2001000665A9 (en) 2002-07-25
CA2374346C (en) 2010-06-22
WO2001000665A3 (en) 2001-09-27
US20040167075A1 (en) 2004-08-26
JP2003503072A (en) 2003-01-28
DE60045005D1 (en) 2010-11-04
AU5771500A (en) 2001-01-31
US7678760B2 (en) 2010-03-16
WO2001000663A2 (en) 2001-01-04
WO2001000663A3 (en) 2001-10-04
CA2374346A1 (en) 2001-01-04
AU5773500A (en) 2001-01-31
EP1194449A2 (en) 2002-04-10
ATE482233T1 (en) 2010-10-15
US7244708B2 (en) 2007-07-17

Similar Documents

Publication Publication Date Title
US6545127B1 (en) Catalytically active recombinant memapsin and methods of use thereof
JP2009100766A (en) Inhibitor of memapsin 2 and use thereof
US6274336B1 (en) Method of inhibiting cathepsin K
AU2002239727A1 (en) Inhibitors of memapsin 2 and use thereof
JP2009001576A (en) Antiangiogenic drug for treating cancer, arthritis and retinopathy
US20020049303A1 (en) Catalytically active recombinant memapsin and methods of use thereof
EP1496124A1 (en) Catalytically active recombinant memapsin and methods of use thereof
AU2004202058B2 (en) Inhibitors of memapsin 2 and use thereof
JPH08508464A (en) Cathepsin D is an amyloidogenic protease in Alzheimer&#39;s disease
AU2004202059A1 (en) Catalytically active recombinant memapsin and methods of use thereof
CN100590132C (en) Inhibitors of MEMAPSIN2 and use thereof
CA2175564A1 (en) Cathepsin d is an amyloidogenic protease in alzheimer&#39;s disease
JP2004337001A (en) New serine protease mp493

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION